
==== Front
Signal Transduct Target Ther
Signal Transduct Target Ther
Signal Transduction and Targeted Therapy
2095-9907
2059-3635
Nature Publishing Group UK London

38594257
1803
10.1038/s41392-024-01803-6
Review Article
G protein-coupled receptors (GPCRs): advances in structures, mechanisms and drug discovery
Zhang Mingyang 12
Chen Ting 3
Lu Xun 2
Lan Xiaobing 1
Chen Ziqiang ziqiang_chensuper81@vip.163.com

4
Lu Shaoyong lushaoyong@sjtu.edu.cn

12
1 grid.412194.b 0000 0004 1761 9803 Key Laboratory of Protection, Development and Utilization of Medicinal Resources in Liupanshan Area, Ministry of Education, Peptide & Protein Drug Research Center, School of Pharmacy, Ningxia Medical University, Yinchuan, 750004 China
2 https://ror.org/0220qvk04 grid.16821.3c 0000 0004 0368 8293 Medicinal Chemistry and Bioinformatics Center, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025 China
3 grid.413810.f Department of Cardiology, Changzheng Hospital, Affiliated to Naval Medical University, Shanghai, 200003 China
4 https://ror.org/02bjs0p66 grid.411525.6 0000 0004 0369 1599 Department of Orthopedics, Changhai Hospital, Affiliated to Naval Medical University, Shanghai, 200433 China
10 4 2024
10 4 2024
2024
9 8815 8 2023
19 2 2024
13 3 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
G protein-coupled receptors (GPCRs), the largest family of human membrane proteins and an important class of drug targets, play a role in maintaining numerous physiological processes. Agonist or antagonist, orthosteric effects or allosteric effects, and biased signaling or balanced signaling, characterize the complexity of GPCR dynamic features. In this study, we first review the structural advancements, activation mechanisms, and functional diversity of GPCRs. We then focus on GPCR drug discovery by revealing the detailed drug-target interactions and the underlying mechanisms of orthosteric drugs approved by the US Food and Drug Administration in the past five years. Particularly, an up-to-date analysis is performed on available GPCR structures complexed with synthetic small-molecule allosteric modulators to elucidate key receptor-ligand interactions and allosteric mechanisms. Finally, we highlight how the widespread GPCR-druggable allosteric sites can guide structure- or mechanism-based drug design and propose prospects of designing bitopic ligands for the future therapeutic potential of targeting this receptor family.

Subject terms

Target identification
Target identification
https://doi.org/10.13039/501100001809 National Natural Science Foundation of China (National Science Foundation of China) 22077082 Lu Shaoyong the Shanghai Frontiers Science Center of Cellular Homeostasis and the Human Diseases, and the Innovative Research Team of High-Level Local Universities in Shanghaiissue-copyright-statement© West China Hospital, Sichuan University 2024
==== Body
pmcIntroduction

G protein-coupled receptors (GPCRs) are the largest superfamily of cell surface membrane receptors and are encoded by approximately 1000 genes, sharing conserved seven-transmembrane (7TM) helices connected by three intra- and three extra-cellular loops.1–3 GPCRs are conformationally dynamic proteins that mediate vital biological functions of signal transduction triggered by various extracellular signals such as photons, ions, lipids, neurotransmitters, hormones, peptides, and odorants.4–8 Due to the distinct topography between the binding sites of extracellular stimuli and the subsequent signaling events at the intracellular site (approximately 40 Å), GPCR signal transduction is allosteric.9–13 Advances in protein engineering, X-ray crystallography, and cryo-electron microscopy (cryo-EM), coupled with innovative technologies such as X-ray free electron lasers (XFELs) and nuclear magnetic resonance (NMR) spectroscopy, have revolutionized our understanding of GPCR structures and dynamics. These studies provide insights into ligand-receptor interactions, conformational changes, and signaling complexes, offering unprecedented opportunities for in-depth investigations into receptor activation, orthosteric/allosteric modulation, biased signaling, and dimerization.

Once activated by exogenous stimuli, GPCRs primarily employ heterotrimeric G-proteins and arrestins as transducers to produce second messengers and further initiate the downstream signaling, resulting in promiscuous signaling profiles within cells.11 Such spectrum of signaling is the prerequisite for function diversity of GPCRs and is fundamental in regulating physiological processes, including sensory perception, neurotransmission, and endocrine processes.14,15 The mutations and truncation of GPCRs; however, can dysregulate GPCR functionality by altering constitutive activity, influencing membrane expression and affecting post-translational behaviors.16 Unraveling the mechanisms of stimuli-GPCR-effector coupling, as well as the concise regulation of GPCR dysfunction will bring about valuable therapeutic potentials and inspire the design of modulators with high potency, selectivity, or biased signaling.

Till date, approximately 34% of the US Food and Drug Administration (FDA)-approved drugs are targeted to GPCRs, with modulators in clinical trials or preclinical stages experiencing exponential growth.17,18 Among them, orthosteric ligands impose an effective alteration on GPCR activity and signaling process by competitively preventing the binding of endogenous ligands.19 However, due to the sequence conservation of orthosteric sites, in most cases, subtype selectivity remains an intractable issue, which implies the inevitable side effects of orthosteric drugs.20 As an alternative or complementary option, targeting allosteric sites alone or targeting both orthosteric and allosteric sites can overcome these major hurdles.21–25 Allosteric modulators are highlighted for their high subtype selectivity and low side effects. A progressive structural understanding of the detailed receptor-ligand interactions is paving the way for fragment-to-lead optimization in structure-based drug design (SBDD) (Fig. 1). Moreover, the knowledge of allosteric sites is useful for the design of bitopic ligands by creating a molecule attached to both an allosteric and orthosteric site. Bitopic ligands have several advantages of improved affinity and enhanced selectivity over a single allosteric or orthosteric ligand. In addition, elucidating allosteric mechanisms of GPCRs provides a viable strategy to develop biased ligands such as G protein- or β-arrestin-based allosteric modulators.26 Bitopic modulators have higher selectivity to reduce side effects since they exert pathway-specific effects on GPCR signaling.26,27Fig. 1 Phylogenetic tree of GPCRs indicating GPCR structures that have been solved in complex with modulators. Nodes represent GPCRs named according to their UniProt gene name and are organized according to the GPCR database. GPCR structures bound to modulators are highlighted by color

In this review, we first summarize the structural progression, activation mechanisms, and functional diversity of GPCRs. To delve into the advancement of GPCR drug discovery, we investigate the detailed drug-target interactions at the orthosteric sites, focusing on GPCR structures in complex with recent FDA-approved orthosteric drugs. Subsequently, allosteric modulators are extensively discussed, with a focus on recent breakthroughs in GPCR structures that bind to synthetic small molecules. Notably, peptides and antibodies are excluded from our analysis. Such investigation systematically clusters the location of allosteric sites in the extracellular vestibule, transmembrane domain, and intracellular surface, highlighting the key binding modes with their target receptors and allosteric mechanisms. This review aims to provide a deeper understanding of GPCR structures, mechanisms, and drug discovery, which has important implications for structure- or mechanism-based drug design and the design of bitopic ligands for the future therapeutic potential of targeting this receptor family.

Structure advances in GPCRS

The low expression of membrane protein GPCRs, combined with their conformational flexibility, initially posed great challenges for high-resolution diffraction.28 The initial crystal structures of rhodopsin and the ligand-activated β2 adrenergic receptor (β2AR) were resolved in 2000 and 2007, respectively.29,30 Over the past two decades, considerable progress has been made in the engineering of proteins and the technique of X-ray crystallography.31 Notably, the use of GPCR engineering with fusion proteins,32,33 antibody fragment crystallization34,35, and thermostabilizing mutations36, has produced numerous antagonist- or agonist-bound GPCR structures. However, only agonist-bound GPCRs frequently exist in an intermediate conformation because the fully active conformation requires stabilizing chaperones, including G proteins, G protein mimetics, conformationally specific nanobodies, and mini-G proteins.37

The first GPCR-G protein complex was determined in 2011 using X-ray diffraction;38 however, the demanding nature of X-ray crystallography has rendered GPCR-G protein complex crystallization a difficult undertaking. Cryo-EM has developed to be an alternative technique, driving a novel trend in GPCR structural biology. Unlike X-ray crystallography, cryo-EM does not rely on crystals and has considerably superior potential to directly visualize detergent- or nanodisc-solubilized GPCRs. This capability enables the determination of previously intractable fully active states and larger protein complexes, including GPCR-G protein complexes.39 Since then, the number of cryo-EM structures depicting GPCRs in complex with intracellular partners has experienced exponential growth (Fig. 2). As of November 2023, the Protein Data Bank has accumulated 554 complex structures, of which 523 are resolved using cryo-EM.40 However, both crystallography and cryo-EM are limited to capturing the most stable and lowest energy conformations under crystallization conditions.4 Moreover, the comprehensive characterization of intermediate states and transition kinetics remains elusive. Crystallographic, spectroscopic, and simulation techniques have offered complementary information on the conformational dynamics of GPCRs.Fig. 2 Timeline of major advancements in GPCR structure study using X-ray crystallography and cryo-EM

The advanced XFELs possess the potential to solve the missing information. The exceptional properties of XFELs, characterized by extreme brilliance and femtosecond short pulses, allow them to overcome radiation damage, facilitating the determination of GPCR structures with atomic-level information at femtosecond timescales.41 NMR spectroscopy offers a valuable technique to detect dynamic features of GPCRs in liquid environments.42,43 The number, position, and shape of signals in the NMR spectra are sensitive to changes in the micro-environment of stable-isotope “probes” incorporated into receptors. Double electron-electron resonance (DEER) spectroscopy enables the assessment of a distance distribution between two different probes. Fluorescence resonance energy transfer (FRET), a technique based on fluorescence, functions as an “atomic ruler” to detect the proximity between two labels, providing valuable data about the number of states and their relative populations.44,45 Among these, DEER and FRET provide only localized details regarding the chemical probes that have been inserted. In addition, molecular dynamics (MD) simulations offer a comprehensive, time-resolved view of complete protein structures, capturing intermediate states along the transition pathway.46–48 Advances in the structural biology of GPCRs have revealed key information on ligand-receptor interactions, conformational changes, and signaling complexes, opening the opportunity for exploration of receptor activation, orthosteric/allosteric modulation, biased signaling, and dimerization.

Mechanism of GPCR activation and signaling

Although the nature of GPCRs and activating stimuli may vary significantly, GPCRs primarily coordinate distinct downstream signaling responses through two types of transducers: heterotrimeric G proteins and arrestins. Human G proteins comprise four major families (Gs, Gi/o, Gq/11, and G12/13) and more than half of GPCRs activate two or more G proteins, each of which exhibits distinct efficacies and kinetics.49,50 The promiscuous coupling leads to fingerprint-like signaling profiles inside the cell, which contributes to the complexity of GPCR signaling.

When bound to GDP, the Gαβγ heterotrimer is inactive. Agonist binding leads to the formation of an active conformation of GPCRs, which initiates signaling cascades involving the recruitment and activation of G-proteins. The activated GPCR catalyzes the GDP/GTP exchange on the Gα subunit, causing the dissociation of Gα from the Gβγ dimer. Due to high cellular concentrations of GTP, Gα rapidly binds a molecule of GTP at the nucleotide-binding site. Both Gα-GTP and Gβγ can modulate subsequent effector proteins. Gα-GTP can activate or inhibit enzymes such as adenylyl cyclase (AC), phospholipase C (PLC), or ion channels, depending on the specific G protein type. Gβγ can also modulate various signaling pathways and interact with target proteins. Activation of effector proteins by Gα-GTP or Gβγ generates second messengers, such as cyclic AMP (cAMP). The cellular response concludes with the Gα subunit hydrolyzing GTP to GDP, leading to its reassociation with Gβγ and G protein inactivation. Subsequently, the Gα subunit completes the G-protein activation cycle by reassociating with Gβγ.

To prevent sustained signaling, activated GPCRs may also undergo C-terminal phosphorylation facilitated by G-protein-coupled receptor kinases (GRKs). This multi-site GPCR phosphorylation determines β-arrestin binding affinity and induces receptor desensitization via steric hindrance, followed by clathrin-mediated endocytosis and ubiquitination of the receptor (Fig. 3a).11,51,52 The receptor-arrestin complex also serves as a scaffold for over 20 different kinases, including mitogen-activated protein (MAP) kinases, ERK1/2, p38 kinases, and c-Jun N-terminal kinases, activating G-protein independent signaling pathway. Four isoforms of arrestin (arrestins 1-4) and multiple GRK isoforms were discovered, with arrestins 1 and 4 being only found in the visual system. β-arrestins 1 and 2, also referred to as arrestins 2 and 3, interact with and regulate numerous non-visual GPCRs.34Fig. 3 a Schematic representation of GPCR activation process. Upon agonist (red circle) binding, the receptor proceeds into a pre-activation state coupling with the G protein heterotrimer, where the exchange of GDP and GTP in G protein α subunit leads to G protein dissociation and mediate G protein signaling pathway. The phosphorylation of the receptor C-terminal tail by GRK binding promotes arrestin recruitment and signaling. When the antagonists (blue circle) bind, the receptor stabilizes in an inactive state. b Crosstalk of downstream pathway of Gs, Gq, Gi and arrestin

Originally classified as monomers, GPCRs were subsequently recognized to engage in homo- or hetero-dimerization, displaying distinct properties in receptor activation, pharmacological cascades, and biological functions.53,54 Recent research indicates that GPCRs can bind to various single transmembrane accessory proteins to regulate their biological functions such as ligand binding, transducer coupling, and intracellular signaling.55,56 Prominent examples include the family of receptor activity-modifying proteins (RAMPs) that majorly regulate the glucagon receptor (GCGR) and the melanocortin receptor accessory proteins (MRAPs) that regulate the melanocortin receptors (MC1R-MC5R).57,58 Currently, the interactions between the negative allosteric modulator RAMP2 and GCGR as well as the positive allosteric modulator MRAP1 and MC2R have been elucidated by cryo-EM.59,60

Structural changes within GPCRs facilitate their function as molecular conduits that transmit extracellular signals across membranes to elicit cellular responses. A distinctive feature of GPCR activation involves notable outward movement of the cytoplasmic end of TM6, creating an intracellular pocket to accommodate the downstream transducers. GPCRs contain several conserved structural motifs relevant to their activation, including the CWxP motif of TM6, the NPxxY motif of TM7, and the ionic lock that involves TM3-TM6, as well as TM3-TM7.61–63 Additionally, Na+ acts as an endogenous negative allosteric modulator (NAM) of class A GPCR activation, stabilizing the inactive state through direct interactions.64,65 High resolution structures reveal that Na+ interacts mainly with residues from TM1, TM2, TM3, and TM7 and these interactions vary across GPCRs.66,67

Ligands can regulate receptor activity by stabilizing distinct conformations. Since the diverse signaling pathways elicit distinct physiological effects, ligands that selectively induce beneficial pathways hold promising therapeutic value. These drugs are commonly referred to as “biased ligands.” For instance, G protein-biased μ-opioid receptor (μOR) agonists are of remarkable clinical relevance as they enhance analgesia effects and reduce adverse reactions associated with the activation of β-arrestin pathways, in contrast to morphine. Several novel biased ligands are currently in clinical use or under investigation, such as TRV130, PZM21, and SR-17018.68–70 Hence, unraveling the coupling mechanisms governing G proteins, GRKs, and arrestins will establish a robust foundation for designing biased ligands tailored to selectively activate or inhibit specific pathways.

In the absence of agonists, GPCRs may display different levels of constitutive activities. The efficacy of diverse ligands acting on a single GPCR in terms of activation or inactivation also varies widely. Considering both receptor constitutive activity and drug efficacy, GPCR ligands are categorized as (full) agonists, partial agonists, antagonists, and inverse agonists. These variations in efficacy significantly influence their therapeutic properties.

Functional diversity of GPCRS

Overview of GPCR subfamilies and their physiological functions

GPCRs can be categorized into class A, class B, class C, class F, and class T according to their structural and functional characteristics. Class A GPCRs, namely the rhodopsin-like family, is the superfamily with the largest proportion and the most extensive research.71 Class A GPCRs can further be divided by function into aminergic, peptide, protein, lipid, melatonin, nucleotide, steroid, dicarboxylic acid, sensory, and orphan subgroups,72 with their corresponding indications ranging from hypertension, cardiovascular diseases, and pulmonary diseases, to depression and psychiatric disorders.17 Class B GPCRs are divided into secretin (B1) and adhesion (B2) subfamilies, with the former characteristic of large extracellular domains (ECD) and the latter possessing a unique long N-terminal motif and autoproteolysis-inducing domain.73 While glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR) are emerging as the famous B1 GPCR targets in regulating blood glucose homeostasis and lipid metabolism;74,75 the B2 subfamily is critical in modulating sensory, endocrine, and gastrointestinal systems.76 Class C GPCRs, the glutamate receptors, are unique in their large ECDs, conserved venus fly traps (VFTs), cysteine-rich domains (CRDs) on the ligand binding sites, and constitutive dimers for receptor activation.77 With mGluRs (metabotropic glutamate receptors) taking the lead in clinical transformation, the physiological functions of class C GPCRs are implicated in cancer, migraine, schizophrenia, and movement disorders.77 Class F GPCRs, comprising 10 frizzled receptors (FZDs) and one smoothened receptor (SMO), are distinctive in their conserved CRD regions and involvement in Hedgehog and Wnt signaling pathways. Therefore, they are mainly associated with cancer, fibrosis, and embryonic development.78 The current drug discovery is only focused on SMO,79 leaving broad exploration space for the therapeutic potential of FZDs. Particularly, although taste 2 receptors (TAS2Rs), the receptors modulating taste perception of humans, show structure similarity with class A GPCRs, their low sequence homology (<20%) with the existing types of GPCRs isolates them to a novel category of class T GPCRs,76 deepening our understanding of the entire GPCR family.

Involvement of GPCRs in sensory perception, neurotransmission, and endocrine regulation

Rhodopsin, TAARs, and TASRs in sensory perception

One of the most significant physiological functions GPCRs exercise is mediating sensory information such as light perception, taste, olfaction, and pheromone sensation. Rhodopsin, which contributes to the first stage of visual activation in vertebrates, exhibits the typical and representative features of class A GPCRs. Upon absorbing photons, the orthosteric ligand of rhodopsin, retinal, experiences conformational flipping within picoseconds, thus rapidly triggering signal propagation from the receptor to G proteins, cGMP phosphodiesterase, or cGMP-gated ion channel.80 The covalent linkage of retinal with the receptor, and the instantaneous overturning and signaling serve as a paradigm for elucidating the efficiency of GPCRs in sensory perception.

Olfactory sensory receptors, which can be categorized into odorant receptors (ORs) and trace amine-associated receptors (TAARs), are a valuable medium for researchers to understand olfactory information encoding. Guo et al.81 has recently revealed the universal mechanism of TAARs recognition of amine odor molecules and the structural basis of “combinatorial coding” of the olfactory receptor in ligand recognition. Notably, the selective coupling of mTAAR9 with Gs and Golf is also delineated, which serves as a pioneer in the field of mammalian olfactory recognition. Apart from selective G-proteins, the downstream transduction mechanism of olfactory receptors is also associated with adenylyl cyclase and cAMP-gated ion channel,82 leaving favorable exploration opportunities.

To regulate the sensory function of taste, which is one of the most important sensations in human life, taste receptors (TASRs) are extensively studied from physiological and pharmacological perspectives. Among them, type I taste GPCRs function by forming heterodimeric complexes to stimulate sweet (TAS1R2/TAS1R3) and umami (TAS1R1/TAS1R3) sensation, whereas Type II are monomeric TAS2Rs that regulate bitter flavor.83 Tastant binding to the receptor activates downstream secondary messengers, resulting in depolarization and sensitizing the transient receptor potential (TRP) channel, which in turn innervates the gustatory cortex in the brain.84 Given the inapplicability of the previous GPCR expression techniques in TAS2Rs,85 overcoming difficulties in the structural determination of taste receptors will further facilitate their physiological research.

μOR and CBR in neurotransmission

Currently, neurological therapeutic demands mainly revolve around neuropathic pain alleviation, treatment of depression, psychiatric disorders, and Parkinson’s diseases. μ-Opioid receptors (μORs), possessing a research history of over 50 years, have been extensively researched about their mechanism of analgesic action in the peripheral nervous system (PNS) and the central nervous system (CNS). For instance, μORs reduce the release of nociceptive substances and decrease Ca2+ production following nerve injury by interacting with TRPV1, H1R, and NK1R in nociceptive receptors,86 whereas in spinal dorsal horn neurons, μORs modulate 5-HT receptors, glycine receptors, and norepinephrine receptors to activate pain inhibitory pathway.87 Orthosteric biased modulators, allosteric modulators, and bitopic modulators have been successively developed to exert analgesic effects while alleviating side effects like respiratory depression and addiction.88 Cannabinoid receptors (CBRs) are also representative targets involved in neurotransmission and neuropathic pain pathophysiology. The subtype CB1R is primarily found in presynaptic terminals of neurons in CNS, the activation of which inhibits neurotransmitter release and algesthesia transmission,89 while CB2R is highly expressed in immune cells, the activation of which can inhibit inflammatory factors that promote pain sensitization.90 No-selective orthosteric CB1R and CB2R activators can produce an antinociceptive effect and improve sleep in several animal models, while selective positive allosteric modulators (PAMs) like ZCZ011 (40) are rising as more promising ligands without inducing cannabis-like side effects.91

GLP-1R and GPR120 in endocrine regulation

Endocrine syndrome has been rising as one of the most critical health issues in the 21st century. Numerous metabolism-related GPCRs, which are usually activated by energy metabolites or substrates, are pivotal sensors of endocrine dysregulation. GLP-1R and GPR120 (also known as free fatty acid receptor 4), for example, are both promising therapeutic targets for the treatment of type 2 diabetes and obesity.74,92 Mechanistically, the endogenous ligand of GLP-1R, GLP-1, can reduce the secretion of glucagon in pancreatic α cells and promote insulin secretion in pancreatic β cells. For GPR120, however, the binding of omega-3 polyunsaturated fatty acids (ω3-FAs) and receptor activation can reduce inflammation of adipose tissue and protect against insulin resistance.93 The receptor’s coupling with Gq/11 subsequently stimulates the PI3K/Akt pathway, resulting in the uptake of glucose in adipocytes.94 As GLP-1R agonist liraglutide takes the lead in FDA-approved drugs treating type 2 diabetes and obesity,95 drug development of more endocrine-related targets such as GPR35, GPR40, GPR41, GPR43, GPR81, and GPR119 are supposed to come into our view.

Receptor promiscuity and cross-talk between different signaling pathways

GPCR receptors convert the extracellular stimuli to intracellular signals to control cellular function and phenotype. GPCR receptors convert the extracellular stimuli to intracellular signals to control cellular phenotype and function. These intracellular signaling pathways intersect with each other to enhance or downgrade relevant responses in a phenomenon known as “cross-talk.” The promiscuity of the GPCR signaling network is consequently outlined, resulting in more extensive regulation, low selectivity, and possible adverse effects.

Promiscuity and cross-talk can occur at three levels, including the GPCR receptors, G-proteins/β-arrestins, and the downstream effectors. The receptor promiscuity lies in the formation of heterodimers, which can either be constituted of subtypes of the same receptor family or those of different families. A compelling case is the heterodimerization of GABAb(1) and GABAb(2) which leads to the functionality of modulating GIRK (G-protein gate inward rectifying channel) potassium channels, whilst neither of them is functional when expressed as a monomer.96 Another well-established example is the plentiful interrelationship of adenosine receptors and dopamine receptors, where the activation of A1A and A2A adenosine receptors decreases dopamine binding to D1 and D2 dopamine receptors.97 The bivalent ligands that bind adenosine receptors and dopamine receptors at each end further demonstrate the occurrence and functionality of heterodimerization.98 The participants of heterodimerization are assumed to share a common G-protein pool, thus contributing to the redistribution of their interaction of G-proteins and reshaping the signaling landscape.99 Given this, by direct cross-talk between two GPCR receptors, ligands can be designed towards one receptor to modulate the affinity and efficacy of the other target, although certain pharmacological profiles remains unclear.

At the second stage of the hierarchical signaling of GPCRs, namely the recruitment of Gs, Gi, Gq, G12, β-arrestin 1, and β-arrestin 2, a spectrum of coupling strengths ranging from highly selective coupling to promiscuous coupling is exhibited. MD simulations performed by Sandhu et al. revealed that engineered mutant GPCRs can alter the coupling of non-cognate G-proteins by reshaping the intracellular interface,99 demonstrating that “dynamic structural plasticity” of the GPCR cytosolic pockets is the foundation of G-protein promiscuity. Mutants, orthosteric and allosteric modulators that exert long-range and delicate effects towards the cytosolic binding interface are therefore principal strategies to achieve selectivity of G-protein signaling.

The promiscuity of distinct downstream effectors, known as the third stage of signaling, is highly correlated with the cross-talk of G-proteins. Normally, stimulation of Gs, Gi, and Gq results in the activation of AC, the inhibition of AC, and the stimulation of PLC, respectively.100 However, once distinct G-proteins are recruited near the membrane at a similar time, βγ subunits released from respective G-protein activation are “exchangeable” between diverse signaling pathways and can potentiate responses mediated by other G-proteins.101 The second messengers then phosphorylate, activate, or deactivate each other to construct a fine-tuning network (Fig. 3b). Albeit conducting a great deal of research, the precise control of GPCR promiscuity remains obscure.

Impact of GPCR mutations on human diseases and therapeutic implications

Besides being involved in numerous physiological processes, mutations in GPCRs can be linked to manifold human diseases, underlying the necessity of GPCR genomics, and imposing therapeutic implications. Till date, over 2350 mutations in GPCR genes have been identified as the major causes of more than 60 inherited monogenic diseases in humans (Fig. 4a), with missense mutations harboring the maximum proportion (>60%) and small inserts/deletions ranking the second (>15%).16Fig. 4 a Categories of Representative human diseases caused by GPCR dysfunctions. b Classification of the effects of mutations on GPCR dysfunctions

Classification of the effects of mutations on GPCR dysfunctions

The effects of mutations in GPCRs can be categorized into gain-of-function (GoF) and loss-of-function (LoF), corresponding to physiological hyperfunction and hypofunction, respectively. Recent studies have provided a more detailed explanation of the diverse underlying mechanisms of GoF and LoF mutations. Compared with the wild-type (WT) GPCR activation, the common pharmacological mechanisms of activating and inactivating mutations lie in three aspects: (1) Mutations transform micro-switch cascades within the receptors and induce active/inactive conformations, thus altering the constitutive activity of GPCRs and affecting the recruitment of downstream effectors. (2) Mutations influence receptor expression directly or indirectly increasing/decreasing receptors’ intracellular transport, degradation, and recycling. (3) Some mutations affect ligand potency, specificity, or promiscuous recognition, thereby exerting regulatory functions by shifting the conformational population, redistributing the downstream couplings, or altering receptor dimerization. Furthermore, all variants are not pathogenic. This provides robust evidence for another classification of “driver” and “passenger” mutations (Fig. 4b).102 Computational approaches are recently emerging to predict the driver ability of mutations in GPCR-related diseases, based on abundant clinical data of mutations and relevant GPCR dysfunctions.

Correlation of GPCR mutations and human diseases

The genomic alterations induced by GPCR mutations serve as the major driver of various monogenic diseases. Some well-established examples include missense mutations in SMO receptor causing basal cell carcinoma,103 missense and nonsense mutations in MC4R causing obesity104, and missense mutations in FSHR inducing ovarian hyperstimulation syndrome. The majority of mutations are highly conserved and thus in an advantageous position during evolution.105 Therefore, the pathological relevance between GPCR mutations and human diseases may be more effectively predicted taking the evolutionary conservation of a certain residue into consideration.

Therapeutic implications and approaches of GPCR pathologies

Terapeutic approaches of GPCR pathologies mainly include symptomatic and etiological treatment. As many GPCR dysfunctions ultimately result in endocrine diseases with end-organ resistance or cancer, the administration of hormones or chemotherapeutics may be considered to reduce pathologic phenotypes.106,107 More state-of-the-art therapeutic implications, however, are oriented towards etiological treatment. Missense mutations in GPCRs can mislead protein folding and post-translational modifications to cause trafficking alterations, in which pharmacological chaperones are applicative therapeutic regimens.108 For receptor truncation resulting from nonsense mutations or frame-shifting mutations, RNA interference, gene replacement approaches, and the genome editing approach CRISPR/Cas9 may rescue the receptor integrality, provided that at least the first three transmembrane helices remain in the mutant receptor.109 Designing peptides or small molecule modulators is the most straightforward means for the restoration of receptor pharmacology, though high expenditure in multiple mutations remain an intractable issue.

Advances in GPCR drug discovery

Overview of traditional and emerging approaches for GPCR drug discovery

Since enkephalin was first recognized as the endogenous ligand of opioid receptors,110 the discovery of modulators with diverse regulatory effects is constantly endowing meaning in the research of GPCRs. Several decades have witnessed the transformation from serendipity to rational design in the field of GPCR drug discovery, and the ligands have been expanded from natural products to synthesized compounds and engineered antibodies. Currently, apart from the traditional molecular docking and SBDD, more screening methodologies of wet experiments have been established to facilitate the selection of high-quality hits, including FRET/ BRET (Bioluminescence Resonance Energy Transfer) assay, NanoBiT (NanoLuc Binary Interaction Technology) assay, Tango assay, and 19F NMR.111 Once the hits were obtained, structure-activity relationship (SAR) optimization in synergistic application of computational methodologies such as fragment-growing, property prediction, and MD simulations, was conducted to initiate the hit-to-lead and lead-to-drug campaign.99

Herein, we specially emphasize on the interaction and signaling mechanism of synthetic small-molecule modulators bound to GPCRs, with the aim of enlightening the discovery of more ingenious molecules with high potency, selectivity, and potential biased effects.

Structure-based drug design targeting the orthosteric sites of GPCRs

Orthosteric small molecule modulators are the most universal non-peptide regulators of GPCRs. By competing with endogenous ligands, they interact with the orthosteric binding pocket (OBP) and exert a full agonistic112,113/partial agonistic114/antagonistic function115,116 by triggering the conformational displacement of GPCR internal structures.117,118 Despite their relatively mature development, side effects derived from low subtype selectivity and promiscuous signaling remain the major hurdle.49,119

Over the past 30 years, the widespread use of X-ray and Cryo-EM has facilitated the characterization of GPCR-orthosteric ligand complexes, with 657 class A, 16 class B1, 6 class B2, 19 class C, 18 class F, and 1 class T structures solved (supplementary Table 1–5).120 Here, we meticulously selected five representative complexes in which ligands have been launched recently to elucidate the mechanisms of ligand recognition, specificity, and elaborate signaling transduction. Furthermore, we exemplified two cases to demonstrate the beneficial engagement of structural information in exploiting not only SAR but also the structure-functional selectivity relationship (SFSR). Considering these seven cases as a paradigm, we aimed to condense valuable hints based on a detailed analysis of approved drugs or selective compounds and provide a constructive outlook for the high-quality discovery of GPCR orthosteric modulators that may overcome the current dilemma.

μOR in complex with oliceridine

With morphine and fentanyl (1) the most effective drugs treating acute or chronic pain,121,122 their common receptor μOR was revealed to be responsible for both analgesic and adverse effects.123–125 To attenuate side effects and broaden the therapeutic window, modulators that can abolish β-arrestin activity while maintaining relatively intact G-protein signaling are of intense pharmaceutical interest.126–128 Oliceridine (2), a partial agonist binding at the orthosteric site of μOR, was approved by the FDA in 2020 for its ability to biased signaling via the G protein pathway and thus alleviating side effects (Fig. 5a, b).129 Therefore, casting light on the oliceridine-μOR complex structure and the underlying mechanism of biased signaling will provide insight in developing a novel generation of analgesic drugs.Fig. 5 a A bridged general view of fentanyl and oliceridine inducing distinct pharmacological profiles. b 2D structure of fentanyl and oliceridine shown for clarity. c Superimposed views of μOR–fentanyl (gray cartoon, gray sticks; PDB: 8EF5) and μOR–oliceridine (light green cartoon, light green sticks; PDB: 8EFB) complex structure, together with the comparison of ligand binding modes and arrestin coupling interfaces, are presented. 2D structures of two designed biased modulators are also presented

By aligning the complex structures of μOR–oliceridine and μOR–fentanyl, a well superimposed binding mode in OBP above Trp2956.48 was found. The only exception was that the pyridine ring of oliceridine tilts 35° toward TM2 relative to the n-aniline group of fentanyl, resulting in weaker hydrophobic interactions with TM6/7 than that with fentanyl. Based on the results of MD performed by Zhang et al.,130 extended interactions with TM6/7 can be inferred to have elicited inward movement of TM6 and TM7-H8 toward the TM core, shaping adaptive intracellular pocket conformation for both G-protein and β-arrestin coupling and thus leading to neutral signaling, whereas reduced interactions may have kept the intracellular end of TM6/7 relatively away from the TM core and therefore stabilize an intracellular pocket preferential for G protein binding and signaling. Two fentanyl-derived μOR agonists (3-4), which substituted the aniline group on fentanyl with n-propyl or isopropyl to reduce hydrophobicity with TM6/7, were thereupon designed as “proof-of-concept” to successfully achieve biased signaling via the G protein pathway (Fig. 5c). Different from the “trial-and-error” mode when developing biased ligand oliceridine,131 the comprehensive study by Zhang et al. serves as a paradigm for dissecting co-crystallized complexes to understand the molecular basis of preferential signaling mechanisms initiated from the orthosteric pocket and broadens the avenue for designing biased modulators of ORs through SBDD strategies.

S1PR in complex with siponimod

Sphingosine-1-phosphate receptor (S1PR), a family of class A GPCR consisting of five subtypes, S1PR1-S1PR5, modulates diverse physiological functions, including lymphocyte trafficking, vascular development, endothelial integrity, and heart rate.132–136 Although Fingolimod received regulatory approval from the FDA in 2010 as a first-in-class S1PR agonist,137 its low subtype selectivity has led to several “off-target” effects, including bradycardia and atrioventricular blockade.138 Therefore, a second-generation, highly subtype-selective S1PR modulator is crucially needed. Siponimod (5) was globally approved in 2019 for the treatment of adults with relapsing MS by selectively targeting S1PR1 and S1PR5.139 Insights into the mechanisms of drug recognition and receptor activation will provide a framework for understanding ligand selectivity and signal transduction in GPCRs.140,141

Yuan et al. presented the cryo-EM structures of siponimod–S1PR1–Gi and siponimod-S1PR5 complexes, in which the ligands exhibited an identical linear conformation across a polar module and the deep hydrophobic cavity of the orthosteric pocket (Fig. 6a).142 Given that members of the S1PR family display different extracellular vestibules, distinct extracellular leaflets have been reported to have contributed to diverse access channels for ligand entry and thus relate to specificity among subtypes (Fig. 6b).143 Moreover, further careful comparison of the siponimod-S1PR1-Gi complex with antagonist ML056-bound S1PR1 structure underlines the “twin toggle mechanism” during receptor activation.144 Upon ligand binding, Leu1283.36 rotates 130° away from TM5 to form a direct interaction with the hydrophobic portion of siponimod, disrupting its previous interaction with Trp2696.48 and triggering a synergistic downward movement of Trp2696.48. The dramatic displacement of the two residues can therefore loosen the interaction between TM3 and TM6, inducing a consequent outward movement of TM6 that can accommodate G protein binding (Fig. 6c, d). Similar activation mechanism involving corresponding mechanical switches can also be found in CB1 and MC4R,145,146 which provides valuable hints that designing ligands forming elaborate hydrophobic interaction with residue 3.36 or directly inducing reconfiguration of 3.36-6.48 may contribute to enhanced activation efficacy.Fig. 6 a Detailed binding modes of S1PR5 in complex with siponimod. Labels of the residues engaged in polar contacts with siponimod are colored in blue, with hydrogen bonds presented by orange dashes. The residues of the hydrophobic pocket that stabilizes ligand binding are marked with green labels, while residues that are critical for signal transduction are labeled in red. b Superimposed views of S1PR1 (orange cartoon, PDB: 7T6B), S1PR2 (light green cartoon, PDB: 7C4S), S1PR3 (light purple cartoon, PDB: 7YXA), and S1PR5 (yellow cartoon, PDB: 7TD4) GPCR structures, where TM1 and TM7 of S1PR5 are highlighted for clarity. c Superimposed views of active S1PR1-siponimod complex (cyan cartoon, cyan stick, PDB: 7TD4) and inactive S1PR1 structure (gray cartoon, gray stick, PDB: 3V2Y) to illustrate the “toggle switch” activation mechanism. d 2D structure of siponimod is shown for clarity

OX2R in complex with lemborexant

Orexin receptors are expressed throughout the central nervous system and demonstrate therapeutic potential for insomnia by regulating the sleep-wake cycle.147–149 The two subtypes, OX1R and OX2R, dominate the respective regulatory behaviors, with OX1R involved in gating rapid eye movement (REM) sleep and OX2R involved in gating non-REM and REM sleep.150 Lemborexant (6), an orthosteric competitive antagonist approved by the FDA in 2019, exhibits outstanding inhibitory activity against OXRs.151,152 However, the most important features of lemborexants lie in two aspects: (1) Why lemborexants show moderate selectivity toward OX2R over OX1R,152 which will facilitate the design of OX1R/OX2R-selective modulators that can be applied to REM and non-REM functionality studies? 2) What is the basis of the dynamic parameters of lemborexant that may explain the relationship between drug-induced improvement of sleep onset and a decrease in wake time after sleep?

To elucidate the mechanism of lemborexant subtype selectivity and provide guidance for anti-insomnia drug development, Asada et al. presented the crystal structure of the OX2R–lemborexant complex and compared its ligand-binding mode with that of the previously solved OX1R–lemborexant complex structure.153 Despite the ligand’s shared hydrogen bonds with Gln1263.32 of OX1R and Gln1343.32 of OX2R, lemborexant binds OX1R as a mixture of two orientations owing to the small side chain of Ala1273.33, whereas lemborexant binds OX2R in only one configuration because of the steric hindrance of Thr1353.33, which is inferred to be the primary cause of the difference in its affinity for OX1R and OX2R (Fig. 7a, b). In contrast, by simulating lemborexant in solution, the intramolecular stacking of two aromatic rings was observed to play a vital role in shaping the conformation of lemborexant close to the bound state before receptor binding, which explains the high kon value of the ligand. In addition, the higher binding free energy of lemborexant compared to other OXR modulators may contribute to a higher koff value. Collectively, these observations highlight the possibility of obtaining a high kon by optimizing the conformation of free molecules via intramolecular interactions (Fig. 7c, d). By extension, separately modulating the enthalpy of molecular binding to the receptor and entropy derived from the intramolecular structure may be important strategies for designing drugs with enhanced kinetics and dynamics.Fig. 7 a Detailed binding mode of lemborexant in complex with OX2R (receptor: light orange, ligand: cyan, PDB: 7XRR), where steric hindrance of T1353.33 only allows one orientation of the ligand. b Detailed binding mode of lemborexant in complex with OX1R (receptor: light pink, ligand: yellow, PDB: 6TOT), where small side chain of A1273.33 accounts for two orientations of the ligand. c Abridged general view of employing MD simulation to predict the conformation of the ligand before receptor binding, to improve Kon values. d 2D structure of lemborexant is shown for clarity

5-HT1F in complex with lasmiditan

The 5-HT1 receptor subtypes, including 5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E, and 5-HT1F, are well-known class A GPCRs that respond to the endogenous neurotransmitter serotonin and have been proven to be promising targets for the treatment of migraine, depression, and schizophrenia.154–156 Although traditional targeted agonists have been clinically used as anti-migraine drugs for decades, side effects such as therapeutic vasoconstrictive actions owing to the non-selective activation of 5-HT1B and 5-HT1D remain a major hindrance.157 Lasmiditan (7), a potent and highly selective drug toward 5-HT1F was approved by the FDA in 2019 because of its vasoconstrictive side effects and high-penetration properties.158 Elucidation of the scaffold features of lasmiditan and the mechanism of 5-HT1F-selective activation will provide a template for the rational design of safer anti-migraine drugs.

Through the 5-HT1F-lasmiditan-Gi1 complex solved by Huang et al., an overview of the lasmiditan-binding mode was presented.159 In the orthosteric binding pocket, the primary amine on the methylpiperidine group largely contributes to the stability of lasmiditan by forming a canonical charge interaction with Asp1033.32 of the receptor while simultaneously forming a hydrogen bond with Tyr3377.42. Notably, in the extended binding pocket (EBP), the trifluorobenzene group of lasmiditan forms additional hydrophobic interactions with Ile174ECL2 and Pro1584.60 and forms hydrogen bonds with residue Glu3136.55, Asn3176.59, Thr1825.40, and His176ECL2. Structural alignment of 5-HT1F with other 5-HT1 receptor subtypes revealed that the TM4-TM5-ECL2 region, which is highly conserved in the other four subtypes, underwent a notable conformational change, thereby disrupting the interaction between lasmiditan and 5-HT1A, 5-HT1B, 5-HT1D, and 5-HT1E. Thus, designing ligands that accommodate EBP and form specific interactions with the TM4-TM5-ECL2 region may enable high 5-HT1F selectivity (Fig. 8a, b). Activation mechanical analysis by Huang et al. revealed that lasmiditan triggers the downward movement of the toggle switch residue Trp6.48 and then induces conformational rearrangement of the PIF, DRY, and NPxxY motifs. Particularly, structural comparison of 5-HT1F-Gi complex and other 5-HT1-Gi/o showed that the αN of 5-HT1F-bound Gi shifts away from other 5-HT1 receptor-bound Gi/o, suggesting unique Gi coupling and corresponding specific downstream effects (Fig. 8c). Therefore, designing modulators that interact with the toggle switch residue and optimize their blood-brain-barrier (BBB) penetration properties may yield effective and safer 5-HT1F agonists.Fig. 8 a Detailed binding mode of 5-HT1F in complex with lasmiditan. Hydrogen bonds are presented by orange dashes, while halogen bonds are presented by green dashes. b Superimposed views of 5-HT1A (light green cartoon, PDB: 7E2X), 5-HT1B (light orange cartoon, PDB: 5V54), 5-HT1D (light gray cartoon, PDB: 7E32), 5-HT1E (light pink cartoon, PDB: 7E33), and 5-HT1F (light purple cartoon, PDB: 7EXD). The TM4-ECL2-TM5 region of the 5-HT1F receptor is highlighted for clarity. c The structure alignment comparison of αN helices of G protein coupling with their corresponding 5-HT receptors. αN helix of Gi protein coupled with 5-HT1F is highlighted for clarity. d 2D structure of lasmiditan

GnRH1 in complex with elagolix

The representative class A GPCR, gonadotropin-releasing hormone 1 receptor (GnRH1R), once activated by its endogenous peptide activator, gonadotropin-releasing hormone (GnRH), can initiate the reproductive hormone cascade and release gonadotropins through the activation of the Gq protein pathway.160–162 With the first availability of GnRH1R non-peptidic antagonist elagolix (8) on the market in 2018,163 structural insights into the GnRH1R-elagolix complex have gained pharmaceutical interest.164 Additionally, unlike other class A GPCRs, GnRH1R lacks a C-terminal helix (helix 8) in the cytoplasmic region and harbors Asn2.50 instead of the highly conserved Asp2.50 present in other receptors,165 leaving a wide space for different microswitches along the signaling cascade within 7TMD.

The crystal structure of the GnRH1R-elagolix complex studied by Yan et al. revealed that polar network residues composed of Lys1213.32 and Asp982.61 play critical roles in forming polar interactions with the ligand, whereas Tyr2836.51 and Tyr2906.58 are engaged in ligand recognition by contributing to hydrophobic interactions (Fig. 9a). Notably, Elagolix is located closer to TM7, resulting in an enlarged orthosteric pocket that allows N-terminal entry and co-occupation of the site. Structural alignment and IP accumulation assays showed that, unlike some GPCRs in which ligands can contact residue Trp6.48 directly and trigger the toggle switch, the special motif Tyr2836.51-Tyr2846.52-Trp2806.48-Phe2766.44 in TM6 was suggested to be a critical structural motif involved in mediating the propagation of signal transmission (Fig. 9b). Moreover, only 4% of class A GPCRs, including GnRH1R, have asparagine at the 5.58 position, which is implicated in a polar interaction with Ser1363.47 GnRH1R, thus leading to TM6 packing tightly with TM3 and TM5 in GnRH1R and exercising an antagonistic function. Collectively, these analyses highlight the distinctive features of GnRH1R in the binding of a representative antagonist and provide insights for structural biologists.Fig. 9 a Detailed binding mode of GnRH1 in complex with elagolix (receptor: light gray, ligand: light pink, PDB: 7BR3), where N-termini of GnRH1R is highlighted in a light purple to present its co-occupation with elagolix in the orthosteric pocket. b Overview of the special signal transduction mechanism in GnRH1R. c 2D structure of elagolix for clarity

SFSR study utilizing structural information

While the development of crystallography over the last decade has revealed an attractive possibility of SBDD, the mainstream strategy of GPCR drug discovery remains extensive SAR study and fragment-based drug design (FBDD).166–168 This is partially due to the “activity-cliff” phenomenon which to some extent, undermines the profits from structural information. Nevertheless, the promising prospect still deserves expecting. Two examples are analyzed here to arouse future interest in SFSR studies utilizing structural information.

The first example is the efficient discovery and optimization of A2AR selective antagonist 1,2,4-triazine derivative 4d (9) via SBDD strategy. With Biophysical Mapping (BPM) approach and crystal structure analysis, compound 4d was revealed to be primarily stabilized by two hydrogen bonds between the triazine core and N2536.55, with ring A oriented towards TM2 and TM7 (Fig. 10a). Hence, the presence of a hydrogen bond acceptor at the para position of ring A to interact with His2787.43, as well as the introduction of one or more flanking lipophilic substituents on the same ring to interact with Ile662.64 was suggested as the focus of the SAR program. Introducing either a phenolic hydroxyl or 4-pyridyl nitrogen at the para position of ring A, and fine-tuning affinity by various combinations of small lipophilic substituents efficiently yielded compound 4k, which proves the best balance of potency and efficacy (Fig. 10b).169 Further research compared the binding pockets of A2AR in complex with adenosine (agonist), ZM241385 (antagonist), and compound 4e (antagonist). The hydrophobic sub-pocket in the lower chamber was observed to be occupied by the ribose ring system of adenosine analogs in agonist complexes, though was typically unoccupied when antagonists bound. The same region also allowed optimization of selectivity for A2AR over A1AR (Fig. 10c). Therefore, expanding chemotypes into this region may harvest a more efficient chemical series when designing selective and diverse functional modulators.170Fig. 10 a Detailed binding mode of A2AR in complex with compound 4d (receptor: light gray, ligand: orange, PDB: 3UZA). b SAR study of A2AR antagonist. c Comparison of the orthosteric binding site of A2AR–Adenosine complex (light blue, PDB: 2YDO), A2AR–ZM241385 complex (light yellow, PDB: 4EIY), A2AR–Compound 4e complex (light green, PDB: 3UZC), the difference in cavity occupation is highlighted by red circles and arrows

The second paradigm entails the structure-based drug design of novel β-arrestin-biased D2R agonists commencing with aripiprazole, so as to alleviate the movement disorders associated with the adverse effects of antipsychotics.171 The dichlorophenylpiperazine portion of aripiprazole was first replaced with an indolepiperazine, leading to 12 that displayed comparable activity in both Gi/o-mediated cAMP inhibition and β-arrestin2 recruitment assays. Molecular docking with a D2R homology model revealed that the indole NH of 12 formed a hydrogen bond with Ser5.42, which has been shown to mediate G-protein-dependent signaling in highly homologous β2 adrenergic receptors. A methyl group was thus attached to the NH of indole to fine-tune the binding conformation of 12 and thereby preclude TM5 engagement (Fig. 11a). Inspired by structural information from homologous 5-HT2B receptor, where ligand interactions with hydrophobic residues on ECL2 appear to promote β-arrestin recruitment (Fig. 11a), a second methyl was introduced to position 2 of the indole ring, yielding 13 with a β-arrestin bias factor of 20 and potentially reduced side effects (Fig. 11b).172 To our knowledge, this is the first successful attempt at using structural information for the rational design of GPCR-biased ligands, underlining the necessity of interactive structural comparison in SFSR study.Fig. 11 a Detailed binding mode of D2R in complex with compound 1 (12) (receptor: light gray, ligand: salmon, the receptor is modeled from PDB: 3PBL). TM5 of the receptor is colored in pink and ECL2 is colored in blue for clarity. b SAR study of β-arrestin biased agonists of D2R

Delineation of GPCR structures complexed with small-molecule allosteric modulators and allosteric signaling

Over the past 10 years, allosteric drug discovery targeting GPCRs has witnessed significant progress in structural understanding, with the advance in knowledge of GPCR allostery.173,174 Till February 2024, the crystal structures of 59 allosteric small-molecule modulators bound to GPCRs have been solved, including 33 class A, 7 class B, 18 class C, and 1 class F modulators. These structures reveal that despite the intrinsic dynamic nature of GPCRs and the structural diversity among different GPCRs, only limited locations function as allosteric pockets, and the same pockets are present in GPCRs with different homologies.175 Even within a single receptor, more than one allosteric site has been identified. In addition, druggable allosteric hotspots spread throughout the receptor and can be divided into the following sections: extracellular vestibule, transmembrane domain, intracellular surface, outside 7TMD, and inside 7TMD domains.174,175 As will be discussed, allosteric binding sites in all GPCRs are currently known to be located at 11 distinct locations with some consensus,176 depicted in Fig. 12. In this figure, the locations of all pockets identified in different GPCRs are mapped onto the structure of an example GPCR to facilitate the comparison of these sites.Fig. 12 11 allosteric binding sites reported across GPCRs mapped onto representative class A GPCR CB1R. Gray pockets represent binding pockets within 7TMD, and white pockets represent binding pockets outside 7TMD. For each pocket, the number of unique ligands is indicated using boldface type, and the number of GPCRs containing the pocket is provided in parentheses. The boundary of the lipid bilayer is indicated by gray dashes

Based on the compounds’ ability to affect the stimulatory activity of orthosteric ligands, allosteric ligands can be classified into several categories, including positive allosteric modulators (PAMs), negative allosteric modulators (NAMs), allosteric modulators, and allosteric inverse agonists.22,177 A PAM, such as cinacalcet, targets the calcium-sensing receptor (CaSR) and potentiates the response of the receptor to its orthosteric agonist. Conversely, NAM attenuates the response of the receptor to its orthosteric agonist, mavoglurant, which targets the metabotropic glutamate receptor 5 (mGluR5).178 Ago allosteric modulators can activate or inhibit a receptor without an orthosteric agonist such as compound 2, which targets the glucagon-like peptide-1 receptor (GLP-1R).

Targeting of GPCR extracellular vestibule (outside and inside 7TMD)

After the first FDA approval of cinacalcet (a PAM of CaSR) in 2004 as a treatment for hyperparathyroidism,179 small-molecule allosteric modulators bound to the extracellular vestibule have developed rapidly. Till date, four of these modulators have been approved by the FDA, and one has entered clinical trials, as summarized in Table 1. Resolved crystal structures have revealed three extracellular binding sites: the pocket outside helices I and II, the pocket outside helices II and III, and the pocket inside 7TMD (Fig. 13).180,181 Due to their proximity to the traditional active sites of class A and B GPCRs, such allosteric modulators may exert their effects by directly altering the binding of orthosteric ligands to the receptor. As GPCRs evolved from a common ancestor, this allosteric site, found on receptors, may represent the ancestral orthosteric site.176,182Table 1 Solved GPCR structures complexed with synthetic allosteric modulators bound to the extracellular vestibule

Structure Type	GPCR Type	GPCR	Modulator	Highest Phase	Modulator type	Number	PDB code	Allosteric site	Refs	
Cryo-EM	Class B	GLP-1R	LSN3160440	Pre-clinical	PAM	(14)	6VCB	outside 7TMD (I-II)	180	
Cryo-EM	class A	GPR101	AA-14	Pre-clinical	Allosteric agonist	(15)	8W8S	outside 7TMD (II-III)	201	
X-ray diffraction	Class A	CCR5	maraviroc	Approved	Allosteric inverse agonist	(16)	4MBS	inside 7TMD	181	
X-ray diffraction	Class A	PAR2	AZ8838	Pre-clinical	Allosteric antagonist	(17)	5NDD	inside 7TMD	451	
X-ray diffraction	Class A	GPR52	c17	Pre-clinical	Allosteric agonist	(18)	6LI0	inside 7TMD	452	
Cryo-EM	Class A	LHCGR	Org43553	Pre-clinical	Allosteric agonist	(19)	7FIH	inside 7TMD	453	
X-ray diffraction	Class A	M2R	LY2119620	Pre-clinical	PAM	(20)	4MQT	inside 7TMD	216	
Cryo-EM	Class A	M4R	LY2119620	Pre-clinical	PAM	(20)	7V68	inside 7TMD	217	
Cryo-EM	Class A	M4R	compound-110	Pre-clinical	Allosteric agonist	(21)	7V6A	inside 7TMD	217	
Cryo-EM	Class A	M4R	LY2033298	Pre-clinical	PAM	(22)	7TRP	inside 7TMD	454	
Cryo-EM	Class A	M4R	VU0467154	Pre-clinical	PAM	(23)	7TRQ	inside 7TMD	454	
Cryo-EM	Class A	TSHR	ML109	Pre-clinical	Allosteric agonist	(24)	7XW6	inside 7TMD	455	
Cryo-EM	Class A	MRGPRX1	ML382	Pre-clinical	PAM	(25)	8DWG	inside 7TMD	456	
X-ray diffraction	Class C	mGluR1	FITM	Pre-clinical	NAM	(26)	4OR2	inside 7TMD	457	
Cryo-EM	Class C	CaSR	cinacalcet	Approved	PAM	(27)	7M3F	inside 7TMD	230	
Cryo-EM	Class C	CaSR	evocalcet	Approved	PAM	(28)	7M3G	inside 7TMD	230	
Cryo-EM	Class C	CaSR	NPS-2143	Pre-clinical	NAM	(29)	7DD5	inside 7TMD	458	
Cryo-EM	Class C	CaSR	R-568	Pre-clinical	PAM	(30)	7SIL	inside 7TMD	459	
Cryo-EM	Class C	mGluR2	JNJ-40411813	Phase 2	PAM	(31)	7E9G	inside 7TMD	460	
X-ray diffraction	Class C	mGluR2	NAM563	Pre-clinical	NAM	(32)	7EPE	inside 7TMD	461	
X-ray diffraction	Class C	mGluR2	NAM597	Pre-clinical	NAM	(33)	7EPF	inside 7TMD	461	
X-ray diffraction	Class F	SMO	vismodegib	Approved	Allosteric antagonist	(34)	5L7I	inside 7TMD	462	

Fig. 13 Three extracellular allosteric binding sites in GPCRs and the corresponding small-molecule allosteric modulators. Stick models of small-molecule ligands are mapped to representative members of outside 7TMD (I and II) (GLP-1R, PDB: 6VCB), outside 7TMD (II and III) (GPR101, PDB: 8W8S), and within 7TMD (M4R, PDB: 7V68) GPCRs. The position of an orthosteric ligand of M4R (shown in gray and sphere-and-stick representation) is mapped onto the overview of allosteric modulators for comparison. For each pocket, the number of unique modulators is indicated in boldface type, and the number of GPCRs containing the pocket is indicated in parentheses

1) Outside 7TMD (TM I-II):

GLP-1R–LSN3160440 structure

The glucagon-like peptide-1 receptor (GLP-1R) is a peptide hormone class B GPCR whose activation stimulates the glucose-dependent stimulation of insulin and decreases glucagon secretion.183–185 For such peptide receptors, allosteric pockets on GPCRs may be easier to target for small-molecule drugs than orthosteric drugs.186 Therefore, highly potent agonists and PAMs of GLP-1R must be developed to treat type 2 diabetes.187–191

LSN3160440 (14) (Fig. 14) is a small-molecule PAM targeted GLP-1R with an EC50 of 1 μM to enhance the potency and efficacy of GLP-1(9-36) becoming a full agonist.180 The cryo-EM structure of GLP-1R in complex with LSN3160440, the orthosteric ligand GLP-1, and the Gs protein revealed a clear depiction of the U-shaped binding mode of LSN3160440. The allosteric site is formed by residues on helices I and II in the extracellular vestibule (Fig. 15a).180 Within the binding pocket, the benzimidazole moiety of LSN3160440 (Fig. 15c) formed hydrophobic contacts with Leu1421.37 (the superscript represents the generic residue numbers of GPCRs) and engaged in aromatic interactions with Tyr1451.40 (Fig. 15b). Mutation and molecular dynamics (MD) simulation results also suggest that water-mediated hydrogen bonds may form between N3 of benzimidazole and Lys2022.72.192,193 Notably, LSN3160440 interacts with GLP-1 and acts as a molecular glue.194 The 2,6-dichloro-3-methoxyl phenyl moiety of LSN3160440 forms van der Waals interactions with Phe12GLP-1, Val16GLP-1 and Leu20GLP-1 simultaneously.Fig. 14 Two-dimensional (2D) chemical structures of synthetic allosteric ligands targeting the GPCR extracellular vestibule

Fig. 15 a Schematic representation of PAM LSN3160440 and orthosteric GLP-1 bound to GLP-1R (PDB: 6VCB). GLP-1 is indicated in pink. b Detailed binding modes of GLP-1R bound to LSN3160440; π–π stacking is indicated in gray dashes. c 2D structure of small-molecule allosteric ligand LSN3160440 presented for clarity. d Superposition of orthosteric small-molecule agonists Boc5 (displayed with purple sticks), TT-OAD2 (displayed with salmon sticks), LY3502970 (displayed with yellow sticks), and CHU-128 (displayed with blue sticks) to LSN3160440–GLP-1–GLP-1R structure reveals a partial overlap in the TM1-TM2 cleft. The conserved residue Tyr1451.40 is highlighted

Several structures of orthosteric small-molecule agonists complexed with GLP-1R were resolved (Fig. 15d).195–198 Structural comparisons of these ligands with LSN3160440 revealed a shared region situated at the extracellular termini of the TM1-TM2 cleft, further suggesting that this is a promising area for lead optimization for both orthosteric and allosteric agonists. Within the binding site, the aromatic interactions with Tyr1451.40 are conserved.

2) Outside 7TMD (TM I-II)

GPR101–AA-14 structure

GPR101 is an orphan class A GPCR that is highly expressed in the nucleus accumbens and the hypothalamus and has constitutive Gs and Gq activity.199 GPR101 gene duplication or mutation modulates its constitutive activity, rendering GPR101 a promising target for metabolic diseases.200 Recent studies have identified AA-14 (15) (Fig. 14) as an allosteric agonist of GPR101, demonstrating robust Gs activation activity and high subtype selectivity.201 In vivo studies have shown that AA-14 exerts rejuvenating effects by activating GPR101 in the pituitary.

The cryo-EM structure of the AA-14–GPR101–Gs complex unveils two distinct binding sites for AA-14 (Fig. 16a): one located outside 7TMD, surrounded by helices I, VI, and VII, while the other is positioned outside TM2–TM3 and ECL1.201 Within the extracellular allosteric site, the 3-(trifluoromethyl) phenyl group (Fig. 16c) establishes polar interactions with Asn100ECL1 and hydrophobic interactions with Phe1033.24 and Trp872.60 (Fig. 16b). The 4-methyl-2-pyridinyl group packs against Phe96ECL1 and Leu99ECL1.Fig. 16 a Schematic representation of allosteric agonist AA-14 bound to GPR101 (PDB: 6VCB). b Detailed binding modes of GPR101 bound to AA-14. c 2D structure of small-molecule allosteric ligand AA-14 presented for clarity

3) Inside 7TMD:

GPR52–c17, MRGPRX1–ML382, PAR2–AZ8838, LHCGR–Org43553, M2R–LY2119620, M4R–LY2119620, M4R–compound-110, TSHR–ML109, CaSR–cinacalcet, CaSR–evocalcet, CaSR–NPS-2143, CaSR–R-568, mGluR1–FITM, SMO–vismodegib, mGluR2–JNJ-40411813, mGluR2–NAM563, mGluR2–NAM597, and CCR5–maraviroc structures

This allosteric site is located in an extracellular pocket surrounded by a 7TM helical bundle, directly above the traditional orthosteric site of family A and B GPCRs and the cholesterol-binding site of the SMO receptor (Fig. 13).202,203 Until now, this allosteric site has been the most frequently targeted binding site for drug-like allosteric modulators, mainly because allosteric modulators can enter from the extracellular region, allowing ligand binding without the need to penetrate the membrane.204 For these receptors, the pocket in the extracellular vestibule can be partitioned into two subpockets, namely the orthosteric and allosteric pockets. The N-terminal group and ECL2 regulate the sizes of the two sub-pockets by pushing the ligand to one side,205–207 thereby contributing to the creation of a new ligand pocket.

As prototypical class A GPCRs, muscarinic M1–M5 acetylcholine receptors (mAChRs) are responsible for the release of acetylcholine into the brain and play fundamental roles in the central and peripheral nervous system.208–210 Muscarinic receptors have garnered attention as potential drug targets to treat several pathophysiological disorders including Alzheimer’s disease, schizophrenia, and drug addiction.211–214 LY2119620 (20) acts as a PAM that has activity at both the M2 and M4 receptors (Fig. 14) but is inappropriate for treatment, probably because of cross-reactivity and cardiovascular liability.215

The structures of the M2 and M4 receptors bound to PAM LY2119620 have been solved.216–218 LY2119620 demonstrated a similar binding pattern to both the M2 and M4 receptors; nonetheless, subtle differences were noted (Fig. 17a). LY2119620 binds to a spacious extracellular vestibule just above the orthosteric pocket and is segregated from the orthosteric pocket via three tyrosine residues: Tyr3.33, Tyr6.51, and Tyr7.39. The thienopyridine ring of LY2119620 is sandwiched by π–π stacking between Tyr177ECL2 and Trp4227.35 in M2 receptor (Fig. 17b), Phe186ECL2 and Trp4357.35 in M4 receptor (Fig. 17c). Particularly, in the M2 receptor, the residues Tyr802.61, Asn4106.58, and Asn419ECL3 formed hydrogen bonds with the modulator, and Glu172ECL2 participated in ionic interactions with piperidine. Contrarily, in the M4 receptor, only Gln427ECL3 formed a hydrogen bond with the modulator.Fig. 17 a Superposition of PAM LY2119620 bound to M2 receptor (pink cartoon, pink sticks; PDB: 4MQT) and M4 receptor (yellow cartoon, yellow sticks; PDB: 7V68). b Detailed binding modes of M2 receptor bound to LY2119620. c Detailed binding modes of M4 receptor bound to LY2119620. Hydrogen bonds are presented as orange dashes and π–π stacking is presented as gray dashes. d Superimposed views of highlighted residue Trp4227.36 on M2 receptor–iperoxo–LY2119620 (pink cartoon, pink sticks; PDB: 6U1N), M2 receptor–LY2119620 (purple cartoon, purple sticks; PDB: 4MQT), and M2 receptor–iperoxo (blue cartoon, blue sticks; PDB: 4MQS) structures. The orthosteric agonist iperoxo is presented in orange

In addition, the structures of M2 receptor–iperoxo–LY2119620 (PDB: 4MQT) and M2 receptor–LY2119620 (PDB: 6U1N) are highly similar, with Trp4227.35 perpendicular to the horizontal plane and forming a π–π stacking with LY2119620 (Fig. 17d). In contrast, Trp4227.35 of the M2 receptor–iperoxo (PDB:4MQS), exhibits a parallel conformation, suggesting that the allosteric binding site is formed predominantly in the presence of an allosteric modulator. MD simulations have revealed that LY2119620 modulates the conformation of Trp4227.35, causing reorientation of Tyr4267.39 within the orthosteric site.219 This reorientation may explain the observed increase in affinity for iperoxo, thereby providing insight into the underlying allosteric mechanism.220

For GPCRs that use other sites to bind endogenous ligands, the traditional orthosteric pocket is potentially druggable for allosteric modulators.221 Calcium-sensing receptors (CaSR), members of the family C GPCR, are found primarily in the parathyroid glands and kidneys to ensure strict control of calcium homeostasis.222,223 Elevated Ca2+ levels trigger the activation of CaSR, leading to the inhibition of parathyroid hormone (PTH) secretion. Thus, CaSR has become a potential target for calcimimetic drugs to treat parathyroid disorders.224–226 Cinacalcet (27) (Fig. 14), an orally active allosteric agonist of CaSR, has been used for the treatment of secondary hyperparathyroidism227,228 whereas calcilytic NPS-2143 (29) (Fig. 14) is a potent NAM-targeting CaSR that exhibits favorable in vitro and in vivo activity.229

When bound to CaSR, PAM cinacalcet adopted extended and bent poses between CaSR homodimers (Fig. 18a). The naphthylethylamine moiety was bound to highly similar poses in both the extended and bent conformations (Fig. 18b, c). The naphthyl group engaged in hydrophobic interactions with Ile7775.44 on one side and formed edge-to-face π–π interactions with Phe6843.36 and Trp8186.50 on the other, thereby effectively securing the side chain of Trp8186.50 inside 7TM helical bundle. The NH group formed a hydrogen bond with Gln6813.33. In the extended conformation (Fig. 18b), the linker and phenyl group were parallel to TM VI, extending upward and driving Tyr8256.57 to orient downward. In the bent conformation (Fig. 18c), the phenyl group folded between TM V and TM VI to form a parallel-displaced π–π stacking with the naphthyl group, whereas Tyr8256.57 assumed a conformation perpendicular to TM VI and stabilized the ligand through a σ–π interaction.Fig. 18 a Schematic representation of PAM cinacalcet bound to CaSR (PDB: 7M3F). b Detailed binding modes of CaSR bound to cinacalcet in extended conformations. c Detailed binding modes of CaSR bound to cinacalcet in bent conformations. Hydrogen bonds are presented as orange dashes and π–π stackings are presented as gray dashes

In the CaSR–NPS-2143 complex, NPS-2143 exhibited the same crescent conformation as the homodimers (Fig. 19a). The naphthyl group at one end of NPS-2143 (Fig. 19c) was lined by residues Phe6843.36, Leu7765.43, Ile7775.44, Trp8186.50, and Ile8417.37 in the interior of the pocket (Fig. 19b). Conversely, the 3-chloro-2-cyano-phenyl ring of NPS-2143 protrudes out toward the lateral opening and forms hydrophobic contacts with Leu7735.40 and π–π stacking interactions with Tyr8256.57. A single hydrogen bond was established between the hydroxyl group and Tyr8256.57. Moreover, the conformation of the NAM-bound CaSR agrees well under both active (in the presence of Ca2+ and L-Trp) and inactive (no Ca2+) conditions.Fig. 19 a Schematic representation of NAM NPS-2143 bound to CaSR (PDB: 7M3E). b Detailed binding modes of CaSR bound to NPS-2143. Hydrogen bond is presented as orange dashes and π–π stacking is presented as gray dashes. c 2D structure of small-molecule allosteric ligand NPS-2143 provided for clarity. d Superimposed views of highlighted residues on CaSR–Cinacalcet–Ca2+–Trp (blue cartoon, blue sticks; PDB: 7M3F), CaSR–Ca2+–Trp (pink cartoon, pink sticks; PDB: 7DD6), and CaSR–NPS-2143–Ca2+–Trp (purple cartoon, purple sticks; PDB: 7M3E) structures. e Workflow of discovery of novel CaSR PAMs utilizing structural information

Despite having highly similar binding sites, NPS-2143 and cinacalcet exhibit quite different pharmacological properties, which may be explained by the conformation of the receptor residues. The conformations of NPS-2143-bound and Ca2+-bound CaSR were similar.230 Nevertheless, cinacalcet binding induced significant conformational changes in Trp8186.50, Phe8216.53, and Tyr8256.57 within the allosteric pocket (Fig. 19d). Trp8186.50 rotates inwardly from a vertical to a horizontal conformation, forming extensive π–π interactions with cinacalcet. Phe8216.53 underwent an outward shift and was inserted into a crevice between TM6 and TM7 facing the dimer interfacial area. Simultaneously, Tyr8256.57 flips down, driven by structural conflicts in the extended conformation of cinacalcet. In summary, cinacalcet induces a bent conformation of TM6 and stabilizes the homodimer interface, thereby contributing to receptor activation.231 Contrarily, NPS-2143 decreased agonist efficacy by enhancing TM VI helicity, which spatially hindered receptor activation.

Based on the special binding conformations of cinacalcet, Liu et al. conducted a virtual screening of 1.2 billion compounds to discover novel PAMs with potentially novel pharmacology. To respectively mimic the “extended” and “bent” conformation, extensive orientations and conformations of library molecules were sampled, which gave 682 trillion configurations overall and finally achieved a 3.8% and 13.6% hit rate. The hits were then optimized to a pharmacologically potent lead (36) via synergistic application of structural information, fragment hybridization, and stereochemistry separation (Fig. 19e).232 Such practice serves as a paradigm for its elaborate utility of solved GPCR structures and conformation sampling strategy and is generalizable in the discovery of CaSR NAMs and other allosteric modulators.

Targeting of GPCR transmembrane domain (outside 7TMD)

As shown by their structures, GPCRs utilize the domain outside 7TMD at the lipid interface to bind allosteric modulators. Till date, five different binding sites outside 7TMD in the transmembrane domain have been defined by their crystal structures (Table 2): the pocket outside helices I–III, the pocket outside helices II–IV, the pocket outside helices III–V, the pocket outside helices V–VI, and the pocket outside helices I, VI, and VII (Fig. 20a, c). Allosteric modulator binding to these regions targets class A GPCRs. These sites are typically shallow and not as well surrounded by the 7TM helical bundle as the traditional orthosteric sites. Polar functional groups are commonly found in allosteric modulators at these sites where they anchor themselves to the pocket. Thus, hydrogen atom donor or acceptor groups exposed between the receptor and lipid bilayer are more likely to mediate the binding of such allosteric ligands. These modulators are also required to preserve their overall hydrophobic character to enter the transmembrane domain. Allosteric modulators bound to the transmembrane domain outside 7TMD appear to regulate receptor signal transduction from outside the 7TM helices in a manner that stabilizes inactive or active interaction networks or impedes or facilitates the interhelical motions required for receptor activation.233–235Table 2 Solved GPCR structures complexed with synthetic allosteric modulators bound to the transmembrane domain outside 7TMD

Structure Type	GPCR type	GPCR	Modulator	Highest Phase	Modulator type	Number	PDB code	Allosteric site	Refs	
X-ray diffraction	class A	P2Y1	BPTU	Pre-clinical	Allosteric antagonist	(37)	4XNV	outside 7TMD (I–III)	242	
X-ray diffraction	class A	PAR2	AZ3451	Pre-clinical	Allosteric antagonist	(38)	5NDZ	outside 7TMD (II–IV)	451	
X-ray diffraction	class A	CB1R	ORG27569	Pre-clinical	NAM	(39)	6KQI	outside 7TMD (II–IV)	257	
X-ray diffraction	class A	CB1R	ZCZ011	Pre-clinical	PAM	(40)	7FEE	outside 7TMD (II–IV)	261	
X-ray diffraction	class A	GPR40	compound 1	Pre-clinical	Allosteric agonist	(41)	5KW2	outside 7TMD (III–V)	463	
X-ray diffraction	class A	GPR40	AP8	Pre-clinical	AgoPAM	(42)	5TZY	outside 7TMD (III–V)	464	
X-ray diffraction	class A	β2AR	Cmpd-6FA	Pre-clinical	PAM	(43)	6N48	outside 7TMD (III–V)	269	
X-ray diffraction	class A	β2AR	AS408	Pre-clinical	NAM	(44)	6OBA	outside 7TMD (III–V)	465	
X-ray diffraction	class A	C5aR1	NDT9513727	Pre-clinical	Allosteric inverse agonist	(45)	5O9H	outside 7TMD (III–V)	466	
X-ray diffraction	class A	C5aR1	avacopan	Approved	Allosteric antagonist	(46)	6C1R	outside 7TMD (III–V)	467	
Cryo-EM	class A	DRD1	LY3154207	Phase 2	PAM	(47)	7CKZ	outside 7TMD (III–V)	277	
Cryo-EM	class A	CXCR3	SCH546738	Pre-clinical	Allosteric antagonist	(48)	8HNN	outside 7TMD (V–VI)	299	
Cryo-EM	class A	A1R	MIPS521	Pre-clinical	PAM	(49)	7LD3	outside 7TMD (I, VI, VII)	305	
Cryo-EM	class A	GPR101	AA-14	Pre-clinical	Allosteric agonist	(15)	8W8S	outside 7TMD (I, VI, VII)	201	
Cryo-EM	class C	mGlu4	VU0364770	Pre-clinical	PAM	(50)	8JD5	outside 7TMD (I, VI, VII)	468	
Cryo-EM	class C	mGlu4	ADX88178	Pre-clinical	PAM	(51)	8JD6	outside 7TMD (I, VI, VII)	468	

Fig. 20 a Five allosteric binding sites in the transmembrane domain outside 7TMD of GPCRs and the corresponding small-molecule allosteric modulators. Stick models of small-molecule ligands are mapped to representative members of outside 7TMD (I–III) (P2Y1, PDB: 4XNV), outside 7TMD (II–IV) (CB1R, PDB: 6KQI), outside 7TMD (III and V) (C5aR1, PDB: 6C1R), outside 7TMD (V and VI) (CXCR3, PDB: 8HNN), and outside 7TMD (I, VI, and VII) (A1R, PDB: 7LD3) GPCRs. For each pocket, the number of unique modulators is indicated in boldface type, and the number of GPCRs containing the pocket is provided in parentheses. b 2D chemical structures of synthetic small-molecule allosteric ligands targeting the transmembrane domain outside 7TMD of GPCRs. c Extracellular view of the five allosteric sites

1) TM I–III:

P2Y 1 –BPTU Structure

To the best of our knowledge, one small molecule allosterically targets this relatively shallow pocket. Because of the flat TM helical bundle surface and relatively narrow cavity of the binding pocket, rational drug design in this area may be challenging.

In this instance, the protein target was the P2Y1 purinergic receptor. Agonists induce the activation of the P2Y1 receptor, leading to the potentiation of platelet aggregation that triggers platelet secretion;236,237 thus, antagonists targeting the P2Y1 receptor offer a prospective approach to treat thrombosis.238,239 BPTU (37) (Fig. 20b), a P2Y1 antagonist, has been gaining attention as an antithrombotic treatment and is the first allosteric GPCR modulator located outside the helical bundle.240 BPTU blocks the P2Y1-induced platelet aggregation with nanomolar potency and presents good selectivity for P2Y1 receptor and highly homologous P2Y12 receptor (P2Y1Ki = 75 nM, P2Y12Ki > 70 μM).241

The binary complex structure of P2Y1 − BPTU was determined and showed that the BPTU binding pocket consists mainly of residues in helices I − III (Fig. 21a).242 Notably, two crucial hydrogen bonds were formed between the two NH moieties of the urea group of BPTU and the main-chain carboxyl group of Leu1022.55 (Fig. 21b). In terms of hydrophobic interactions, the BPTU pyridyl group makes contact with the residues Ala1062.59 and Phe119ECL1. Hydrophobic interactions of the tert-butyl phenyl group occur within a distinct subpocket shaped by helices II and III, including residues Leu1022.55, Thr1032.56, Met1233.24, Leu1263.27, and Gln1273.28. On the opposite side of the ligand, the trifluoromethoxyphenyl group participated in hydrophobic interactions with Phe621.43 and Phe661.47.Fig. 21 a Schematic representation of the allosteric antagonist BPTU bound to P2Y1 receptor (PDB code 4XNV). b Detailed binding modes of P2Y1 receptor bound to BPTU. Hydrogen bonds are presented as orange dashes. c Superimposed views of the highlighted residues on 2MeSADP − P2Y1R − G11 (pink cartoon, pink sticks; PDB: 7XXH) and P2Y1R − BPTU structures (blue cartoon, blue sticks; PDB: 4XNV)

This case suggests an effective shape-complementary mechanism for allosteric ligands: bulges on 7TM helices can be utilized as anchors for fixation. In this instance, Pro1052.58 serves as the corresponding anchor, which is conserved in 74% of non-olfactory class A GPCRs.243 A comparison between the P2Y1 receptor bound to the agonist 2MeSADP and the allosteric antagonist BPTU revealed that the BPTU induces a 1.4 Å shift in Tyr1002.53 toward TM3 (Fig. 21c), preventing the conformational change of Phe1313.32.244 Thus, Phe1313.32 interacts with Phe2766.51 and limits the TM6 transition, which is required for the activation of class A GPCRs.245 In addition, MD simulations have demonstrated that the binding of BPTU stabilizes the helical bundle, leading to an increase in lipid order.246 This, in turn, stabilizes the ionic lock formed between Lys461.46 and Arg195ECL2 in the inactive receptor.

2) TM II−IV:

CB1R−ORG27569, CB1R − ZCZ011, and PAR2 − AZ3451 Structures

Cannabinoid receptors, which consist of two subtypes, CB1R and CB2R, are activated by neurotransmitter endocannabinoids and play key modulatory roles in synaptic transmission.247,248 Among them is the most abundant GPCR in the human brain is CB1R.249 Because of its widespread distribution and regulatory roles in various physiological functions, CB1R is considered an important target for the treatment of various central nervous system (CNS) disorders.250–253

ORG27569 (39) (Fig. 20b) is the first and most comprehensively studied NAM of CB1R.254,255 However, when tested in vivo, Org27569 was not sufficiently effective in modulating the effects of orthosteric cannabinoids.256 The co-crystal structure of CB1R and NAM ORG27569, together with its orthosteric CP55940 agonist, has been solved.257 ORG27569 occupied an allosteric site outside helices II and IV in the inner lobe of the phospholipid bilayer (Fig. 22a).258 Specifically, the chloro-indole ring of ORG27569 establishes a key aromatic interaction with the indole group of Trp2414.50 and buries in a hydrophobic pocket surrounded by His1542.41 and Val1612.48. Cys2384.47, Trp2414.50, Thr2424.51, and Ile2454.54 supply hydrophobic interactions for the amide-linked piperidinylphenyl chain (Fig. 22b).Fig. 22 a Superposition of the cocrystal structures of NAM ORG27569 (yellow, PDB: 6KQI) and PAM ZCZ011 (pink, PDB: 7FEE) with orthosteric ligand-bound CB1R. b Detailed binding modes of CB1R binding to ORG27569. c Detailed binding modes of CB1R binding to ZCZ011. Hydrogen bond is presented as orange dashes, and π–π stacking is presented as gray dashes. d Superimposed views of highlighted residues on CB1R–CP55940–ORG27569 (pink cartoon, pink sticks; PDB: 6KQI) and CB1R–AMG315–Gi structures (blue cartoon, blue sticks; PDB: 8GHV). e Superimposed views of highlighted residues on CB1R–AM6538 (pink cartoon, pink sticks; PDB: 5TGZ) and CB1R-CP55940–ZCZ011 structures (blue cartoon, blue sticks; PDB: 7FEE)

The recently developed ZCZ011 (Fig. 20b) is also an indole derivative that exerts PAM and partial agonist effects in vivo assays.259,260 ZCZ011 showed good shape complementarity with the pocket outside 7TMD comprising helices II−IV (Fig. 22a). The indole group in ZCZ011 is anchored by Phe1913.27 and forms a hydrogen bond with the main chain of Phe1913.27 while forming π−π stacking interactions with the side chain. (Fig. 22c).261 In addition, the indole group interacted with Leu1652.52, Ile1692.56, Ile2454.54, and Val2494.58 from TM II and TM IV, respectively.

NAM ORG27569 and AZ3451 (38), as well as PAM ZCZ011, bind to the same TM II−IV surface, however, exert opposite allosteric effects.262 Unlike traditional NAMs, ORG27569 enhances the affinity of the agonist though reduces the activity of Gi turnover.263 Structurally, the inactivating efficacy of ORG27569 acts by stabilizing the “activation switch” formed by Phe1552.42 and Phe2374.46 in CB1R (Fig. 22d).264,265 Furthermore, a hydrogen bond was formed between ORG27569 and Trp2414.50, which, together with the hydrogen bond formed between Trp2414.50, Ser1582.45, and Ser2063.42 (Fig. 22b), created a polar network that contributed to maintaining the inactive conformation.266 However, the precise mechanism through which ORG27569 augments agonist affinity remains to be elucidated. Upon comparing the CB1 structures bound to the PAM ZCZ011 and the antagonist AM6538, a notable shift of Ile1692.56 in TM2 towards TM3 was observed. This shift results in the contraction of the receptor“s active site (Fig. 22e), and is believed to be associated with activation.267,268 Additionally, Ser1732.60 undergoes notable inward movement and forms a hydrogen bond with CP55940, thereby stabilizing the agonist binding.

3) TM III–V:

GPR40–compound 1, GPR40–AP8, β2AR–AS408, β2AR–Cmpd-6FA, C5aR1–NDT9513727, C5aR1–avacopan, and DRD1–LY3154207 structures

A deep pocket is present outside the transmembrane helices III–V among GPCRs, which allows for the presence of a population of allosteric regulators bound to this pocket. In this case, allosteric agonists and PAMs (i.e., compound 1 (41), AP8 (42), Cmpd-6FA (43), and LY3154207 (47)) localize to regions near ICL2 and stabilize the ICL2 α helix through direct interactions, facilitating the inward movement of ProICL2. This movement leads to a ~3° inward displacement of TM III, which in turn determines the outward shift of TM V together with TM VI, which is a hallmark of GPCR activation.269,270 Thus, the binding of allosteric modulators increases the proportion of receptors that adopt active conformations, thereby increasing their affinity for agonists. Contrarily, allosteric antagonists and NAMs (i.e., AS408 (44), NDT9513727 (45), and avacopan (46)) bind to regions far from ICL2. As these ligands are bound close to the proline kink of TM V, the receptor-ligand interactions collectively inhibit the interhelical movements and rotations within TM III, TM IV, and TM V, which are required for receptor activation.271

The dopamine D1 receptor is a prototypical example. Dopamine functions as an essential catecholamine neurotransmitter that signals via the dopamine D1 to D5 receptors.272,273 The dopamine D1 receptor (DRD1) regulates neuronal growth, memory, and learning in the central nervous system.274,275 LY3154207 (Fig. 20b) is a selective PAM of the dopamine D1 receptor that improved motor symptoms associated with Lewy body dementia in a 2022 phase 2 clinical trial.276 Two distinct binding modes of LY3154207 to DRD1 have been reported, and structural comparisons have demonstrated upright and boat conformations (Fig. 23a).277–280 In both binding modes, LY3154207 was localized at the receptor–lipid bilayer interface surrounded by TM III, TM IV, and ICL2.Fig. 23 a Superposition of the cocrystal structures of PAM LY3154207 bound to dopamine D1 receptor in upright (pink, PDB: 7CKZ) and boat (yellow, PDB: 7LJC and 7X2F) conformations. b Detailed binding modes of dopamine D1 receptor binding to LY3154207 in upright conformations. c Detailed binding modes of dopamine D1 receptor binding to LY3154207 in boat conformations. Hydrogen bonds are presented as orange dashes; π–π stacking and π–cation stacking interactions are presented as gray dashes

In the upright conformation, the tertiary alcohol group of LY3154207 extends toward TM III, establishing a single hydrogen bond with Cys1153.44 (Fig. 23b). The central tetrahydroisoquinoline ring of LY3154207 engages in extensive hydrophobic interactions with Val1193.48, Trp1233.52, and Leu1434.45. Additionally, the dichlorophenyl group forms a π-cation interaction with the side chain of Arg130ICL2. In the boat conformation, the dichlorophenyl group participates in π–cation interactions with the side chains of Arg130ICL2, and interacts sandwich-like π–π stacking with Trp1233.52 (Fig. 23c). The tetrahydroisoquinoline ring of LY3154207 established hydrophobic interactions with neighboring residues, including Met135ICL2, Ala1394.41, Ile1424.44, Leu1434.45, and the alkyl chain of Lys134ICL2. In addition, two hydrogen bonds were observed between LY3154207 and the polar residues Arg130ICL2 and Lys1384.40.

Superposition of the D1R–LY3154207–dopamine and D1R–dopamine structures showed near-identical binding positions for dopamine and the surrounding residues. Instead, LY3154207 interacted with Arg130ICL2 and Lys134ICL2 and stabilized ICL2, which interacts directly with G-proteins, thereby increasing the population of D1R adopting active conformations (Fig. 23b, c).279

Another example of an allosteric modulator that binds outside 7TMD formed by helices III–V is the allosteric antagonist avacopan of C5a receptor 1. Human C5a receptor 1 (C5aR1), which binds to the pro-inflammatory mediator C5a, is primarily expressed on the surfaces of various immune cells, such as neutrophils, eosinophils, and dendritic cells.281,282 Overactivation of the C5aR1-C5a axis will cause uncontrolled inflammation;283 thus, C5aR1 antagonists are ideal candidates for treating various inflammatory conditions, including sepsis COVID-19, etc.284–286

Avacopan (Fig. 20b) is an orally administered allosteric antagonist of C5aR1 approved by the FDA in 2021 to treat severe autoantibody (ANCA)-ANCA-associated vasculitis (granulomatosis with polyangiitis and microscopic polyangiitis).287,288 Pharmacological studies have indicated the ability of avacopan for biased inhibition of β-arrestin coupling.289–291 The co-crystal structure of C5aR1 was reported with avacopan, highlighting the binding site outside 7TMD between helices III and V (Fig. 24a). The cyclopentane group of avacopan extended into the crevice between helices III and IV and occupied the hydrophobic pocket consisting of Leu1253.41, Val1594.48, Leu1634.52, and Leu1674.56 (Fig. 24b). The o-methyltrifluoromethylbenzene group exhibited hydrophobic and aromatic interactions mediated by residues Ile1243.40, Leu1253.41, Leu2095.45, Trp2135.49, Pro2145.50, and Leu2185.45 in the binding cleft between helices III and V. The m-methylfluorobenzene group lies deeper and forms non-polar interactions with residues Phe1353.52, Ile2205.56, Cys2215.57, and Phe2245.60 in C5aR1. Only one hydrogen bond was observed between the carbonyl substituent of the amide bond of avacopan and Trp2135.49. Additionally, there is a water-mediated polar interaction between avacopan and Thr2175.53.Fig. 24 a Schematic representation of the allosteric antagonist avacopan bound to C5a receptor 1 (PDB: 6C1R). b Detailed binding modes of C5a receptor 1 bound to avacopan. Hydrogen bond is presented as orange dashes. c Superimposed views of highlighted residue Trp2135.49 on C5aR1–PMX53–avacopan (pink cartoon, pink sticks; PDB: 6C1R) and C5aR1–C5a–Go (blue cartoon, blue sticks; PDB: 8IA2) structures

In the inactive C5aR1 structure, Trp2135.49 undergoes a conformational transition to accommodate avacopan binding, in contrast to the active C5aR1 structure (Fig. 24c). Avacopan may stabilize the conformation of the residues Ile1243.40, Pro2145.50, and Phe2516.44 in their inactive states through direct hydrophobic interactions (Fig. 24b). This stabilization, in turn, hinders conformational changes in transmembrane helices TM5 and TM6, which are necessary for receptor activation.292,293

4) TM V–VI:

CXCR3–SCH546738 structure

C-X-C chemokine receptor type 3 (CXCR3), a class A GPCR, is highly expressed on effector T cells and is activated by chemokines CXCL9, CXCL10 and CXCL11.294 Due to the critical role of CXCR3 in type 1 immunity, agonists and antagonists targeting CXCR3 have been synthesized to treat infection, autoimmune diseases, allograft rejection and cancers.295–297 Among these, SCH546738 (48) (Fig. 25c) has shown remarkable efficacy in several preclinical trials by effectively inhibiting the activation of T cell chemotaxis with an affinity of 0.4 nM.298Fig. 25 a Schematic representation of the allosteric antagonist SCH546738 bound to CXCR3 (PDB code 8HNN). b Detailed binding modes of CXCR3 binding to SCH546738. c 2D structure of small-molecule allosteric ligand SCH546738 provided for clarity

In the CXCR3–SCH546738 structure, SCH546738 is trapped in a narrow hydrophobic pocket surrounded by TM3, TM5 and TM6 (Fig. 25a).299 The head of SCH546738 is surrounded by a hydrophobic pocket formed by residues Phe1353.36, Ala1393.40, Phe2245.47, Leu2285.51, Met2315.54, Ile2616.41, Ala2736.53 (Fig. 25b). The tail of SCH546738 stretches out to the lipid bilayer and interacts with Tyr2355.58, Leu2395.62 and Leu2586.38. Given the unique allosteric site of SCH546738, the interposition of SCH546738 may weaken the repacking between TM5-TM6, maintaining the receptor in an inactive state.

5) TM I, VI, VII:

A1R–MIPS521, GPR101–AA-14, mGlu4–VU0364770, and mGlu4–ADX88178 Structures

The adenosine A1 receptor (A1R), a subtype of the adenosine receptor,300 has been a highly pursued non-opioid analgesic target for the treat chronic pain.301–304 Nonetheless, no selective clinically approved A1R agonists or antagonists are currently available.

MIPS521 (49) (Fig. 20b), a PAM of A1R, suppressed spinal nociceptive signaling and displayed an analgesic effect in a rat model with a pEC50 of 6.9 ± 0.4.305 Structural analysis revealed that MIPS521 binds outside 7TMD surrounded by helices I, VI, and VII (Fig. 26a). Residues Leu181.41, Ile191.42, Val221.45, Leu2426.43, Leu2456.46, Ser2466.47, Phe2757.40, Leu2767.41, and Met2837.48 formed shallow hydrophobic pockets at the allosteric site (Fig. 26b). The amino group of MIPS521 (Fig. 26c) was hydrogen-bonded to the main-chain carbonyl groups in Ser2466.47 and Leu2767.41. Comparing the ADO–A1R–Gi2 and MIPS521–ADO–A1R–Gi2 structures showed that MIPS521 has minimal impact on the binding position of ADO and receptor conformations. Mechanistically, the binding of MIPS521 may stabilize the active conformation by interacting with the allosteric site, which, in turn, promotes the collapse of the Na+ pocket (a nearby conserved class A activation motif).245,306Fig. 26 a Schematic representation of PAM MIPS521 bound to A1R (PDB code 7LD3). b Detailed binding modes of A1R binding to MIPS521. Hydrogen bonds are presented as orange dashes. c 2D structure of small-molecule allosteric ligand MIPS521 provided for clarity

Targeting of GPCR transmembrane domain (inside 7TMD)

An empty pocket is present in the middle of the GPCR transmembrane domain that serves as an allosteric site inside 7TMD, as shown in Fig. 27. Allosteric modulators bound to this pocket primarily interact with helices other than TM I and TM IV. To date, a PAM of FFAR3, an allosteric antagonist of CRF1R, an allosteric agonist of PTH1R, and five NAM and one PAM of mGluR5 have been reported to bind to this region (Table 3). In contrast, the binding of NAMs and an allosteric antagonist blocks the outward movement of TM VI, thereby acting as an antagonist. Notably, the binding of only the allosteric agonist stabilizes the G protein through direct interactions.Fig. 27 Allosteric binding sites in the transmembrane domain within 7TMD of GPCRs and corresponding small-molecule allosteric modulators. Stick models of small-molecule ligands are mapped to representative member CRF1R, PDB: 4K5Y. The number of unique modulators is indicated in boldface type, and the number of GPCRs containing the pocket is provided in parentheses

Table 3 Solved GPCR structures complexed with synthetic allosteric modulators bound to the transmembrane domain inside 7TMD

Structure Type	GPCR type	GPCR	Modulator	Highest Phase	Modulator type	Number	PDB code	Allosteric site	Refs	
Cryo-EM	class A	FFAR3	AR420626	Pre-clinical	PAM	(52)	8J20	inside 7TMD	469	
X-ray diffraction	class B	CRF1R	CP-376395	Pre-clinical	Allosteric antagonist	(53)	4K5Y	inside 7TMD	470	
Cryo-EM	class B	PTH1R	PCO371	Pre-clinical	Allosteric agonist	(54)	8GW8	inside 7TMD	335	
X-ray diffraction	class C	mGluR5	mavoglurant	Phase 3	NAM	(55)	4OO9	inside 7TMD	178	
X-ray diffraction	class C	mGluR5	compound 14	Pre-clinical	NAM	(56)	5CGC	inside 7TMD	321	
X-ray diffraction	class C	mGluR5	HTL14242	Phase 1	NAM	(57)	5CGD	inside 7TMD	321	
X-ray diffraction	class C	mGluR5	Fenobam	Phase 1	NAM	(58)	6FFH	inside 7TMD	471	
X-ray diffraction	class C	mGluR5	M-MPEP	Pre-clinical	NAM	(59)	6FFI	inside 7TMD	471	
Cryo-EM	class C	mGluR5	CDPPB	Pre-clinical	PAM	(60)	8TAO	inside 7TMD	325	

1) Inside 7TMD:

FFAR3–AR420626, CRF1R–CP-376395, mGluR5–mavoglurant, mGluR5–compound 14, mGluR5–HTL14242, mGluR5–Fenobam, mGluR5–M-MPEP, and PTH1R–PCO371 structures

The metabotropic glutamate (mGlu) receptor type 5 is among the eight most widely expressed mGlu receptors in the brain.307 Recently, mGluR5 has been shown to be involved in a growing number of cognitive and psychiatric disorders including schizophrenia.308–310 The mGlu receptor family is abundant in allosteric pharmacology among the class C GPCRs.311–315 In particular, allosteric regulation of mGlu5 receptors has received significant attention as a novel modality to treat diseases, including Parkinson’s disease and schizophrenia.316–318 NAMs of the mGlu5 receptors may serve to normalize excessive glutamate activity without blocking the physiological roles of the brain; thus, they are regarded as prospective agents for the treatment of multiple neurological disorders.319,320

The key binding determinants of these NAMs were identified in TM III, VI, and VII (Fig. 29a). Among these, HTL14242 (57) (Fig. 28) is an advanced and orally active NAM that progresses in early clinical testing for the potential treatment of amyotrophic lateral sclerosis (ALS) (Fig. 29). Crystal structures of mGluR5 with the lead compound of HTL14242, compound 14 (56), demonstrate the underlying basis for SAR optimization. With the pyrimidine linker traversing the narrow channel in the allosteric pocket formed by Tyr6593.44, Ser8097.39, Val8067.36, and Pro6553.40, the benzene ring and pyrazole ring of compound 56 respectively sit in two sub-pockets. The presence of the nitrile moiety on the benzene ring is crucial due to its delicate orientation that mediates the formation of hydrogen bonds with Val7405.40 via the bridging of a water molecule (Fig. 29b). Therefore, removal or replacement of the nitrile moiety caused a substantial drop in affinity, underlying the significance of maintaining this moiety during SAR studies (proved by compounds 57 and 58) (Fig. 29c). Notably, the conformation of the pyrazole end allows for slightly bulkier rings and small substitutes, as long as the hydrogen bond between the nitrogen atom and Ser8097.39, and the surrounding polar network is maintained (Fig. 29b). Such SBDD analysis thereupon yielded HTL14242, which harbors highly similar binding modes with 56 while simultaneously benefiting from its favorable physicochemical and pharmacokinetic properties (Fig. 29c).321Fig. 28 2D chemical structures of synthetic small-molecule allosteric ligands targeting the transmembrane domain within 7TMD of GPCRs

Fig. 29 a Schematic representation of the NAM fenobam bound to mGlu5 receptor (PDB: 5CGC). b Detailed binding modes of mGlu5 receptor binding to compound 14; polar interactions are shown in orange dashes. c SAR optimization of mGlu5 receptor NAMs. d Superimposed views of the highlighted residues on mGlu5–mavoglurant (purple cartoon, purple sticks; PDB: 4OO9), mGlu5–HTL14242 (orange cartoon, orange sticks; PDB: 5CGD), mGlu5–fenobam (blue cartoon, blue sticks; PDB: 6FFH), and mGlu5–CDPPB (pink cartoon, pink sticks; PDB: 8TAO) structures

Furthermore, by aligning mGlu5-NAM structures, a common salt bridge interaction was found between the residue pair Lys6653.50 and Glu7706.35, whereas it was absent in the PAM-bound complex, suggesting that NAM hinders the outward motion of TM VI by enhancing the interactions between TM III and TM VI at the cytoplasmic end.322–324 Conformational transitions of the highly conserved Trp7856.50 occur in the allosteric modulator-bound mGluR5 structure to adjust the size of the allosteric pocket and accommodate binding (Fig. 29d).178,325 Trp7856.50 within the FxxCWxP6.50 motif serves as a “toggle switch” in class A receptors, undergoing a conformation change during activation.321,326 It is plausible that this residue may also play a role in class C GPCR activation, though further investigation is required to elucidate its involvement.178

Other allosteric inhibitors bound to the transmembrane domain include allosteric PTH1R agonists. The parathyroid hormone receptor (PTH1R), a class B1 GPCR,327 is activated by parathyroid hormone and parathyroid hormone-related peptides and plays a central role in maintaining mineral ion homeostasis and skeletal metabolism.328–330 Recently, a highly selective PTH1R agonist, the orally active non-peptidic small molecule PCO371 (54) (Fig. 28), was identified and is currently undergoing phase 1 clinical trials to treat hypoparathyroidism.331,332 PCO371 consists of four chemical modules, from left to right: trifluoromethoxyphenyl, spiro-imidazolone, dimethylphenyl, and dimethylhydantoin.333

The solved crystal structure complex of PTH1R–PCO371 reveals important information regarding the PCO371 binding cavity,334 which was observed to reside in a pocket surrounded by residues on TM II, TM III, TM VI, and TM VII, analogous to mGluR5 (Fig. 30a).335,336 In the PCO371 binding site, the NH moiety of the spiro-imidazolone in PCO371 is engaged in a hydrogen binding interacts with Tyr4597.57 (Fig. 30b). The carbonyl group of dimethylhydantoin in PCO371 forms a salt bridge interaction with the protonated nitrogen of Arg2192.46. In addition to polar contacts, the trifluoromethoxyphenyl group formed nonpolar interactions with Met4146.46, Leu4166.48, and Phe4547.52; the spiroimidazolone group formed hydrophobic interactions with Leu2262.53, Ile2993.47, Pro4156.47, and Phe4176.49; the dimethylphenyl group formed hydrophobic interactions with His2232.50, Leu3063.54, Val4126.44, Leu4136.45 and Tyr4597.57; and the dimethylhydantoin group formed hydrophobic interactions with Asn4638.47. Notably, Glu394G.H5.24 in the Gs protein was hydrogen-bonded to the carbonyl group of dimethylhydantoin, and Tyr393G.H5.23 formed a hydrophobic interaction with dimethylhydantoin, thus stabilizing the ternary PCO371–PTH1R–Gs complex.Fig. 30 a Schematic representation of the allosteric agonist PCO371 bound to PTH1R (PDB: 8GW8). b Detailed binding modes of PTH1R binding to PCO371. Hydrogen bonds are presented as orange dashes. c Superposition of the PTH1R bound to PCO371 (displayed in pink) and PTH (displayed in blue) reveals conformational changes upon PCO371 binding

As the binding of PCO371 precludes the endogenous ligand from occupying the core of the 7TM helical bundle, only structures in which PCO371 alone binds to PTH1R exist. The presence of PCO371 induced inward displacement of the extracellular and cytoplasmic termini of TM6 cells (Fig. 30c). Comparison of the structures of PCO371–PTH1R and CP-376395–CRF1R revealed that PCO371 has a deeper binding site and therefore does not impede the formation of the conserved Pro6.47-X-X-Gly6.50 kink, as CP-376395 does. In addition, the binding site of PCO371 is shallower than that of allosteric modulators that bind to the intracellular surface inside 7TMD and therefore does not impede G-protein or arrestin binding. Till date, PCO371 is probably the only receptor allosteric agonist reported to stabilize the active state through direct interactions with downstream transducers.

Targeting of GPCR Intracellular Surface (outside and inside 7TMD)

In these instances, allosteric modulators bind to interfaces located between the cytoplasmic terminus of the 7TM helical bundle and downstream transducers,337 including the outside and inside of 7TMD.46 Till date, only two different binding sites in the intracellular surface have been identified using crystal structures (Table 4), namely the pocket outside helices V − VII and the pocket inside 7TMD (Fig. 31).Table 4 Solved GPCR structures complexed with synthetic allosteric modulators bound to the intracellular surface

Structure Type	GPCR type	GPCR	Modulator	Highest Phase	Modulator type	Number	PDB code	Allosteric site	Refs	
Cryo-EM	class A	GPR88	2-PCCA	Pre-clinical	Allosteric agonist	(64)	7EJX	outside 7TMD (V−VII)	472	
X-ray diffraction	class B	GCGR	MK-0893	Phase 2	Allosteric antagonist	(65)	5EE7	outside 7TMD (V−VII)	363	
X-ray diffraction	class B	GCGR	NNC0640	Pre-clinical	NAM	(66)	5XEZ	outside 7TMD (V−VII)	364	
X-ray diffraction	class B	GLP-1R	NNC0640	Pre-clinical	NAM	(66)	5VEX	outside 7TMD (V−VII)	365	
X-ray diffraction	class B	GLP-1R	PF-06372222	Pre-clinical	NAM	(67)	5VEW	outside 7TMD (V−VII)	365	
Cryo-EM	class B	GLP-1R	compound 2	Pre-clinical	ago-PAM	(68)	7EVM	outside 7TMD (V−VII)	358	
Cryo-EM	class C	GABAB	GS39783	Pre-clinical	PAM	(69)	6UO8	outside 7TMD (V−VII)	352	
Cryo-EM	class C	GABAB	BHFF	Pre-clinical	ago-PAM	(70)	7C7Q	outside 7TMD (V−VII)	351	
X-ray diffraction	class A	β2AR	Cmp-15PA	Pre-clinical	Allosteric antagonist	(71)	5X7D	inside 7TMD	473	
X-ray diffraction	class A	CCR2	CCR2-RA-[R]	Pre-clinical	Allosteric antagonist	(72)	5T1A	inside 7TMD	474	
X-ray diffraction	class A	CCR9	vercirnon	Phase 3	Allosteric antagonist	(73)	5LWE	inside 7TMD	385	
X-ray diffraction	class A	CCR7	Cmp2105	Pre-clinical	Allosteric antagonist	(74)	6QZH	inside 7TMD	475	
X-ray diffraction	class A	CXCR2	00767013	Pre-clinical	Allosteric antagonist	(75)	6LFL	inside 7TMD	476	
Cryo-EM	class A	GPR61	Compound 1	Pre-clinical	Allosteric inverse agonist	(76)	8TB7	inside 7TMD	477	
Cryo-EM	class A	NTSR1	SBI-553	Pre-clinical	PAM	(77)	8JPB	inside 7TMD	478	

Fig. 31 Two intracellular allosteric binding sites in GPCRs and the corresponding small-molecule allosteric modulators. Stick models of small-molecule ligands are mapped to representative members of outside 7TMD (V−VII) (GCGR, PDB: 5EE7) and inside 7TMD (CCR2, PDB: 5T1A) GPCRs. For each pocket, the number of unique modulators is indicated in boldface type, and the number of GPCRs containing the pocket is provided in parentheses

1) Outside 7TMD (V−VII):

GPR88−2-PCCA, GCGR−MK-0893, GCGR−NNC0640, GLP-1R−PF-06372222, GLP-1R−compound 2, GABA B −GS39783, and GABA B −BHFF structures

The reported allosteric sites on the intracellular surface outside 7TMD are all attached to TM VI, located between helices V and VII, suggesting that TM VI plays a functional role in transmitting ligand-binding information to the orthosteric pocket.338 G-protein coupling requires outward motion of the intracellular end of TM VI, a key signature for activating GPCR,339 which inspired the design of small-molecule allosteric modulators that target this site.

The GABAB receptor, classified as a heterodimeric class C GPCR, comprises two distinct subunits, GB1 and GB2, which can be activated by γ-aminobutyric acid (GABA), a primary inhibitory neurotransmitter in the central nervous system.340,341 GABAB receptors are key therapeutic targets in the treatment of multiple neurological disorders, including depression, schizophrenia, and drug addiction.342–344 Dimerization of GABAB receptors results in the emergence of this new dimer-specific allosteric binding site (Fig. 33a),345–349 which prevents GS39783 (69) and BHFF (70) from acting on the monomer, but instead specifically controls GPCR dimer activity.

BHFF (Fig. 32), a potent PAM of the GABAB receptor that enhances receptor potency only when activated by orthosteric agonists, lacks efficacy in mouse experiments.350 Determination of the BHFF−GABAB receptor co-crystal structure clearly shows that BHFF is bound between TM V−TM VI of GB1 and TM VI of GB2 within the intracellular tips (Fig. 33a).351 The 3-hydroxy group and ketone of BHFF formed two hydrogen bonds with the Lys792ICL3 side chain of GB1 (Fig. 33b). For hydrophobic interactions, BHFF is buried in a cavity defined by the residues Ala7885.58, Tyr7895.59, Met8076.41, Tyr8106.44 of GB1, and Tyr6916.38 and Met6946.41 of GB2.Fig. 32 2D structures of synthetic allosteric ligands targeting the GPCR intracellular surface

Fig. 33 a Schematic representation of PAM BHFF bound to GABAB receptor (PDB: 7C7Q). b Detailed binding modes of GABAB receptor binding to BHFF. Hydrogen bonds are presented by orange dashes. c Superimposed views of the N-terminal α-helix on compound 2–GLP-1R–Gs (blue cartoon, blue sticks; PDB: 7DUR) and GLP-1–GLP-1R–Gs (pink cartoon, pink sticks; PDB: 6×18) structures. d Schematic representation of ago-PAM compound 2 bound to GLP-1R (PDB: 7EVM). e Detailed binding modes of GLP-1R bound to compound 2. f Superimposed views of highlighted residues on compound 2–GLP-1R–Gs (blue cartoon, blue sticks; PDB: 7DUR), GLP-1–GLP-1R–Gs (pink cartoon, pink sticks; PDB: 6×18), and compound 2–GLP-1–GLP-1R–Gs (purple cartoon, purple sticks; PDB: 7DUQ) structures

Compared with GS39783, another PAM molecule for the GABAB receptor, both PAM molecules bind to highly similar locations within the dimer interface, and the overall complex structure is almost identical. In contrast to the binding of the orthosteric agonist baclofen alone, the PAM induces a straightening and inward shift of TM3 and TM5 in GB2 on the intracellular side and stabilizes the TM6-mediated dimerization. This alteration contributes to the stabilization of the receptor in its active state.352–354

Compound 2 (68) (Fig. 32) is a novel ago-PAM of GLP-1R that covalently binds to Cys3476.36 on helices VI and displays partial and almost full agonism.355,356 However, clinical trials of compound 2 failed because of its poor pharmacokinetic properties.357 In the co-crystal structure of GLP-1R complexed with compound 2, it was demonstrated that compound 2 was located on the TM VI membrane-facing surface and formed interactions only with residues on TM VI (Fig. 33d), among which a covalent disulfide bond was formed between the sulfonic group of compound 2 and Cys3476.36.358 In addition, the tert-butyl group of compound 2 extended toward TM VII and formed nonpolar interactions with Ala3506.39 and Lys3516.40 (Fig. 33e). The dichloroquinoxaline group was directed toward ICL3, forming van der Waals contacts with Lys3466.35 and Cys3476.36.

The binding of compound 2 alone, GLP-1 alone, and compound 2 − GLP-1 together all led to a similar extent of outward movement in the intracellular terminus of TM6 (Fig. 33c). Nonetheless, in the compound 2–GLP-1–GLP-1R–Gs structure, two additional salt bridge interactions have arisen (R1762.46 and E4088.49, E4238.64 and R46 in Gβ) (Fig. 33f), offering the potential to strengthen G-protein binding through long-range allosteric communications.358 Furthermore, the N-terminal α-helix of the GLP‐1 R extends downward into the orthosteric pocket upon binding to compound 2, which may serve to stabilize the active conformation (Fig. 33c).359

Covalent binding confers a higher potential energy barrier upon compound 2 dissociation, thus minimizing potential off-target effects.360–362 This suggests that the protruding free cysteine residues in the transmembrane helix provide an opportunity to develop irreversible GPCR allosteric modulators.

All allosteric antagonists and NAMs (MK-0893 (65), NNC0640 (66), and PF-06372222 (67)) bind to the other side of TM VI near TM VII and appear to be well conserved with respect to the allosteric site and binding modes.363–365 In this case, the protruding TM VI can serve as a base for the attachment of modulators in a clamp shape. The binding of such allosteric modulators requires certain conditions, such as a cleft between helices for the insertion of the pincers and adequate hydrophobic contacts with the surrounding residues for stable binding. The outward displacement within the TM VI required for transducer binding is restricted, preventing receptor activation.366

The glucagon receptor belongs to the class B GPCR and plays a critical role in the maintenance of glucose homeostasis.367,368 Given the key role of glucagon in elevating glycemia, small-molecule antagonists targeting GCGR are considered promising treatments for diabetes.369–371 In support of this concept, a novel allosteric antagonist targeting GCGR, MK-0893 (Fig. 32), has advanced into phase 2 clinical studies to treat type 2 diabetes mellitus;372 however, side effects, including increased LDL-C, have hindered its clinical use.373

The X-ray crystal structure of MK-0893 with GCGR was solved, revealing the atomic details of allosteric modulator binding.363 In this structure, MK-0893 is situated within an intracellular pocket outside helices V–VII (Fig. 34a). In terms of polar interactions, the terminal anionic carboxylic acid moiety of MK-0893 (Fig. 34c) established a salt-bridge interaction with Arg3466.37 (Fig. 34b).374 It contributes to the establishment of a hydrogen-bonding network involving the side chain of Asn4047.61 and the main-chain amine of Lys4057.62. It also forms a water-mediated hydrogen bond with the side chain of Ser3506.44. Additionally, the amide group of the ligand formed hydrogen bonds with the backbone carbonyl groups of Ser3506.41, Leu3997.56, and the side chain of Lys3496.40. Regarding hydrophobic interactions, the methoxynaphthalene moiety wedges into a cavity formed by helices V and VI and interacts with residues Leu3295.61, Phe3456.36, Leu3526.43, and Thr3536.44, and the alkyl chain of Lys3496.40. The phenylethylpyrazole core scaffold engages in hydrophobic interactions with residues Thr3536.44, and Leu3997.56, and forms a π−cation interaction with Lys3496.40. This structure closely resembles other inactive structures (PDB:5XEZ, 8JRV, and 8JRU)375 and does not exhibit specific conformations induced by MK-0893.Fig. 34 a Schematic representation of the allosteric antagonist MK-0893 bound to GCGR (PDB: 5EE7). b Detailed binding modes of GCGR binding to MK-0893. Hydrogen bonds are presented as orange dashes. c 2D structure of small-molecule allosteric ligand MK-0893 shown for clarity

2) Inside 7TMD:

β2AR–Cmp-15PA, CCR2–CCR2-RA-[R], CCR9–vercirnon, CCR7–Cmp2105, CXCR2–00767013, GPR61–Compound 1, and NTSR1–SBI-553 structures

In contrast to orthosteric ligands, GPCRs utilize their intracellular surface inside 7TMD to directly mediate downstream signaling via G proteins or arrestins. This site has also been found to act as a binding site for allosteric regulators and is quite similar in all solved complexes (a cavity composed of the cytoplasmic region of helices I, II, VI, and VII) (Fig. 31).24,376,377 Allosteric antagonists bound to this region inhibit GPCR-mediated signaling through a novel dual mechanism, which appears to be a powerful way to antagonize the receptor. These allosteric modulators not only compete with G-proteins or arrestins by occupying their binding sites but also display π-π interactions (parallel or T-shaped) with Tyr7.53 from the conserved NPxxY motif in TM VII, acting as a molecular glue to hold together the cytoplasmic ends of the helical bundle, further preventing conformational transitions associated with activation. Therefore, targeting this druggable allosteric pocket in receptors using small-molecule allosteric antagonists may provide new opportunities for the discovery of GPCR drugs.

Chemokine receptors and their ligands are involved in chemotactic trafficking during the inflammatory responses.378–380 CC chemokine receptor 9 (CCR9) activated by CCL25 has emerged as a potential therapeutic target for inflammatory bowel disease because it is essential for mediating leukocyte homing to the gut.381–383

Vercirnon (73) (Fig. 32), an allosteric antagonist of CCR9 used in Crohn’s treatment, has progressed to Phase 3 clinical studies. However, its efficacy is limited due to the requirement for significantly high doses to effectively block receptor activation.384 This uncertainty may stem from the fact that drug molecules might not necessarily bind to the intracellular G protein region upon entering the cytoplasm.271 This challenge could be common among this class of modulators, but only vercirnon has entered clinical trials at present.

The binding site of vercirnon has been shown via X-ray crystallography to be the center of the 7TM helical bundle on the intracellular side (Fig. 35a). The sulfone group (Fig. 35c) of vercirnon engages in a trivalent hydrogen bond with the main-chain amino groups of three neighboring residues: Glu3228.48, Arg3238.49, and Phe3248.50.385 Additionally, the pyridine-N-oxide group is hydrogen-bonded to the side chain of Thr81ICL1, and the ketone group forms a hydrogen bond with the side chain of Thr2566.37 (Fig. 35b). Regarding hydrophobic interactions, the tert-butylphenyl group is deeply buried in the hydrophobic pocket surrounded by Val691.53, Val721.56, Tyr731.57, Leu872.42, Tyr3177.53, and Phe3248.50. The chlorophenyl group was situated within a narrow crevice formed by the hydrophobic parts of residues Leu872.43, Ile1403.46, Val2596.40, and Tyr3177.53. Furthermore, the pyridine-N-oxide group is enclosed within a polar cavity formed by residues Thr81ICL1, Thr832.39, Asp842.40, Arg1443.50, and Arg3238.49.Fig. 35 a Schematic representation of the allosteric antagonist vercirnon bound to CCR9 (PDB: 5LWE). b Detailed binding modes of CCR9 binding to vercirnon. Hydrogen bonds are presented as orange dashes. c 2D structure of small-molecule allosteric ligand vercirnon shown for clarity

Conclusions and perspectives

Over the past few decades, crystallographic, biochemical, and computational studies have provided unprecedented atomic and structural insights into the comprehensive regulation of GPCR structures.386–389 Till date, 388 orthosteric modulators, as well as 717 complex structures of GPCRs bound to the orthosteric modulators, have been reported. In addition, 53 different allosteric small-molecule modulators bound to GPCR complex structures and nine different allosteric sites were also solved. In this study, we first review the structure advances, signaling mechanisms, and functional diversity of GPCRs to outline the current profile and up-to-date development in this field. Importantly, by means of the aforementioned crystallographic advancements, orthosteric and allosteric modulators are discussed separately in terms of their complex structures, signaling mechanisms, and consequential implications for drug discovery. Such in-depth investigation underlines the significance of understanding GPCR structures and mechanisms for developing effective therapeutics.

Because of the relatively large amount of orthosteric modulators and their shared functional mechanism of competing with the endogenous ligands, representative cases of orthosteic drugs launched within the past five years have been carefully selected and dissected, including μ-OR-oliceridine complex (stand-out for G-protein biased signaling), S1PR-siponimod complex (stand-out for subtype selectivity and “toggle switch” activation mechanism), OX2R-lemborexant complex (stand-out for kinetics and dynamics parameters), 5-HT1F-lasmiditan complex (distinctive for subtype selectivity), and GnRH1-elagolix complex (distinctive for signal transmission based on atypical receptor structure). Structural analysis revealed that modulators are stabilized within the orthosteric pockets by key polar interactions with residues on the TM bundles, in which residues that are unconserved among the family subtypes are often determinants of selectivity. Furthermore, the “toggle switch”, PIF, DRY, and NPxxY motifs are critical mechanical switches that transmit extracellular stimuli to the intracellular regions, and some specific polar interactions between TM3 and TM5/6 may also serve as a boost for the displacement of TM5/6, which is a hallmark of receptor activation/deactivation.

Since the binding patterns and action mechanisms of allosteric modulators tend to be unique, we placed special emphasis on the depiction of allosteric regulators.390 From the analysis of these structural complexes, the extracellular vestibule inside 7TMD was identified as the most prevalent binding site for allosteric modulators, and induced-fit shape matching and charge matching are the determinants of allosteric ligand accommodation. The binding of allosteric modulators alters the free-energy landscape and stabilizes the different dominant conformations of the receptor.391 Specifically, we established a novel classification of allosteric modulators into two categories. First, the allosteric effects of the modulators can be realized by directly modulating the binding of orthosteric ligands or intracellular transducer proteins to receptors. In this instance, allosteric modulators may occupy a pocket above the orthosteric binding pocket and interact directly with orthosteric ligands and/or surrounding residues to alter association or dissociation. Allosteric modulators may also occupy the binding pockets of G-proteins and arrestins to impede their binding or occupy the pockets above their binding sites to regulate binding. Second, allosteric modulators regulate the ability of receptor complexes to interact with intracellular transducer proteins by indirectly altering their activation pathways. In this instance, allosteric modulators appear to act as steric wedges, stabilizing or destabilizing certain interactions to restrict or facilitate conformational rearrangements of the receptor.

In addition to the commonalities summarized above, it is of broad pharmaceutical interest to understand how the drug recognition basis and delicate mechanistic regulation of orthosteric/allosteric modulators can expand upon drug design and why we need to pursue this line of research.117,392,393 From a structural and chemical biology perspective, understanding the mechanical switch cascade assists in acquiring insights into fine-tuning regulation and enables human control of different downstream functions of GPCRs.62 Therefore, GPCRs after mutagenesis may be employed as biosensors to initiate distinct intracellular signaling events.394

Medicinal chemists can be inspired by five perspectives based on the analysis presented in this review:With orthosteric small-molecule modulators remaining the mainstream therapeutic agents for GPCRs, the rational design of orthosteric ligands with high affinity, efficacy, and selectivity has been a long-standing topic.395–398 Concerning with enhancement of affinity and efficacy, designing ligands that constitute “anchors” and “drivers” has been suggested.399,400 The “anchors” represent the primary parts of the ligands that contribute to affinity by binding with utmost residues and remain nearly unchanged during the transition between different states of the receptor. The “drivers” should be designed to form certain interactions with “toggle switches” and thus trigger activation/deactivation signaling. The “anchors” provide a foundation that allows the “drivers” to exert a “pull” and/or “push” action that shifts the receptor population, thereby enhancing efficacy. This “mechanism-based drug design” concept, expanding upon the traditional “structure-based drug design” strategy, may shed light on effective and efficient GPCR drug discovery.401,402 Regarding the improvement of selectivity, although the orthosteric sites are highly conserved in one family, capturing slight differences in loop/TM bundle/key residue conformation from other receptor subtypes and specifically interacting with these hotspots may result in a multifold increase in selectivity, thus alleviating side effects.

Uncovering the appropriate allosteric pockets and further conducting allosteric drug design are also durable and questionable research topics.403–405 With the development of crystallography offering credible initial structures, MD simulations, together with enhanced sampling methodologies, have enabled the characterization of various intermediate conformations where cryptic allosteric sites may emerge.406–414 Based on the identified allosteric sites, allosteric modulators can be designed using a three-dimensional (3D) molecular generation algorithm that uses the topological surface and geometric structure.415 Although the low conservation of allosteric sites may result in a lack of a general formula concerning the scaffold of allosteric modulators,416 it can be concluded that while the hydrophobic nature of allosteric ligands will contribute to receptor binding and regulation in most instances, polar groups can also interact, especially when the modulators bind outside 7TMD and require immobilization to the receptor. Moreover, an “allosteric-like” rule condensed by our group (molecular weight ≤600; 2≤ number of rotatable bonds ≤6; number of rings ≤5; number of rings in the largest ring system= 1 or 2, 3≤ SlogP ≤7) can serve as a filter criteria when designing molecules.417

With the GPCR-ligand complex structural information in hand, the topic of whether the kinetic and dynamic properties of ligands can also be modified by medicinal chemists is considered.177,418,419 Based on the desirable kon and koff values of lemborexant analyzed above, it is inferred that designing a ligand that can assemble to its receptor-bound state in advance may help achieve a high kon value, in which case a simple MD simulation of designed ligands in a solvent can acquire the preferential conformation of the ligand and guide our selection. In contrast, estimating the binding free energy of the designed ligands may help predict and rank their koff values, thus providing valuable guidance for ligand optimization from a kinetic perspective.420,421

For both orthosteric and allosteric modulators, achieving biased signaling is of scientific and clinical significance for any GPCR target.26,422–428 With the design of G-protein-biased modulators of μ-OR as a paradigm, it is suggested that comparison of the biased and unbiased ligands binding modes may help locate the key residues or regions that contribute to biased signaling. A “mechanism-based drug design” that designs ligand forming/avoiding interactions with hotspots may lead to the successful distinguishing of promiscuous signals.

In the regulation of PAM and NAM, orthosteric and allosteric sites are coupled through mutual signal perturbations within the protein.429–431 Thus, bitopic ligands, which connect the pharmacophores of both orthosteric and allosteric ligands through a linker, may facilitate a deeper investigation of site-site coupling within GPCRs and harvest ligands with higher selectivity and biased signaling abilities.432–437 With GPCR bitopic ligands occupying a relatively blank zone, linker optimization while immobilizing fragments at both ends, as well as fixing the orthosteric fragment while attaching a warhead to the allosteric fragment to anchor it in an allosteric pocket containing nucleophilic amino acids, may prove to be promising strategies for exploiting this field.

Despite significant technological advances and studies on GPCR structure and drug discovery,438–442 obstacles still exist. As GPCR crystallography is still a time-consuming and labor-intensive process,31 structure-dependent scenarios can somewhat hinder the study of GPCR mechanism and drug discovery, even with the use of AlphaFold and RoseTTAFold.443–445 For example, modeling from AlphaFold is not precise in residue orientation and can thus mislead the analysis of signaling mechanisms.446 Moreover, MD simulations do not guarantee the identification of novel cryptic allosteric sites in allosteric drug design.447 Therefore, other novel perspectives such as sequence, coarse-grained topology,448 and evolution are urgently required and may alleviate structural dependencies.449 One possibility is the use of available large data of sequences and end-to-end concepts in deep learning to develop “sequence-to-mechanism” or “sequence-to-drug discovery” methodologies,450 which can help avoid error accumulation from various models if the experimental strategies fail to provide the crystal structures.

In summary, we are at a stage of in-depth research on the orthosteric and allosteric modulation of GPCRs. Although our understanding of drug-target interactions, binding hotspots, and mechanisms for small-molecule modulators has become increasingly clear, some aspects still require further study. The present study contributes to a better understanding of the ligand recognition and regulatory mechanisms of GPCRs. Furthermore, by proposing a novel classification of the mechanism of allosteric modulators and an innovative concept of “mechanism-based drug discovery,” we aim to outline the latest landscape of GPCRs and interest researchers to facilitate this field. More effective, selective, and safer small-molecule therapeutics for GPCRs should be the focus of future studies in this field.

Supplementary information

Supplementary Material

Supplementary information

The online version contains supplementary material available at 10.1038/s41392-024-01803-6.

Acknowledgements

This study was supported by grants from the National Key R&D Program of the Ministry of Science and Technology (No. 2023YFC3404700), the National Natural Science Foundation of China (No. 22077082), the Shanghai Frontiers Science Center of Cellular Homeostasis and the Human Diseases, and the Innovative Research Team of High-Level Local Universities in Shanghai.

Author contributions

S.L. and Z.C. conceived and designed the study. M.Z., T.C., X.L., and X.L. analyzed the results. M.Z. and X.L. made the figures and tables. M.Z., X.L., and T.C. wrote the original manuscript. S.L. revised the manuscript and supervised the project. All authors have discussed the results and approved the manuscript.

Competing interests

The authors declare no competing interests.

These authors contributed equally: Mingyang Zhang, Ting Chen, Xun Lu
==== Refs
References

1. Eichel K von Zastrow M Subcellular organization of GPCR signaling Trends Pharmacol. Sci. 2018 39 200 208 10.1016/j.tips.2017.11.009 29478570
Eichel, K. & von Zastrow, M. Subcellular organization of GPCR signaling. Trends Pharmacol. Sci. 39, 200–208 (2018).29478570 10.1016/j.tips.2017.11.009
2. Rosenbaum DM Rasmussen SGF Kobilka BK The structure and function of G-protein-coupled receptors Nature 2009 459 356 363 10.1038/nature08144 19458711
Rosenbaum, D. M., Rasmussen, S. G. F. & Kobilka, B. K. The structure and function of G-protein-coupled receptors. Nature 459, 356–363 (2009).19458711 10.1038/nature08144
3. Katritch V Cherezov V Stevens RC Diversity and modularity of G protein-coupled receptor structures Trends Pharmacol. Sci. 2012 33 17 27 10.1016/j.tips.2011.09.003 22032986
Katritch, V., Cherezov, V. & Stevens, R. C. Diversity and modularity of G protein-coupled receptor structures. Trends Pharmacol. Sci. 33, 17–27 (2012).22032986 10.1016/j.tips.2011.09.003
4. Latorraca NR Venkatakrishnan AJ Dror RO GPCR dynamics: structures in motion Chem. Rev. 2017 117 139 155 10.1021/acs.chemrev.6b00177 27622975
Latorraca, N. R., Venkatakrishnan, A. J. & Dror, R. O. GPCR dynamics: structures in motion. Chem. Rev. 117, 139–155 (2017).27622975 10.1021/acs.chemrev.6b00177
5. Mannes M Martin C Menet C Ballet S Wandering beyond small molecules: peptides as allosteric protein modulators Trends Pharmacol. Sci. 2022 43 406 423 10.1016/j.tips.2021.10.011 34857409
Mannes, M., Martin, C., Menet, C. & Ballet, S. Wandering beyond small molecules: peptides as allosteric protein modulators. Trends Pharmacol. Sci. 43, 406–423 (2022).34857409 10.1016/j.tips.2021.10.011
6. Nussinov R Introduction to protein ensembles and allostery Chem. Rev. 2016 116 6263 6266 10.1021/acs.chemrev.6b00283 27268255
Nussinov, R. Introduction to protein ensembles and allostery. Chem. Rev. 116, 6263–6266 (2016).27268255 10.1021/acs.chemrev.6b00283
7. Dunn HA Orlandi C Martemyanov KA Beyond the ligand: extracellular and transcellular g protein-coupled receptor complexes in physiology and pharmacology Pharmacol. Rev. 2019 71 503 519 10.1124/pr.119.018044 31515243
Dunn, H. A., Orlandi, C. & Martemyanov, K. A. Beyond the ligand: extracellular and transcellular g protein-coupled receptor complexes in physiology and pharmacology. Pharmacol. Rev. 71, 503–519 (2019).31515243 10.1124/pr.119.018044
8. Zarzycka B Zaidi SA Roth BL Katritch V Harnessing ion-binding sites for GPCR pharmacology Pharmacol. Rev. 2019 71 571 595 10.1124/pr.119.017863 31551350
Zarzycka, B., Zaidi, S. A., Roth, B. L. & Katritch, V. Harnessing ion-binding sites for GPCR pharmacology. Pharmacol. Rev. 71, 571–595 (2019).31551350 10.1124/pr.119.017863
9. Flock T Universal allosteric mechanism for Gα activation by GPCRs Nature 2015 524 173 179 10.1038/nature14663 26147082
Flock, T. et al. Universal allosteric mechanism for Gα activation by GPCRs. Nature 524, 173–179 (2015).26147082 10.1038/nature14663
10. Dawaliby R Allosteric regulation of G protein-coupled receptor activity by phospholipids Nat. Chem. Biol. 2016 12 35 39 10.1038/nchembio.1960 26571351
Dawaliby, R. et al. Allosteric regulation of G protein-coupled receptor activity by phospholipids. Nat. Chem. Biol. 12, 35–39 (2016).26571351 10.1038/nchembio.1960
11. Hilger D Masureel M Kobilka BK Structure and dynamics of GPCR signaling complexes Nat. Struct. Mol. Biol. 2018 25 4 12 10.1038/s41594-017-0011-7 29323277
Hilger, D., Masureel, M. & Kobilka, B. K. Structure and dynamics of GPCR signaling complexes. Nat. Struct. Mol. Biol. 25, 4–12 (2018).29323277 10.1038/s41594-017-0011-7
12. Dokholyan NV Controlling allosteric networks in proteins Chem. Rev. 2016 116 6463 6487 10.1021/acs.chemrev.5b00544 26894745
Dokholyan, N. V. Controlling allosteric networks in proteins. Chem. Rev. 116, 6463–6487 (2016).26894745 10.1021/acs.chemrev.5b00544
13. Canals M A Monod-Wyman-Changeux mechanism can explain G Protein-coupled Receptor (GPCR) allosteric modulation J. Biol. Chem. 2012 287 650 659 10.1074/jbc.M111.314278 22086918
Canals, M. et al. A Monod-Wyman-Changeux mechanism can explain G Protein-coupled Receptor (GPCR) allosteric modulation. J. Biol. Chem. 287, 650–659 (2012).22086918 10.1074/jbc.M111.314278
14. Hauser AS Trends in GPCR drug discovery: new agents, targets and indications Nat. Rev. Drug Discov. 2017 16 829 842 10.1038/nrd.2017.178 29075003
Hauser, A. S. et al. Trends in GPCR drug discovery: new agents, targets and indications. Nat. Rev. Drug Discov. 16, 829–842 (2017).29075003 10.1038/nrd.2017.178
15. Sriram K Insel PA G protein-coupled receptors as targets for approved drugs: how many targets and how many drugs? Mol. Pharmacol. 2018 93 251 258 10.1124/mol.117.111062 29298813
Sriram, K. & Insel, P. A. G protein-coupled receptors as targets for approved drugs: how many targets and how many drugs? Mol. Pharmacol. 93, 251–258 (2018).29298813 10.1124/mol.117.111062
16. Schöneberg T Liebscher I Mutations in G protein-coupled receptors: mechanisms, pathophysiology and potential therapeutic approaches Pharmacol. Rev. 2021 73 89 119 10.1124/pharmrev.120.000011 33219147
Schöneberg, T. & Liebscher, I. Mutations in G protein-coupled receptors: mechanisms, pathophysiology and potential therapeutic approaches. Pharmacol. Rev. 73, 89–119 (2021).33219147 10.1124/pharmrev.120.000011
17. Yang DH G protein-coupled receptors: structure- and function-based drug discovery Signal Transduct. Target. Ther. 2021 6 7 10.1038/s41392-020-00435-w 33414387
Yang, D. H. et al. G protein-coupled receptors: structure- and function-based drug discovery. Signal Transduct. Target. Ther. 6, 7 (2021).33414387 10.1038/s41392-020-00435-w
18. Casadó V Casadó-Anguera V What are the current trends in G protein-coupled receptor targeted drug discovery? Expert Opin. Drug Discov. 2023 18 815 820 10.1080/17460441.2023.2216014 37204339
Casadó, V. & Casadó-Anguera, V. What are the current trends in G protein-coupled receptor targeted drug discovery? Expert Opin. Drug Discov. 18, 815–820 (2023).37204339 10.1080/17460441.2023.2216014
19. Mohr K Rational design of dualsteric GPCR ligands: quests and promise Br. J. Pharmacol. 2010 159 997 1008 10.1111/j.1476-5381.2009.00601.x 20136835
Mohr, K. et al. Rational design of dualsteric GPCR ligands: quests and promise. Br. J. Pharmacol. 159, 997–1008 (2010).20136835 10.1111/j.1476-5381.2009.00601.x
20. Goupil E Laporte SA Hébert TE Functional selectivity in GPCR signaling: understanding the full spectrum of receptor conformations Mini Rev. Med. Chem. 2012 12 817 830 10.2174/138955712800959143 22681252
Goupil, E., Laporte, S. A. & Hébert, T. E. Functional selectivity in GPCR signaling: understanding the full spectrum of receptor conformations. Mini Rev. Med. Chem. 12, 817–830 (2012).22681252 10.2174/138955712800959143
21. Lu SY He XH Ni D Zhang J Allosteric modulator discovery: from serendipity to structure-based design J. Med. Chem. 2019 62 6405 6421 10.1021/acs.jmedchem.8b01749 30817889
Lu, S. Y., He, X. H., Ni, D. & Zhang, J. Allosteric modulator discovery: from serendipity to structure-based design. J. Med. Chem. 62, 6405–6421 (2019).30817889 10.1021/acs.jmedchem.8b01749
22. Wootten D Christopoulos A Sexton PM Emerging paradigms in GPCR allostery: implications for drug discovery Nat. Rev. Drug Discov. 2013 12 630 644 10.1038/nrd4052 23903222
Wootten, D., Christopoulos, A. & Sexton, P. M. Emerging paradigms in GPCR allostery: implications for drug discovery. Nat. Rev. Drug Discov. 12, 630–644 (2013).23903222 10.1038/nrd4052
23. Wang Y Allosteric binding sites at the receptor-lipid bilayer interface: novel targets for GPCR drug discovery Drug Discov. Today 2020 26 690 703 10.1016/j.drudis.2020.12.001 33301977
Wang, Y. et al. Allosteric binding sites at the receptor-lipid bilayer interface: novel targets for GPCR drug discovery. Drug Discov. Today 26, 690–703 (2020).33301977 10.1016/j.drudis.2020.12.001
24. Zhang M Lan X Li X Lu S Pharmacologically targeting intracellular allosteric sites of GPCRs for drug discovery Drug Discov. Today 2023 28 103803 10.1016/j.drudis.2023.103803 37852356
Zhang, M., Lan, X., Li, X. & Lu, S. Pharmacologically targeting intracellular allosteric sites of GPCRs for drug discovery. Drug Discov. Today 28, 103803 (2023).37852356 10.1016/j.drudis.2023.103803
25. Smith RD Lu J Carlson HA Are there physicochemical differences between allosteric and competitive ligands? Plos Comput. Biol. 2017 13 e1005813 10.1371/journal.pcbi.1005813 29125840
Smith, R. D., Lu, J. & Carlson, H. A. Are there physicochemical differences between allosteric and competitive ligands? Plos Comput. Biol. 13, e1005813 (2017).29125840 10.1371/journal.pcbi.1005813
26. Slosky LM Caron MG Barak LS Biased allosteric modulators: new frontiers in GPCR drug discovery Trends Pharmacol. Sci. 2021 42 283 299 10.1016/j.tips.2020.12.005 33581873
Slosky, L. M., Caron, M. G. & Barak, L. S. Biased allosteric modulators: new frontiers in GPCR drug discovery. Trends Pharmacol. Sci. 42, 283–299 (2021).33581873 10.1016/j.tips.2020.12.005
27. Tan L Yan WZ McCorvy JD Cheng JJ Biased ligands of G Protein-Coupled Receptors (GPCRs): Structure-Functional Selectivity Relationships (SFSRs) and therapeutic potential J. Med. Chem. 2018 61 9841 9878 10.1021/acs.jmedchem.8b00435 29939744
Tan, L., Yan, W. Z., McCorvy, J. D. & Cheng, J. J. Biased ligands of G Protein-Coupled Receptors (GPCRs): Structure-Functional Selectivity Relationships (SFSRs) and therapeutic potential. J. Med. Chem. 61, 9841–9878 (2018).29939744 10.1021/acs.jmedchem.8b00435
28. Robertson MJ Meyerowitz JG Skiniotis G Drug discovery in the era of cryo-electron microscopy Trends Biochem. Sci. 2022 47 124 135 10.1016/j.tibs.2021.06.008 34281791
Robertson, M. J., Meyerowitz, J. G. & Skiniotis, G. Drug discovery in the era of cryo-electron microscopy. Trends Biochem. Sci. 47, 124–135 (2022).34281791 10.1016/j.tibs.2021.06.008
29. Palczewski K Crystal structure of rhodopsin: A G protein-coupled receptor Science 2000 289 739 745 10.1126/science.289.5480.739 10926528
Palczewski, K. et al. Crystal structure of rhodopsin: A G protein-coupled receptor. Science 289, 739–745 (2000).10926528 10.1126/science.289.5480.739
30. Rasmussen SGF Crystal structure of the human β2 adrenergic G-protein-coupled receptor Nature 2007 450 383 387 10.1038/nature06325 17952055
Rasmussen, S. G. F. et al. Crystal structure of the human β2 adrenergic G-protein-coupled receptor. Nature 450, 383–387 (2007).17952055 10.1038/nature06325
31. Ghosh E Kumari P Jaiman D Shukla AK Methodological advances: the unsung heroes of the GPCR structural revolution Nat. Rev. Mol. Cell Biol. 2015 16 69 81 10.1038/nrm3933 25589408
Ghosh, E., Kumari, P., Jaiman, D. & Shukla, A. K. Methodological advances: the unsung heroes of the GPCR structural revolution. Nat. Rev. Mol. Cell Biol. 16, 69–81 (2015).25589408 10.1038/nrm3933
32. Cherezov V High-resolution crystal structure of an engineered human β2-adrenergic G protein-coupled receptor Science 2007 318 1258 1265 10.1126/science.1150577 17962520
Cherezov, V. et al. High-resolution crystal structure of an engineered human β2-adrenergic G protein-coupled receptor. Science 318, 1258–1265 (2007).17962520 10.1126/science.1150577
33. Rosenbaum DM GPCR engineering yields high-resolution structural insights into β2-adrenergic receptor function Science 2007 318 1266 1273 10.1126/science.1150609 17962519
Rosenbaum, D. M. et al. GPCR engineering yields high-resolution structural insights into β2-adrenergic receptor function. Science 318, 1266–1273 (2007).17962519 10.1126/science.1150609
34. Chen QY Tesmer JJG G protein-coupled receptor interactions with arrestins and GPCR kinases: The unresolved issue of signal bias J. Biol. Chem. 2022 298 102279 10.1016/j.jbc.2022.102279 35863432
Chen, Q. Y. & Tesmer, J. J. G. G protein-coupled receptor interactions with arrestins and GPCR kinases: The unresolved issue of signal bias. J. Biol. Chem. 298, 102279 (2022).35863432 10.1016/j.jbc.2022.102279
35. Li DF Caffrey M Structure and functional characterization of membrane integral proteins in the lipid cubic phase J. Mol. Biol. 2020 432 5104 5123 10.1016/j.jmb.2020.02.024 32113953
Li, D. F. & Caffrey, M. Structure and functional characterization of membrane integral proteins in the lipid cubic phase. J. Mol. Biol. 432, 5104–5123 (2020).32113953 10.1016/j.jmb.2020.02.024
36. Srivastava A High-resolution structure of the human GPR40 receptor bound to allosteric agonist TAK-875 Nature 2014 513 124 127 10.1038/nature13494 25043059
Srivastava, A. et al. High-resolution structure of the human GPR40 receptor bound to allosteric agonist TAK-875. Nature 513, 124–127 (2014).25043059 10.1038/nature13494
37. Manglik A Kobilka BK Steyaert J Nanobodies to study G protein-coupled receptor structure and function Annu. Rev. Pharmacol. Toxicol. 2017 57 19 37 10.1146/annurev-pharmtox-010716-104710 27959623
Manglik, A., Kobilka, B. K. & Steyaert, J. Nanobodies to study G protein-coupled receptor structure and function. Annu. Rev. Pharmacol. Toxicol. 57, 19–37 (2017).27959623 10.1146/annurev-pharmtox-010716-104710
38. Scheerer P Crystal structure of opsin in its G-protein-interacting conformation Nature 2008 455 497 502 10.1038/nature07330 18818650
Scheerer, P. et al. Crystal structure of opsin in its G-protein-interacting conformation. Nature 455, 497–502 (2008).18818650 10.1038/nature07330
39. Shimada I GPCR drug discovery: integrating solution NMR data with crystal and cryo-EM structures Nat. Rev. Drug Discov. 2019 18 59 82 10.1038/nrd.2018.180 30410121
Shimada, I. et al. GPCR drug discovery: integrating solution NMR data with crystal and cryo-EM structures. Nat. Rev. Drug Discov. 18, 59–82 (2019).30410121 10.1038/nrd.2018.180
40. Berman HM The protein data bank Nucleic Acids Res 2000 28 235 242 10.1093/nar/28.1.235 10592235
Berman, H. M. et al. The protein data bank. Nucleic Acids Res 28, 235–242 (2000).10592235 10.1093/nar/28.1.235
41. Ishchenko A Gati C Cherezov V Structural biology of G protein-coupled receptors: new opportunities from XFELs and cryoEM Curr. Opin. Struct. Biol. 2018 51 44 52 10.1016/j.sbi.2018.03.009 29554543
Ishchenko, A., Gati, C. & Cherezov, V. Structural biology of G protein-coupled receptors: new opportunities from XFELs and cryoEM. Curr. Opin. Struct. Biol. 51, 44–52 (2018).29554543 10.1016/j.sbi.2018.03.009
42. Bostock MJ Solt AS Nietlispach D The role of NMR spectroscopy in mapping the conformational landscape of GPCRs Curr. Opin. Struct. Biol. 2019 57 145 156 10.1016/j.sbi.2019.03.030 31075520
Bostock, M. J., Solt, A. S. & Nietlispach, D. The role of NMR spectroscopy in mapping the conformational landscape of GPCRs. Curr. Opin. Struct. Biol. 57, 145–156 (2019).31075520 10.1016/j.sbi.2019.03.030
43. Park SH Lee JH Dynamic G protein-coupled receptor signaling probed by solution NMR Spectroscopy Biochemistry 2020 59 1065 1080 10.1021/acs.biochem.0c00032 32092261
Park, S. H. & Lee, J. H. Dynamic G protein-coupled receptor signaling probed by solution NMR Spectroscopy. Biochemistry 59, 1065–1080 (2020).32092261 10.1021/acs.biochem.0c00032
44. Asher WB Single-molecule FRET imaging of GPCR dimers in living cells Nat. Methods 2021 18 397 405 10.1038/s41592-021-01081-y 33686301
Asher, W. B. et al. Single-molecule FRET imaging of GPCR dimers in living cells. Nat. Methods 18, 397–405 (2021).33686301 10.1038/s41592-021-01081-y
45. Shi P A genetically encoded small-size fluorescent pair reveals allosteric conformational changes of G proteins upon its interaction with GPCRs by fluorescence lifetime based FRET Chem. Commun. 2020 56 6941 6944 10.1039/D0CC02691C
Shi, P. et al. A genetically encoded small-size fluorescent pair reveals allosteric conformational changes of G proteins upon its interaction with GPCRs by fluorescence lifetime based FRET. Chem. Commun. 56, 6941–6944 (2020).10.1039/D0CC02691C
46. Sandhu M Conformational plasticity of the intracellular cavity of GPCR-G-protein complexes leads to G-protein promiscuity and selectivity Proc. Natl Acad. Sci. USA 2019 116 11956 11965 10.1073/pnas.1820944116 31138704
Sandhu, M. et al. Conformational plasticity of the intracellular cavity of GPCR-G-protein complexes leads to G-protein promiscuity and selectivity. Proc. Natl Acad. Sci. USA 116, 11956–11965 (2019).31138704 10.1073/pnas.1820944116
47. Zhang MY Decoding the conformational selective mechanism of FGFR Isoforms: A comparative molecular dynamics simulation Molecules 2023 28 2709 2727 10.3390/molecules28062709 36985681
Zhang, M. Y. et al. Decoding the conformational selective mechanism of FGFR Isoforms: A comparative molecular dynamics simulation. Molecules 28, 2709–2727 (2023).36985681 10.3390/molecules28062709
48. Aydin Y Structural details of a Class B GPCR-arrestin complex revealed by genetically encoded crosslinkers in living cells Nat. Commun. 2023 14 1151 10.1038/s41467-023-36797-2 36859440
Aydin, Y. et al. Structural details of a Class B GPCR-arrestin complex revealed by genetically encoded crosslinkers in living cells. Nat. Commun. 14, 1151 (2023).36859440 10.1038/s41467-023-36797-2
49. Hauser AS Common coupling map advances GPCR-G protein selectivity Elife 2022 11 e74107 10.7554/eLife.74107 35302494
Hauser, A. S. et al. Common coupling map advances GPCR-G protein selectivity. Elife 11, e74107 (2022).35302494 10.7554/eLife.74107
50. Inoue A Illuminating G-protein-coupling selectivity of GPCRs Cell 2019 177 1933 1947 10.1016/j.cell.2019.04.044 31160049
Inoue, A. et al. Illuminating G-protein-coupling selectivity of GPCRs. Cell 177, 1933–1947 (2019).31160049 10.1016/j.cell.2019.04.044
51. Leftowitz RJ Shenoy SK Transduction of receptor signals by β-arrestins Science 2005 308 512 517 10.1126/science.1109237 15845844
Leftowitz, R. J. & Shenoy, S. K. Transduction of receptor signals by β-arrestins. Science 308, 512–517 (2005).15845844 10.1126/science.1109237
52. Ranjan R Novel structural insights into GPCR-β-Arrestin interaction and signaling Trends Cell Biol. 2017 27 861 872 10.1016/j.tcb.2017.05.008
Ranjan, R. et al. Novel structural insights into GPCR-β-Arrestin interaction and signaling. Trends Cell Biol. 27, 861–872 (2017).10.1016/j.tcb.2017.05.008
53. Milligan G Ward RJ Marsango S GPCR homo-oligomerization Curr. Opin. Cell Biol. 2019 57 40 47 10.1016/j.ceb.2018.10.007 30453145
Milligan, G., Ward, R. J. & Marsango, S. GPCR homo-oligomerization. Curr. Opin. Cell Biol. 57, 40–47 (2019).30453145 10.1016/j.ceb.2018.10.007
54. Bulenger S Marullo S Bouvier M Emerging role of homo- and heterodimerization in G-protein-coupled receptor biosynthesis and maturation Trends Pharmacol. Sci. 2005 26 131 137 10.1016/j.tips.2005.01.004 15749158
Bulenger, S., Marullo, S. & Bouvier, M. Emerging role of homo- and heterodimerization in G-protein-coupled receptor biosynthesis and maturation. Trends Pharmacol. Sci. 26, 131–137 (2005).15749158 10.1016/j.tips.2005.01.004
55. Sato M Blumer JB Simon V Lanier SM Accessory proteins for G proteins: Partners in signaling Annu. Rev. Pharmacol. Toxicol. 2006 46 151 187 10.1146/annurev.pharmtox.46.120604.141115 16402902
Sato, M., Blumer, J. B., Simon, V. & Lanier, S. M. Accessory proteins for G proteins: Partners in signaling. Annu. Rev. Pharmacol. Toxicol. 46, 151–187 (2006).16402902 10.1146/annurev.pharmtox.46.120604.141115
56. Rouault AAJ The GPCR accessory protein MRAP2 regulates both biased signaling and constitutive activity of the ghrelin receptor GHSR1a Sci. Signal. 2020 13 eaax4569 10.1126/scisignal.aax4569 31911434
Rouault, A. A. J. et al. The GPCR accessory protein MRAP2 regulates both biased signaling and constitutive activity of the ghrelin receptor GHSR1a. Sci. Signal. 13, eaax4569 (2020).31911434 10.1126/scisignal.aax4569
57. Serafin DS Dawn of a New RAMPage Trends Pharmacol. Sci. 2020 41 249 265 10.1016/j.tips.2020.01.009 32115276
Serafin, D. S. et al. Dawn of a New RAMPage. Trends Pharmacol. Sci. 41, 249–265 (2020).32115276 10.1016/j.tips.2020.01.009
58. Wang, M., Lyu, J. J. & Zhang, C. Single transmembrane GPCR modulating proteins: neither single nor simple. Protein Cell pwad035 (2023).
59. Kumar KK Negative allosteric modulation of the glucagon receptor by RAMP2 Cell 2023 186 1465 1477 10.1016/j.cell.2023.02.028 37001505
Kumar, K. K. et al. Negative allosteric modulation of the glucagon receptor by RAMP2. Cell 186, 1465–1477 (2023).37001505 10.1016/j.cell.2023.02.028
60. Luo P Structural basis of signaling regulation of the human melanocortin-2 receptor by MRAP1 Cell Res 2023 33 46 54 10.1038/s41422-022-00751-6 36588120
Luo, P. et al. Structural basis of signaling regulation of the human melanocortin-2 receptor by MRAP1. Cell Res 33, 46–54 (2023).36588120 10.1038/s41422-022-00751-6
61. Manglik A Kruse AC Structural basis for G protein-coupled receptor activation Biochemistry 2017 56 5628 5634 10.1021/acs.biochem.7b00747 28967738
Manglik, A. & Kruse, A. C. Structural basis for G protein-coupled receptor activation. Biochemistry 56, 5628–5634 (2017).28967738 10.1021/acs.biochem.7b00747
62. Filipek S Molecular switches in GPCRs Curr. Opin. Struct. Biol. 2019 55 114 120 10.1016/j.sbi.2019.03.017 31082695
Filipek, S. Molecular switches in GPCRs. Curr. Opin. Struct. Biol. 55, 114–120 (2019).31082695 10.1016/j.sbi.2019.03.017
63. Mafi A Kim S-K Goddard III WA The mechanism for ligand activation of the GPCR–G protein complex Proc. Natl Acad. Sci. USA 2022 119 e2110085119 10.1073/pnas.2110085119 35452328
Mafi, A., Kim, S.-K. & Goddard III, W. A. The mechanism for ligand activation of the GPCR–G protein complex. Proc. Natl Acad. Sci. USA 119, e2110085119 (2022).35452328 10.1073/pnas.2110085119
64. Hori T Na+-mimicking ligands stabilize the inactive state of leukotriene B4 receptor BLT1 Nat. Chem. Biol. 2018 14 262 269 10.1038/nchembio.2547 29309055
Hori, T. et al. Na+-mimicking ligands stabilize the inactive state of leukotriene B4 receptor BLT1. Nat. Chem. Biol. 14, 262–269 (2018).29309055 10.1038/nchembio.2547
65. Selvam B Shamsi Z Shukla D Universality of the sodium ion binding mechanism in Class A G-protein-coupled receptors Angew. Chem. Int. Ed. 2018 57 3048 3053 10.1002/anie.201708889
Selvam, B., Shamsi, Z. & Shukla, D. Universality of the sodium ion binding mechanism in Class A G-protein-coupled receptors. Angew. Chem. Int. Ed. 57, 3048–3053 (2018).10.1002/anie.201708889
66. Liu W Structural basis for allosteric regulation of GPCRs by Sodium ions Science 2012 337 232 236 10.1126/science.1219218 22798613
Liu, W. et al. Structural basis for allosteric regulation of GPCRs by Sodium ions. Science 337, 232–236 (2012).22798613 10.1126/science.1219218
67. Katritch V Allosteric sodium in class A GPCR signaling Trends Biochem. Sci. 2014 39 233 244 10.1016/j.tibs.2014.03.002 24767681
Katritch, V. et al. Allosteric sodium in class A GPCR signaling. Trends Biochem. Sci. 39, 233–244 (2014).24767681 10.1016/j.tibs.2014.03.002
68. DeWire SM AG protein-biased ligand at the μ-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine J. Pharmacol. Exp. Ther. 2013 344 708 717 10.1124/jpet.112.201616 23300227
DeWire, S. M. et al. AG protein-biased ligand at the μ-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine. J. Pharmacol. Exp. Ther. 344, 708–717 (2013).23300227 10.1124/jpet.112.201616
69. Manglik A Structure-based discovery of opioid analgesics with reduced side effects Nature 2016 537 185 190 10.1038/nature19112 27533032
Manglik, A. et al. Structure-based discovery of opioid analgesics with reduced side effects. Nature 537, 185–190 (2016).27533032 10.1038/nature19112
70. Schmid CL Bias factor and therapeutic window correlate to predict safer opioid analgesics Cell 2017 171 1165 1175 10.1016/j.cell.2017.10.035 29149605
Schmid, C. L. et al. Bias factor and therapeutic window correlate to predict safer opioid analgesics. Cell 171, 1165–1175 (2017).29149605 10.1016/j.cell.2017.10.035
71. Hu GM Mai TL Chen CM Visualizing the GPCR network: classification and evolution Sci. Rep. 2017 7 15495 10.1038/s41598-017-15707-9 29138525
Hu, G. M., Mai, T. L. & Chen, C. M. Visualizing the GPCR network: classification and evolution. Sci. Rep. 7, 15495 (2017).29138525 10.1038/s41598-017-15707-9
72. Foster SR Discovery of human signaling systems: pairing peptides to G protein-coupled receptors Cell 2019 179 895 908 10.1016/j.cell.2019.10.010 31675498
Foster, S. R. et al. Discovery of human signaling systems: pairing peptides to G protein-coupled receptors. Cell 179, 895–908 (2019).31675498 10.1016/j.cell.2019.10.010
73. Pal K Melcher K Xu HE Structure and mechanism for recognition of peptide hormones by Class B G-protein-coupled receptors Acta Pharmacol. Sin. 2012 33 300 311 10.1038/aps.2011.170 22266723
Pal, K., Melcher, K. & Xu, H. E. Structure and mechanism for recognition of peptide hormones by Class B G-protein-coupled receptors. Acta Pharmacol. Sin. 33, 300–311 (2012).22266723 10.1038/aps.2011.170
74. Yu MZ Battle of GLP-1 delivery technologies Adv. Drug Deliv. Rev. 2018 130 113 130 10.1016/j.addr.2018.07.009 30009885
Yu, M. Z. et al. Battle of GLP-1 delivery technologies. Adv. Drug Deliv. Rev. 130, 113–130 (2018).30009885 10.1016/j.addr.2018.07.009
75. Williams DM Nawaz A Evans M Drug therapy in obesity: a review of current and emerging treatments Diabetes Ther. 2020 11 1199 1216 10.1007/s13300-020-00816-y 32297119
Williams, D. M., Nawaz, A. & Evans, M. Drug therapy in obesity: a review of current and emerging treatments. Diabetes Ther. 11, 1199–1216 (2020).32297119 10.1007/s13300-020-00816-y
76. Bondarev AD Opportunities and challenges for drug discovery in modulating Adhesion G protein-coupled receptor (GPCR) functions Expert Opin. Drug Discov. 2020 15 1291 1307 10.1080/17460441.2020.1791075 32648789
Bondarev, A. D. et al. Opportunities and challenges for drug discovery in modulating Adhesion G protein-coupled receptor (GPCR) functions. Expert Opin. Drug Discov. 15, 1291–1307 (2020).32648789 10.1080/17460441.2020.1791075
77. Pin JP Allosteric functioning of dimeric class C G-protein-coupled receptors Febs J. 2005 272 2947 2955 10.1111/j.1742-4658.2005.04728.x 15955055
Pin, J. P. et al. Allosteric functioning of dimeric class C G-protein-coupled receptors. Febs J. 272, 2947–2955 (2005).15955055 10.1111/j.1742-4658.2005.04728.x
78. Schulte G Wright SC Frizzleds as GPCRs - More conventional than we thought! Trends Pharmacol. Sci. 2018 39 828 842 10.1016/j.tips.2018.07.001 30049420
Schulte, G. & Wright, S. C. Frizzleds as GPCRs - More conventional than we thought! Trends Pharmacol. Sci. 39, 828–842 (2018).30049420 10.1016/j.tips.2018.07.001
79. Ruat M Hoch L Faure H Rognan D Targeting of smoothened for therapeutic gain Trends Pharmacol. Sci. 2014 35 237 246 10.1016/j.tips.2014.03.002 24703627
Ruat, M., Hoch, L., Faure, H. & Rognan, D. Targeting of smoothened for therapeutic gain. Trends Pharmacol. Sci. 35, 237–246 (2014).24703627 10.1016/j.tips.2014.03.002
80. Gruhl T Ultrafast structural changes direct the first molecular events of vision Nature 2023 615 939 944 10.1038/s41586-023-05863-6 36949205
Gruhl, T. et al. Ultrafast structural changes direct the first molecular events of vision. Nature 615, 939–944 (2023).36949205 10.1038/s41586-023-05863-6
81. Guo LL Structural basis of amine odorant perception by a mammal olfactory receptor Nature 2023 618 193 200 10.1038/s41586-023-06106-4 37225986
Guo, L. L. et al. Structural basis of amine odorant perception by a mammal olfactory receptor. Nature 618, 193–200 (2023).37225986 10.1038/s41586-023-06106-4
82. Dewan A Olfactory signaling via trace amine-associated receptors Cell Tissue Res 2021 383 395 407 10.1007/s00441-020-03331-5 33237477
Dewan, A. Olfactory signaling via trace amine-associated receptors. Cell Tissue Res. 383, 395–407 (2021).33237477 10.1007/s00441-020-03331-5
83. Ozeck M Brust P Xu H Servant G Receptors for bitter, sweet and umami taste couple to inhibitory G protein signaling pathways Eur. J. Pharm. 2004 489 139 149 10.1016/j.ejphar.2004.03.004
Ozeck, M., Brust, P., Xu, H. & Servant, G. Receptors for bitter, sweet and umami taste couple to inhibitory G protein signaling pathways. Eur. J. Pharm. 489, 139–149 (2004).10.1016/j.ejphar.2004.03.004
84. Ahmad R Dalziel JEG Protein-coupled receptors in taste physiology and pharmacology Front. Pharmacol. 2020 11 587664 10.3389/fphar.2020.587664 33390961
Ahmad, R. & Dalziel, J. E. G. Protein-coupled receptors in taste physiology and pharmacology. Front. Pharmacol. 11, 587664 (2020).33390961 10.3389/fphar.2020.587664
85. Xu WX Structural basis for strychnine activation of human bitter taste receptor TAS2R46 Science 2022 377 1298 1303 10.1126/science.abo1633 36108005
Xu, W. X. et al. Structural basis for strychnine activation of human bitter taste receptor TAS2R46. Science 377, 1298–1303 (2022).36108005 10.1126/science.abo1633
86. Rubovitch V Gafni M Sarne Y The mu opioid agonist DAMGO stimulates cAMP production in SK-N-SH cells through a PLC-PKC-Ca++ pathway Mol. Brain Res. 2003 110 261 266 10.1016/S0169-328X(02)00656-3 12591162
Rubovitch, V., Gafni, M. & Sarne, Y. The mu opioid agonist DAMGO stimulates cAMP production in SK-N-SH cells through a PLC-PKC-Ca++ pathway. Mol. Brain Res. 110, 261–266 (2003).12591162 10.1016/S0169-328X(02)00656-3
87. Zhu C Allosteric modulation of G protein-coupled receptors as a novel therapeutic strategy in neuropathic pain Acta Pharm. Sin. B 2023 14 67 86 10.1016/j.apsb.2023.07.020 38239234
Zhu, C. et al. Allosteric modulation of G protein-coupled receptors as a novel therapeutic strategy in neuropathic pain. Acta Pharm. Sin. B 14, 67–86 (2023).38239234 10.1016/j.apsb.2023.07.020
88. Faouzi A Structure-based design of bitopic ligands for the μ-opioid receptor Nature 2023 613 767 774 10.1038/s41586-022-05588-y 36450356
Faouzi, A. et al. Structure-based design of bitopic ligands for the μ-opioid receptor. Nature 613, 767–774 (2023).36450356 10.1038/s41586-022-05588-y
89. Katona I Freund TF Endocannabinoid signaling as a synaptic circuit breaker in neurological disease Nat. Med. 2008 14 923 930 10.1038/nm.f.1869 18776886
Katona, I. & Freund, T. F. Endocannabinoid signaling as a synaptic circuit breaker in neurological disease. Nat. Med. 14, 923–930 (2008).18776886 10.1038/nm.f.1869
90. Galve-Roperh I Cannabinoid receptor signaling in progenitor/stem cell proliferation and differentiation Prog. Lipid Res. 2013 52 633 650 10.1016/j.plipres.2013.05.004 24076098
Galve-Roperh, I. et al. Cannabinoid receptor signaling in progenitor/stem cell proliferation and differentiation. Prog. Lipid Res. 52, 633–650 (2013).24076098 10.1016/j.plipres.2013.05.004
91. Ignatowska-Jankowska BM A Cannabinoid CB1 receptor-positive allosteric modulator reduces neuropathic pain in the mouse with no psychoactive effects Neuropsychopharmacol 2015 40 2948 2959 10.1038/npp.2015.148
Ignatowska-Jankowska, B. M. et al. A Cannabinoid CB1 receptor-positive allosteric modulator reduces neuropathic pain in the mouse with no psychoactive effects. Neuropsychopharmacol 40, 2948–2959 (2015).10.1038/npp.2015.148
92. Husted AS GPCR-mediated signaling of metabolites Cell Metab. 2017 25 777 796 10.1016/j.cmet.2017.03.008 28380372
Husted, A. S. et al. GPCR-mediated signaling of metabolites. Cell Metab. 25, 777–796 (2017).28380372 10.1016/j.cmet.2017.03.008
93. Oh DY A Gpr120-selective agonist improves insulin resistance and chronic inflammation in obese mice Nat. Med. 2014 20 942 947 10.1038/nm.3614 24997608
Oh, D. Y. et al. A Gpr120-selective agonist improves insulin resistance and chronic inflammation in obese mice. Nat. Med. 20, 942–947 (2014).24997608 10.1038/nm.3614
94. Oh DY GPR120 Is an Omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects Cell 2010 142 687 698 10.1016/j.cell.2010.07.041 20813258
Oh, D. Y. et al. GPR120 Is an Omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell 142, 687–698 (2010).20813258 10.1016/j.cell.2010.07.041
95. Divino V Glucagon-like Peptide-1 receptor agonist treatment patterns among Type 2 diabetes patients in six European countries Diabetes Ther. 2014 5 499 520 10.1007/s13300-014-0087-6 25366334
Divino, V. et al. Glucagon-like Peptide-1 receptor agonist treatment patterns among Type 2 diabetes patients in six European countries. Diabetes Ther. 5, 499–520 (2014).25366334 10.1007/s13300-014-0087-6
96. Kaupmann K GABA(B)-receptor subtypes assemble into functional heteromeric complexes Nature 1998 396 683 687 10.1038/25360 9872317
Kaupmann, K. et al. GABA(B)-receptor subtypes assemble into functional heteromeric complexes. Nature 396, 683–687 (1998).9872317 10.1038/25360
97. Ginés S Dopamine D and adenosine A receptors form functionally interacting heteromeric complexes Proc. Natl Acad. Sci. USA 2000 97 8606 8611 10.1073/pnas.150241097 10890919
Ginés, S. et al. Dopamine D and adenosine A receptors form functionally interacting heteromeric complexes. Proc. Natl Acad. Sci. USA 97, 8606–8611 (2000).10890919 10.1073/pnas.150241097
98. Pulido D Heterobivalent ligand for the Adenosine A2A-Dopamine D2 receptor heteromer J. Med. Chem. 2022 65 616 632 10.1021/acs.jmedchem.1c01763 34982555
Pulido, D. et al. Heterobivalent ligand for the Adenosine A2A-Dopamine D2 receptor heteromer. J. Med. Chem. 65, 616–632 (2022).34982555 10.1021/acs.jmedchem.1c01763
99. AbdAlla S Lother H Quitterer U AT1-receptor heterodimers show enhanced G-protein activation and altered receptor sequestration Nature 2000 407 94 98 10.1038/35024095 10993080
AbdAlla, S., Lother, H. & Quitterer, U. AT1-receptor heterodimers show enhanced G-protein activation and altered receptor sequestration. Nature 407, 94–98 (2000).10993080 10.1038/35024095
100. Selbie LA Hill SJ G protein-coupled-receptor cross-talk: the fine-tuning of multiple receptor-signalling pathways Trends Pharmacol. Sci. 1998 19 87 93 10.1016/S0165-6147(97)01166-8 9584624
Selbie, L. A. & Hill, S. J. G protein-coupled-receptor cross-talk: the fine-tuning of multiple receptor-signalling pathways. Trends Pharmacol. Sci. 19, 87–93 (1998).9584624 10.1016/S0165-6147(97)01166-8
101. Cordeaux Y Hill SJ Mechanisms of cross-talk between G-protein-coupled receptors Neurosignals 2002 11 45 57 10.1159/000057321 11943882
Cordeaux, Y. & Hill, S. J. Mechanisms of cross-talk between G-protein-coupled receptors. Neurosignals 11, 45–57 (2002).11943882 10.1159/000057321
102. Maziarz M Naturally occurring hotspot cancer mutations in Gα13 promote oncogenic signaling J. Biol. Chem. 2020 295 16897 16904 10.1074/jbc.AC120.014698 33109615
Maziarz, M. et al. Naturally occurring hotspot cancer mutations in Gα13 promote oncogenic signaling. J. Biol. Chem. 295, 16897–16904 (2020).33109615 10.1074/jbc.AC120.014698
103. Khamaysi Z Segmental basal cell naevus syndrome caused by an activating mutation in smoothened Br. J. Dermatol. 2016 175 178 181 10.1111/bjd.14425 26822128
Khamaysi, Z. et al. Segmental basal cell naevus syndrome caused by an activating mutation in smoothened. Br. J. Dermatol. 175, 178–181 (2016).26822128 10.1111/bjd.14425
104. Vaisse C Clement K Guy-Grand B Froguel P A frameshift mutation in human MC4R is associated with a dominant form of obesity Nat. Genet. 1998 20 113 114 10.1038/2407 9771699
Vaisse, C., Clement, K., Guy-Grand, B. & Froguel, P. A frameshift mutation in human MC4R is associated with a dominant form of obesity. Nat. Genet. 20, 113–114 (1998).9771699 10.1038/2407
105. Schöneberg T Mutant G-protein-coupled receptors as a cause of human diseases Pharmacol. Ther. 2004 104 173 206 10.1016/j.pharmthera.2004.08.008 15556674
Schöneberg, T. et al. Mutant G-protein-coupled receptors as a cause of human diseases. Pharmacol. Ther. 104, 173–206 (2004).15556674 10.1016/j.pharmthera.2004.08.008
106. Bockenhauer D Bichet DG Pathophysiology, diagnosis and management of nephrogenic diabetes insipidus Nat. Rev. Nephrol. 2015 11 576 588 10.1038/nrneph.2015.89 26077742
Bockenhauer, D. & Bichet, D. G. Pathophysiology, diagnosis and management of nephrogenic diabetes insipidus. Nat. Rev. Nephrol. 11, 576–588 (2015).26077742 10.1038/nrneph.2015.89
107. Franco R Rivas-Santisteban R Navarro G Reyes-Resina I Adenosine receptor antagonists to combat cancer and to boost anti-cancer chemotherapy and immunotherapy Cells 2021 10 2831 2843 10.3390/cells10112831 34831054
Franco, R., Rivas-Santisteban, R., Navarro, G. & Reyes-Resina, I. Adenosine receptor antagonists to combat cancer and to boost anti-cancer chemotherapy and immunotherapy. Cells 10, 2831–2843 (2021).34831054 10.3390/cells10112831
108. Beerepoot P Nazari R Salahpour A Pharmacological chaperone approaches for rescuing GPCR mutants: Current state, challenges, and screening strategies Pharmacol. Res. 2017 117 242 251 10.1016/j.phrs.2016.12.036 28027910
Beerepoot, P., Nazari, R. & Salahpour, A. Pharmacological chaperone approaches for rescuing GPCR mutants: Current state, challenges, and screening strategies. Pharmacol. Res. 117, 242–251 (2017).28027910 10.1016/j.phrs.2016.12.036
109. Schöneberg T Schultz G Gudermann T Structural basis of G protein-coupled receptor function Mol. Cell Endocrinol. 1999 151 181 193 10.1016/S0303-7207(99)00017-9 10411333
Schöneberg, T., Schultz, G. & Gudermann, T. Structural basis of G protein-coupled receptor function. Mol. Cell Endocrinol. 151, 181–193 (1999).10411333 10.1016/S0303-7207(99)00017-9
110. Sora I Funada M Uhl GR The mu-opioid receptor is necessary for [D-Pen(2),D-Pen(5)]enkephalin-induced analgesia Eur. J. Pharm. 1997 324 R1 R2 10.1016/S0014-2999(97)10016-4
Sora, I., Funada, M. & Uhl, G. R. The mu-opioid receptor is necessary for [D-Pen(2),D-Pen(5)]enkephalin-induced analgesia. Eur. J. Pharm. 324, R1–R2 (1997).10.1016/S0014-2999(97)10016-4
111. Dogra S Sona C Kumar A Yadav PN Tango assay for ligand-induced GPCR-β-arrestin2 interaction: application in drug discovery Method Cell Biol. 2016 132 233 254 10.1016/bs.mcb.2015.11.001
Dogra, S., Sona, C., Kumar, A. & Yadav, P. N. Tango assay for ligand-induced GPCR-β-arrestin2 interaction: application in drug discovery. Method Cell Biol. 132, 233–254 (2016).10.1016/bs.mcb.2015.11.001
112. Di Fruscia P The discovery of indole full agonists of the neurotensin receptor 1 (NTSR1) Bioorg. Med. Chem. Lett. 2014 24 3974 3978 10.1016/j.bmcl.2014.06.033 24997685
Di Fruscia, P. et al. The discovery of indole full agonists of the neurotensin receptor 1 (NTSR1). Bioorg. Med. Chem. Lett. 24, 3974–3978 (2014).24997685 10.1016/j.bmcl.2014.06.033
113. Hershberger PM Imidazole-derived agonists for the neurotensin 1 receptor Bioorg. Med. Chem. Lett. 2014 24 262 267 10.1016/j.bmcl.2013.11.026 24332089
Hershberger, P. M. et al. Imidazole-derived agonists for the neurotensin 1 receptor. Bioorg. Med. Chem. Lett. 24, 262–267 (2014).24332089 10.1016/j.bmcl.2013.11.026
114. Fan Y The identification of neurotensin NTS1 receptor partial agonists through a ligand-based virtual screening approach Bioorg. Med. Chem. Lett. 2008 18 5789 5791 10.1016/j.bmcl.2008.09.075 18849166
Fan, Y. et al. The identification of neurotensin NTS1 receptor partial agonists through a ligand-based virtual screening approach. Bioorg. Med. Chem. Lett. 18, 5789–5791 (2008).18849166 10.1016/j.bmcl.2008.09.075
115. Gully D Biochemical and pharmacological profile of a potent and selective nonpeptide antagonist of the neurotensin receptor Proc. Natl Acad. Sci. USA 1993 90 65 69 10.1073/pnas.90.1.65 8380498
Gully, D. et al. Biochemical and pharmacological profile of a potent and selective nonpeptide antagonist of the neurotensin receptor. Proc. Natl Acad. Sci. USA 90, 65–69 (1993).8380498 10.1073/pnas.90.1.65
116. Gully D Biochemical and pharmacological activities of SR 142948A, a new potent neurotensin receptor antagonist J. Pharmacol. Exp. Ther. 1997 280 802 812 9023294
Gully, D. et al. Biochemical and pharmacological activities of SR 142948A, a new potent neurotensin receptor antagonist. J. Pharmacol. Exp. Ther. 280, 802–812 (1997).9023294
117. Wacker D Stevens RC Roth BL How ligands illuminate GPCR molecular pharmacology Cell 2017 170 414 427 10.1016/j.cell.2017.07.009 28753422
Wacker, D., Stevens, R. C. & Roth, B. L. How ligands illuminate GPCR molecular pharmacology. Cell 170, 414–427 (2017).28753422 10.1016/j.cell.2017.07.009
118. Lu X Mechanistic elucidation of activation/deactivation signal transduction within neurotensin Receptor 1 triggered by ‘driver chemical groups’ of modulators: a comparative molecular dynamics simulation Pharmaceutics 2023 15 2000 2015 10.3390/pharmaceutics15072000 37514186
Lu, X. et al. Mechanistic elucidation of activation/deactivation signal transduction within neurotensin Receptor 1 triggered by ‘driver chemical groups’ of modulators: a comparative molecular dynamics simulation. Pharmaceutics 15, 2000–2015 (2023).37514186 10.3390/pharmaceutics15072000
119. Avet C Effector membrane translocation biosensors reveal G protein and βarrestin coupling profiles of 100 therapeutically relevant GPCRs Elife 2022 11 e74101 10.7554/eLife.74101 35302493
Avet, C. et al. Effector membrane translocation biosensors reveal G protein and βarrestin coupling profiles of 100 therapeutically relevant GPCRs. Elife 11, e74101 (2022).35302493 10.7554/eLife.74101
120. Pándy-Szekeres G GPCRdb in 2023: state-specific structure models using AlphaFold2 and new ligand resources Nucleic Acids Res. 2023 51 D395 D402 10.1093/nar/gkac1013 36395823
Pándy-Szekeres, G. et al. GPCRdb in 2023: state-specific structure models using AlphaFold2 and new ligand resources. Nucleic Acids Res. 51, D395–D402 (2023).36395823 10.1093/nar/gkac1013
121. Manglik A Molecular basis of opioid action: from structures to new leads Biol. Psychiatry 2020 87 6 14 10.1016/j.biopsych.2019.08.028 31653480
Manglik, A. Molecular basis of opioid action: from structures to new leads. Biol. Psychiatry 87, 6–14 (2020).31653480 10.1016/j.biopsych.2019.08.028
122. Radoux-Mergault A Subcellular location defines GPCR signal transduction Sci. Adv. 2023 9 eadf6059 10.1126/sciadv.adf6059 37075112
Radoux-Mergault, A. et al. Subcellular location defines GPCR signal transduction. Sci. Adv. 9, eadf6059 (2023).37075112 10.1126/sciadv.adf6059
123. Matthes HWD Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene Nature 1996 383 819 823 10.1038/383819a0 8893006
Matthes, H. W. D. et al. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene. Nature 383, 819–823 (1996).8893006 10.1038/383819a0
124. Bartuzi D Kaczor AA Matosiuk D Activation and allosteric modulation of human μ opioid receptor in molecular dynamics J. Chem. Inf. Model. 2015 55 2421 2434 10.1021/acs.jcim.5b00280 26517559
Bartuzi, D., Kaczor, A. A. & Matosiuk, D. Activation and allosteric modulation of human μ opioid receptor in molecular dynamics. J. Chem. Inf. Model. 55, 2421–2434 (2015).26517559 10.1021/acs.jcim.5b00280
125. Raehal KM Schmid CL Groer CE Bohn LM Functional selectivity at the μ-opioid receptor: implications for understanding opioid analgesia and tolerance Pharmacol. Rev. 2011 63 1001 1019 10.1124/pr.111.004598 21873412
Raehal, K. M., Schmid, C. L., Groer, C. E. & Bohn, L. M. Functional selectivity at the μ-opioid receptor: implications for understanding opioid analgesia and tolerance. Pharmacol. Rev. 63, 1001–1019 (2011).21873412 10.1124/pr.111.004598
126. Raehal KM Walker JKL Bohn LM Morphine side effects in β-arrestin 2 knockout mice J. Pharmacol. Exp. Ther. 2005 314 1195 1201 10.1124/jpet.105.087254 15917400
Raehal, K. M., Walker, J. K. L. & Bohn, L. M. Morphine side effects in β-arrestin 2 knockout mice. J. Pharmacol. Exp. Ther. 314, 1195–1201 (2005).15917400 10.1124/jpet.105.087254
127. Bohn LM Enhanced morphine analgesia in mice lacking β-arrestin 2 Science 1999 286 2495 2498 10.1126/science.286.5449.2495 10617462
Bohn, L. M. et al. Enhanced morphine analgesia in mice lacking β-arrestin 2. Science 286, 2495–2498 (1999).10617462 10.1126/science.286.5449.2495
128. Kaneko S Activation mechanism of the μ-opioid receptor by an allosteric modulator Proc. Natl Acad. Sci. USA 2022 119 e2121918119 10.1073/pnas.2121918119 35412886
Kaneko, S. et al. Activation mechanism of the μ-opioid receptor by an allosteric modulator. Proc. Natl Acad. Sci. USA 119, e2121918119 (2022).35412886 10.1073/pnas.2121918119
129. Altarifi AA Effects of acute and repeated treatment with the biased mu opioid receptor agonist TRV130 (oliceridine) on measures of antinociception, gastrointestinal function, and abuse liability in rodents J. Psychopharmacol. 2017 31 730 739 10.1177/0269881116689257 28142305
Altarifi, A. A. et al. Effects of acute and repeated treatment with the biased mu opioid receptor agonist TRV130 (oliceridine) on measures of antinociception, gastrointestinal function, and abuse liability in rodents. J. Psychopharmacol. 31, 730–739 (2017).28142305 10.1177/0269881116689257
130. Zhuang YW Molecular recognition of morphine and fentanyl by the human μ-opioid receptor Cell 2022 185 4361 4375 10.1016/j.cell.2022.09.041 36368306
Zhuang, Y. W. et al. Molecular recognition of morphine and fentanyl by the human μ-opioid receptor. Cell 185, 4361–4375 (2022).36368306 10.1016/j.cell.2022.09.041
131. Chen, X. T. et al. Structure Activity Relationships and Discovery of a G Protein Biased μ Opioid Receptor Ligand, [(3-Methoxythiophen-2-yl)methyl]a2[(9R)-9-(pyridin-2-y1)-6-oxaspiro-[4.5]clecan-9-yl]ethylpamine (TRV130), for the Treatment of Acute Severe Pain. J. Med. Chem. 56, 8019–8031 (2013).
132. Proia RL Hla T Emerging biology of sphingosine-1-phosphate: its role in pathogenesis and therapy J. Clin. Investig. 2015 125 1379 1387 10.1172/JCI76369 25831442
Proia, R. L. & Hla, T. Emerging biology of sphingosine-1-phosphate: its role in pathogenesis and therapy. J. Clin. Investig. 125, 1379–1387 (2015).25831442 10.1172/JCI76369
133. Rosen H Sphingosine-1-phosphate and its receptors: structure, signaling, and influence Annu. Rev. Biochem. 2013 82 637 662 10.1146/annurev-biochem-062411-130916 23527695
Rosen, H. et al. Sphingosine-1-phosphate and its receptors: structure, signaling, and influence. Annu. Rev. Biochem. 82, 637–662 (2013).23527695 10.1146/annurev-biochem-062411-130916
134. Wang JL Gareri C Rockman HA G-protein-coupled receptors in heart disease Circ. Res. 2018 123 716 735 10.1161/CIRCRESAHA.118.311403 30355236
Wang, J. L., Gareri, C. & Rockman, H. A. G-protein-coupled receptors in heart disease. Circ. Res. 123, 716–735 (2018).30355236 10.1161/CIRCRESAHA.118.311403
135. O’Sullivan C Dev KK The structure and function of the S1P1 receptor Trends Pharmacol. Sci. 2013 34 401 412 10.1016/j.tips.2013.05.002 23763867
O’Sullivan, C. & Dev, K. K. The structure and function of the S1P1 receptor. Trends Pharmacol. Sci. 34, 401–412 (2013).23763867 10.1016/j.tips.2013.05.002
136. Liu SA Differential activation mechanisms of lipid GPCRs by lysophosphatidic acid and sphingosine 1-phosphate Nat. Commun. 2022 13 731 741 10.1038/s41467-022-28417-2 35136060
Liu, S. A. et al. Differential activation mechanisms of lipid GPCRs by lysophosphatidic acid and sphingosine 1-phosphate. Nat. Commun. 13, 731–741 (2022).35136060 10.1038/s41467-022-28417-2
137. McGinley MP Cohen JA Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions Lancet 2021 398 1184 1194 10.1016/S0140-6736(21)00244-0 34175020
McGinley, M. P. & Cohen, J. A. Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions. Lancet 398, 1184–1194 (2021).34175020 10.1016/S0140-6736(21)00244-0
138. Strader CR Pearce CJ Oberlies NH Fingolimod (FTY720): A recently approved multiple sclerosis drug based on a fungal secondary metabolite J. Nat. Prod. 2011 74 900 907 10.1021/np2000528 21456524
Strader, C. R., Pearce, C. J. & Oberlies, N. H. Fingolimod (FTY720): A recently approved multiple sclerosis drug based on a fungal secondary metabolite. J. Nat. Prod. 74, 900–907 (2011).21456524 10.1021/np2000528
139. Al-Salama ZT Siponimod: First global approval Drugs 2019 79 1009 1015 10.1007/s40265-019-01140-x 31144287
Al-Salama, Z. T. Siponimod: First global approval. Drugs 79, 1009–1015 (2019).31144287 10.1007/s40265-019-01140-x
140. Yang F Structural basis of GPBAR activation and bile acid recognition Nature 2020 587 499 504 10.1038/s41586-020-2569-1 32698187
Yang, F. et al. Structural basis of GPBAR activation and bile acid recognition. Nature 587, 499–504 (2020).32698187 10.1038/s41586-020-2569-1
141. Zhao C Biased allosteric activation of ketone body receptor HCAR2 suppresses inflammation Mol. Cell 2023 83 3171 3187 10.1016/j.molcel.2023.07.030 37597514
Zhao, C. et al. Biased allosteric activation of ketone body receptor HCAR2 suppresses inflammation. Mol. Cell 83, 3171–3187 (2023).37597514 10.1016/j.molcel.2023.07.030
142. Yuan Y Structures of signaling complexes of lipid receptors S1PR1 and S1PR5 reveal mechanisms of activation and drug recognition Cell Res 2021 31 1263 1274 10.1038/s41422-021-00566-x 34526663
Yuan, Y. et al. Structures of signaling complexes of lipid receptors S1PR1 and S1PR5 reveal mechanisms of activation and drug recognition. Cell Res 31, 1263–1274 (2021).34526663 10.1038/s41422-021-00566-x
143. Xu XY Binding pathway determines norepinephrine selectivity for the human β1AR over β2AR Cell Res 2021 31 569 579 10.1038/s41422-020-00424-2 33093660
Xu, X. Y. et al. Binding pathway determines norepinephrine selectivity for the human β1AR over β2AR. Cell Res 31, 569–579 (2021).33093660 10.1038/s41422-020-00424-2
144. Hanson MA Crystal structure of a lipid G protein-coupled receptor Science 2012 335 851 855 10.1126/science.1215904 22344443
Hanson, M. A. et al. Crystal structure of a lipid G protein-coupled receptor. Science 335, 851–855 (2012).22344443 10.1126/science.1215904
145. McAllister SD Structural mimicry in class A G protein-coupled receptor rotamer toggle switches -: The importance of the F3.36(201)/W6.48(357) interaction in cannabinoid CB1 receptor activation J. Biol. Chem. 2004 279 48024 48037 10.1074/jbc.M406648200 15326174
McAllister, S. D. et al. Structural mimicry in class A G protein-coupled receptor rotamer toggle switches -: The importance of the F3.36(201)/W6.48(357) interaction in cannabinoid CB1 receptor activation. J. Biol. Chem. 279, 48024–48037 (2004).15326174 10.1074/jbc.M406648200
146. Israeli H Structure reveals the activation mechanism of the MC4 receptor to initiate satiation signaling Science 2021 372 808 814 10.1126/science.abf7958 33858992
Israeli, H. et al. Structure reveals the activation mechanism of the MC4 receptor to initiate satiation signaling. Science 372, 808–814 (2021).33858992 10.1126/science.abf7958
147. Roecker AJ Cox CD Colemant PJ Orexin receptor antagonists: new therapeutic agents for the treatment of Insomnia J. Med. Chem. 2016 59 504 530 10.1021/acs.jmedchem.5b00832 26317591
Roecker, A. J., Cox, C. D. & Colemant, P. J. Orexin receptor antagonists: new therapeutic agents for the treatment of Insomnia. J. Med. Chem. 59, 504–530 (2016).26317591 10.1021/acs.jmedchem.5b00832
148. Scammell TE Winrow CJ Orexin receptors: pharmacology and therapeutic opportunities Annu. Rev. Pharmacol. Toxicol. 2011 51 243 266 10.1146/annurev-pharmtox-010510-100528 21034217
Scammell, T. E. & Winrow, C. J. Orexin receptors: pharmacology and therapeutic opportunities. Annu. Rev. Pharmacol. Toxicol. 51, 243–266 (2011).21034217 10.1146/annurev-pharmtox-010510-100528
149. Tsuneki H Sasaoka T Sakurai T Sleep control, GPCRs, and glucose metabolism Trends Endocrinol. Metab. 2016 27 633 642 10.1016/j.tem.2016.06.011 27461005
Tsuneki, H., Sasaoka, T. & Sakurai, T. Sleep control, GPCRs, and glucose metabolism. Trends Endocrinol. Metab. 27, 633–642 (2016).27461005 10.1016/j.tem.2016.06.011
150. Sakurai T The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness Nat. Rev. Neurosci. 2007 8 171 181 10.1038/nrn2092 17299454
Sakurai, T. The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness. Nat. Rev. Neurosci. 8, 171–181 (2007).17299454 10.1038/nrn2092
151. Landry I Pharmacokinetics, pharmacodynamics, and safety of the dual orexin receptor antagonist lemborexant: findings from single-dose and multiple-ascending-dose Phase 1 studies in healthy adults Clin. Pharmacol. Drug Dev. 2021 10 153 165 10.1002/cpdd.817 32468649
Landry, I. et al. Pharmacokinetics, pharmacodynamics, and safety of the dual orexin receptor antagonist lemborexant: findings from single-dose and multiple-ascending-dose Phase 1 studies in healthy adults. Clin. Pharmacol. Drug Dev. 10, 153–165 (2021).32468649 10.1002/cpdd.817
152. Beuckmann CT In vitro and in silico characterization of Lemborexant (E2006), a novel dual orexin receptor antagonist J. Pharmacol. Exp. Ther. 2017 362 287 295 10.1124/jpet.117.241422 28559480
Beuckmann, C. T. et al. In vitro and in silico characterization of Lemborexant (E2006), a novel dual orexin receptor antagonist. J. Pharmacol. Exp. Ther. 362, 287–295 (2017).28559480 10.1124/jpet.117.241422
153. Asada H Molecular basis for anti-insomnia drug design from structure of lemborexant-bound orexin 2 receptor Structure 2022 30 1582 1589 10.1016/j.str.2022.11.001 36417909
Asada, H. et al. Molecular basis for anti-insomnia drug design from structure of lemborexant-bound orexin 2 receptor. Structure 30, 1582–1589 (2022).36417909 10.1016/j.str.2022.11.001
154. McCorvy JD Roth BL Structure and function of serotonin G protein-coupled receptors Pharmacol. Ther. 2015 150 129 142 10.1016/j.pharmthera.2015.01.009 25601315
McCorvy, J. D. & Roth, B. L. Structure and function of serotonin G protein-coupled receptors. Pharmacol. Ther. 150, 129–142 (2015).25601315 10.1016/j.pharmthera.2015.01.009
155. Pytliak M Vargová V Mechírová V Felsöci M Serotonin receptors - from molecular biology to clinical applications Physiol. Res. 2011 60 15 25 10.33549/physiolres.931903 20945968
Pytliak, M., Vargová, V., Mechírová, V. & Felsöci, M. Serotonin receptors - from molecular biology to clinical applications. Physiol. Res. 60, 15–25 (2011).20945968 10.33549/physiolres.931903
156. Calderon JC General metadynamics protocol to simulate activation/deactivation of Class A GPCRs: Proof of principle for the Serotonin receptor J. Chem. Inf. Model. 2023 63 3105 3117 10.1021/acs.jcim.3c00208 37161278
Calderon, J. C. et al. General metadynamics protocol to simulate activation/deactivation of Class A GPCRs: Proof of principle for the Serotonin receptor. J. Chem. Inf. Model. 63, 3105–3117 (2023).37161278 10.1021/acs.jcim.3c00208
157. Negro A Koverech A Martelletti P Serotonin receptor agonists in the acute treatment of migraine: a review on their therapeutic potential J. Pain. Res. 2018 11 515 526 10.2147/JPR.S132833 29563831
Negro, A., Koverech, A. & Martelletti, P. Serotonin receptor agonists in the acute treatment of migraine: a review on their therapeutic potential. J. Pain. Res. 11, 515–526 (2018).29563831 10.2147/JPR.S132833
158. Clemow DB Lasmiditan mechanism of action - review of a selective 5-HT1F agonist J. Headache Pain. 2020 21 1 13 10.1186/s10194-020-01132-3 31898478
Clemow, D. B. et al. Lasmiditan mechanism of action - review of a selective 5-HT1F agonist. J. Headache Pain. 21, 1–13 (2020).31898478 10.1186/s10194-020-01132-3
159. Huang SJ Structural basis for recognition of anti-migraine drug lasmiditan by the serotonin receptor 5-HT1F-G protein complex Cell Res. 2021 31 1036 1038 10.1038/s41422-021-00527-4 34239069
Huang, S. J. et al. Structural basis for recognition of anti-migraine drug lasmiditan by the serotonin receptor 5-HT1F-G protein complex. Cell Res. 31, 1036–1038 (2021).34239069 10.1038/s41422-021-00527-4
160. Wierman ME Molecular mechanisms of gonadotropin-releasing hormone neuronal migration Trends Endocrinol. Metab. 2004 15 96 102 10.1016/j.tem.2004.02.003 15046737
Wierman, M. E. et al. Molecular mechanisms of gonadotropin-releasing hormone neuronal migration. Trends Endocrinol. Metab. 15, 96–102 (2004).15046737 10.1016/j.tem.2004.02.003
161. Yang X Discovery of small molecule agonist of Gonadotropin-Releasing Hormone Receptor (GnRH1R) J. Chem. Inf. Model. 2022 62 5009 5022 10.1021/acs.jcim.2c00639 36184840
Yang, X. et al. Discovery of small molecule agonist of Gonadotropin-Releasing Hormone Receptor (GnRH1R). J. Chem. Inf. Model. 62, 5009–5022 (2022).36184840 10.1021/acs.jcim.2c00639
162. Stojilkovic SS Reinhart J Catt KJ Gonadotropin-releasing-hormone receptors - structure and signal-transduction pathways Endocr. Rev. 1994 15 462 499 10.1210/edrv-15-4-462 7988482
Stojilkovic, S. S., Reinhart, J. & Catt, K. J. Gonadotropin-releasing-hormone receptors - structure and signal-transduction pathways. Endocr. Rev. 15, 462–499 (1994).7988482 10.1210/edrv-15-4-462
163. Lamb YN Elagolix: First global approval Drugs 2018 78 1501 1508 10.1007/s40265-018-0977-4 30194661
Lamb, Y. N. Elagolix: First global approval. Drugs 78, 1501–1508 (2018).30194661 10.1007/s40265-018-0977-4
164. Zou FX Discovery of the thieno[2,3-d]pyrimidine-2,4-dione derivative 21a: A potent and orally bioavailable gonadotropin-releasing hormone receptor antagonist Eur. J. Med. Chem. 2022 242 114679 10.1016/j.ejmech.2022.114679 35998545
Zou, F. X. et al. Discovery of the thieno[2,3-d]pyrimidine-2,4-dione derivative 21a: A potent and orally bioavailable gonadotropin-releasing hormone receptor antagonist. Eur. J. Med. Chem. 242, 114679 (2022).35998545 10.1016/j.ejmech.2022.114679
165. Yan W Structure of the human gonadotropin-releasing hormone receptor GnRH1R reveals an unusual ligand binding mode Nat. Commun. 2020 11 5287 5296 10.1038/s41467-020-19109-w 33082324
Yan, W. et al. Structure of the human gonadotropin-releasing hormone receptor GnRH1R reveals an unusual ligand binding mode. Nat. Commun. 11, 5287–5296 (2020).33082324 10.1038/s41467-020-19109-w
166. Möller D Discovery of G Protein-biased Dopaminergics with a Pyrazolo[1,5-]pyridine substructure J. Med. Chem. 2017 60 2908 2929 10.1021/acs.jmedchem.6b01857 28248104
Möller, D. et al. Discovery of G Protein-biased Dopaminergics with a Pyrazolo[1,5-]pyridine substructure. J. Med. Chem. 60, 2908–2929 (2017).28248104 10.1021/acs.jmedchem.6b01857
167. Szabo M Structure-activity relationships of privileged structures lead to the discovery of novel biased ligands at the Dopamine D2 receptor J. Med. Chem. 2014 57 4924 4939 10.1021/jm500457x 24827597
Szabo, M. et al. Structure-activity relationships of privileged structures lead to the discovery of novel biased ligands at the Dopamine D2 receptor. J. Med. Chem. 57, 4924–4939 (2014).24827597 10.1021/jm500457x
168. Zhang GP Discovery of -Substituted (2-Phenylcyclopropyl)methylamines as functionally selective Serotonin 2C receptor agonists for potential use as antipsychotic medications J. Med. Chem. 2017 60 6273 6288 10.1021/acs.jmedchem.7b00584 28657744
Zhang, G. P. et al. Discovery of -Substituted (2-Phenylcyclopropyl)methylamines as functionally selective Serotonin 2C receptor agonists for potential use as antipsychotic medications. J. Med. Chem. 60, 6273–6288 (2017).28657744 10.1021/acs.jmedchem.7b00584
169. Congreve M Discovery of 1,2,4-Triazine derivatives as Adenosine A2A antagonists using structure based drug design J. Med. Chem. 2012 55 1898 1903 10.1021/jm201376w 22220592
Congreve, M. et al. Discovery of 1,2,4-Triazine derivatives as Adenosine A2A antagonists using structure based drug design. J. Med. Chem. 55, 1898–1903 (2012).22220592 10.1021/jm201376w
170. Congreve M de Graaf C Swain NA Tate CG Impact of GPCR structures on drug discovery Cell 2020 181 81 91 10.1016/j.cell.2020.03.003 32243800
Congreve, M., de Graaf, C., Swain, N. A. & Tate, C. G. Impact of GPCR structures on drug discovery. Cell 181, 81–91 (2020).32243800 10.1016/j.cell.2020.03.003
171. Selfani K Soland VL Chouinard S Huot P Movement disorders induced by the “Atypical” antipsychotic Aripiprazole Neurologist 2017 22 24 28 10.1097/NRL.0000000000000096 28009769
Selfani, K., Soland, V. L., Chouinard, S. & Huot, P. Movement disorders induced by the “Atypical” antipsychotic Aripiprazole. Neurologist 22, 24–28 (2017).28009769 10.1097/NRL.0000000000000096
172. McCorvy JD Structure-inspired design of β-arrestin-biased ligands for aminergic GPCRs Nat. Chem. Biol. 2018 14 126 10.1038/nchembio.2527 29227473
McCorvy, J. D. et al. Structure-inspired design of β-arrestin-biased ligands for aminergic GPCRs. Nat. Chem. Biol. 14, 126 (2018).29227473 10.1038/nchembio.2527
173. Lu SY Zhang J Small molecule allosteric modulators of G-protein-coupled receptors: drug-target interactions J. Med. Chem. 2019 62 24 45 10.1021/acs.jmedchem.7b01844 29457894
Lu, S. Y. & Zhang, J. Small molecule allosteric modulators of G-protein-coupled receptors: drug-target interactions. J. Med. Chem. 62, 24–45 (2019).29457894 10.1021/acs.jmedchem.7b01844
174. Thal DM Glukhova A Sexton PM Christopoulos A Structural insights into G-protein-coupled receptor allostery Nature 2018 559 45 53 10.1038/s41586-018-0259-z 29973731
Thal, D. M., Glukhova, A., Sexton, P. M. & Christopoulos, A. Structural insights into G-protein-coupled receptor allostery. Nature 559, 45–53 (2018).29973731 10.1038/s41586-018-0259-z
175. Wakefield AE Conservation of allosteric ligand binding sites in G-protein coupled receptors J. Chem. Inf. Model. 2022 62 4937 4954 10.1021/acs.jcim.2c00209 36195573
Wakefield, A. E. et al. Conservation of allosteric ligand binding sites in G-protein coupled receptors. J. Chem. Inf. Model. 62, 4937–4954 (2022).36195573 10.1021/acs.jcim.2c00209
176. Casadó-Anguera V Casadó V Unmasking allosteric-binding sites: novel targets for GPCR drug discovery Expert Opin. Drug Discov. 2022 17 897 923 10.1080/17460441.2022.2085684 35649692
Casadó-Anguera, V. & Casadó, V. Unmasking allosteric-binding sites: novel targets for GPCR drug discovery. Expert Opin. Drug Discov. 17, 897–923 (2022).35649692 10.1080/17460441.2022.2085684
177. Lane JR A kinetic view of GPCR allostery and biased agonism Nat. Chem. Biol. 2017 13 929 937 10.1038/nchembio.2431 28820879
Lane, J. R. et al. A kinetic view of GPCR allostery and biased agonism. Nat. Chem. Biol. 13, 929–937 (2017).28820879 10.1038/nchembio.2431
178. Dore AS Structure of class C GPCR metabotropic glutamate receptor 5 transmembrane domain Nature 2014 511 557 562 10.1038/nature13396 25042998
Dore, A. S. et al. Structure of class C GPCR metabotropic glutamate receptor 5 transmembrane domain. Nature 511, 557–562 (2014).25042998 10.1038/nature13396
179. Barman Balfour JA Scott LJ Cinacalcet hydrochloride Drugs 2005 65 271 281 10.2165/00003495-200565020-00007 15631545
Barman Balfour, J. A. & Scott, L. J. Cinacalcet hydrochloride. Drugs 65, 271–281 (2005).15631545 10.2165/00003495-200565020-00007
180. Bueno AB Structural insights into probe-dependent positive allosterism of the GLP-1 receptor Nat. Chem. Biol. 2020 16 1105 1110 10.1038/s41589-020-0589-7 32690941
Bueno, A. B. et al. Structural insights into probe-dependent positive allosterism of the GLP-1 receptor. Nat. Chem. Biol. 16, 1105–1110 (2020).32690941 10.1038/s41589-020-0589-7
181. Tan QX Structure of the CCR5 Chemokine Receptor-HIV entry inhibitor Maraviroc Complex Science 2013 341 1387 1390 10.1126/science.1241475 24030490
Tan, Q. X. et al. Structure of the CCR5 Chemokine Receptor-HIV entry inhibitor Maraviroc Complex. Science 341, 1387–1390 (2013).24030490 10.1126/science.1241475
182. Congreve M Oswald C Marshall FH Applying structure-based drug design approaches to allosteric modulators of GPCRs Trends Pharmacol. Sci. 2017 38 837 847 10.1016/j.tips.2017.05.010 28648526
Congreve, M., Oswald, C. & Marshall, F. H. Applying structure-based drug design approaches to allosteric modulators of GPCRs. Trends Pharmacol. Sci. 38, 837–847 (2017).28648526 10.1016/j.tips.2017.05.010
183. de Graaf C Glucagon-like Peptide-1 and its Class B G protein-coupled receptors: a long march to therapeutic successes Pharmacol. Rev. 2016 68 954 1013 10.1124/pr.115.011395 27630114
de Graaf, C. et al. Glucagon-like Peptide-1 and its Class B G protein-coupled receptors: a long march to therapeutic successes. Pharmacol. Rev. 68, 954–1013 (2016).27630114 10.1124/pr.115.011395
184. de Graaf C Extending the structural view of Class B GPCRs Trends Biochem. Sci. 2017 42 946 960 10.1016/j.tibs.2017.10.003 29132948
de Graaf, C. et al. Extending the structural view of Class B GPCRs. Trends Biochem. Sci. 42, 946–960 (2017).29132948 10.1016/j.tibs.2017.10.003
185. Baggio LL Drucker DJ Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease Mol. Metab. 2020 46 101090 10.1016/j.molmet.2020.101090 32987188
Baggio, L. L. & Drucker, D. J. Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease. Mol. Metab. 46, 101090 (2020).32987188 10.1016/j.molmet.2020.101090
186. Muratspahic E Freissmuth M Gruber CW Nature-derived peptides: a growing niche for GPCR ligand discovery Trends Pharmacol. Sci. 2019 40 309 326 10.1016/j.tips.2019.03.004 30955896
Muratspahic, E., Freissmuth, M. & Gruber, C. W. Nature-derived peptides: a growing niche for GPCR ligand discovery. Trends Pharmacol. Sci. 40, 309–326 (2019).30955896 10.1016/j.tips.2019.03.004
187. Frias JP Tirzepatide versus Semaglutide once weekly in patients with Type 2 Diabetes N. Engl. J. Med. 2021 385 503 515 10.1056/NEJMoa2107519 34170647
Frias, J. P. et al. Tirzepatide versus Semaglutide once weekly in patients with Type 2 Diabetes. N. Engl. J. Med. 385, 503–515 (2021).34170647 10.1056/NEJMoa2107519
188. Gerstein HC Cardiovascular and renal outcomes with Efpeglenatide in Type 2 Diabetes N. Engl. J. Med. 2021 385 896 907 10.1056/NEJMoa2108269 34215025
Gerstein, H. C. et al. Cardiovascular and renal outcomes with Efpeglenatide in Type 2 Diabetes. N. Engl. J. Med. 385, 896–907 (2021).34215025 10.1056/NEJMoa2108269
189. Broichhagen J Allosteric optical control of a Class B G-protein-coupled receptor Angew. Chem. Int. Ed. 2016 55 5865 5868 10.1002/anie.201600957
Broichhagen, J. et al. Allosteric optical control of a Class B G-protein-coupled receptor. Angew. Chem. Int. Ed. 55, 5865–5868 (2016).10.1002/anie.201600957
190. Willard FS Discovery of an orally efficacious positive allosteric modulator of the Glucagon-like Peptide-1 Receptor J. Med. Chem. 2021 64 3439 3448 10.1021/acs.jmedchem.1c00029 33721487
Willard, F. S. et al. Discovery of an orally efficacious positive allosteric modulator of the Glucagon-like Peptide-1 Receptor. J. Med. Chem. 64, 3439–3448 (2021).33721487 10.1021/acs.jmedchem.1c00029
191. Xin Y Affinity selection of double-click triazole libraries for rapid discovery of allosteric modulators for GLP-1 receptor Proc. Natl Acad. Sci. USA 2023 120 e2220767120 10.1073/pnas.2220767120 36893261
Xin, Y. et al. Affinity selection of double-click triazole libraries for rapid discovery of allosteric modulators for GLP-1 receptor. Proc. Natl Acad. Sci. USA 120, e2220767120 (2023).36893261 10.1073/pnas.2220767120
192. McRobb FM Negri A Beuming T Sherman W Molecular dynamics techniques for modeling G protein-coupled receptors Curr. Opin. Pharmacol. 2016 30 69 75 10.1016/j.coph.2016.07.001 27490828
McRobb, F. M., Negri, A., Beuming, T. & Sherman, W. Molecular dynamics techniques for modeling G protein-coupled receptors. Curr. Opin. Pharmacol. 30, 69–75 (2016).27490828 10.1016/j.coph.2016.07.001
193. Ribeiro JML Filizola M Allostery in G protein-coupled receptors investigated by molecular dynamics simulations Curr. Opin. Struct. Biol. 2019 55 121 128 10.1016/j.sbi.2019.03.016 31096158
Ribeiro, J. M. L. & Filizola, M. Allostery in G protein-coupled receptors investigated by molecular dynamics simulations. Curr. Opin. Struct. Biol. 55, 121–128 (2019).31096158 10.1016/j.sbi.2019.03.016
194. Wu HY Molecular glues modulate protein functions by inducing protein aggregation: A promising therapeutic strategy of small molecules for disease treatment Acta Pharm. Sin. B 2022 12 3548 3566 10.1016/j.apsb.2022.03.019 36176907
Wu, H. Y. et al. Molecular glues modulate protein functions by inducing protein aggregation: A promising therapeutic strategy of small molecules for disease treatment. Acta Pharm. Sin. B 12, 3548–3566 (2022).36176907 10.1016/j.apsb.2022.03.019
195. Cong ZT Structural basis of peptidomimetic agonism revealed by small-molecule GLP-1R agonists Boc5 and WB4-24 Proc. Natl Acad. Sci. USA 2022 119 e2200155119 10.1073/pnas.2200155119 35561211
Cong, Z. T. et al. Structural basis of peptidomimetic agonism revealed by small-molecule GLP-1R agonists Boc5 and WB4-24. Proc. Natl Acad. Sci. USA 119, e2200155119 (2022).35561211 10.1073/pnas.2200155119
196. Zhao PS Activation of the GLP-1 receptor by a non-peptidic agonist Nature 2020 577 432 436 10.1038/s41586-019-1902-z 31915381
Zhao, P. S. et al. Activation of the GLP-1 receptor by a non-peptidic agonist. Nature 577, 432–436 (2020).31915381 10.1038/s41586-019-1902-z
197. Kawai T Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist Proc. Natl Acad. Sci. USA 2020 117 29959 29967 10.1073/pnas.2014879117 33177239
Kawai, T. et al. Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist. Proc. Natl Acad. Sci. USA 117, 29959–29967 (2020).33177239 10.1073/pnas.2014879117
198. Zhang X Differential GLP-1R binding and activation by peptide and non-peptide agonists Mol. Cell 2020 80 485 500 10.1016/j.molcel.2020.09.020 33027691
Zhang, X. et al. Differential GLP-1R binding and activation by peptide and non-peptide agonists. Mol. Cell 80, 485–500 (2020).33027691 10.1016/j.molcel.2020.09.020
199. Abboud D GPR101 drives growth hormone hypersecretion and gigantism in mice via constitutive activation of Gs and Gq/11 Nat. Commun. 2020 11 4752 10.1038/s41467-020-18500-x 32958754
Abboud, D. et al. GPR101 drives growth hormone hypersecretion and gigantism in mice via constitutive activation of Gs and Gq/11. Nat. Commun. 11, 4752 (2020).32958754 10.1038/s41467-020-18500-x
200. Garrett L GPR101 loss promotes insulin resistance and diet-induced obesity risk Neurosci. Appl. 2023 2 101126 10.1016/j.nsa.2023.101126
Garrett, L. et al. GPR101 loss promotes insulin resistance and diet-induced obesity risk. Neurosci. Appl. 2, 101126 (2023).10.1016/j.nsa.2023.101126
201. Yang, Z. et al. Structure of GPR101-Gs enables identification of ligands with rejuvenating potential. Nat. Chem. Biol. 10.1038/s41589-023-01456-6 (2023).
202. Xiao X Cholesterol modification of smoothened is required for Hedgehog signaling Mol. Cell 2017 66 154 162 10.1016/j.molcel.2017.02.015 28344083
Xiao, X. et al. Cholesterol modification of smoothened is required for Hedgehog signaling. Mol. Cell 66, 154–162 (2017).28344083 10.1016/j.molcel.2017.02.015
203. Huang PX Cellular cholesterol directly activates smoothened in Hedgehog signaling Cell 2016 166 1176 1187 10.1016/j.cell.2016.08.003 27545348
Huang, P. X. et al. Cellular cholesterol directly activates smoothened in Hedgehog signaling. Cell 166, 1176–1187 (2016).27545348 10.1016/j.cell.2016.08.003
204. Bokoch MP Ligand-specific regulation of the extracellular surface of a G-protein-coupled receptor Nature 2010 463 108 U121 10.1038/nature08650 20054398
Bokoch, M. P. et al. Ligand-specific regulation of the extracellular surface of a G-protein-coupled receptor. Nature 463, 108–U121 (2010).20054398 10.1038/nature08650
205. Peeters MC van Westen GJP Li Q IJzerman AP Importance of the extracellular loops in G protein-coupled receptors for ligand recognition and receptor activation Trends Pharmacol. Sci. 2011 32 35 42 10.1016/j.tips.2010.10.001 21075459
Peeters, M. C., van Westen, G. J. P., Li, Q. & IJzerman, A. P. Importance of the extracellular loops in G protein-coupled receptors for ligand recognition and receptor activation. Trends Pharmacol. Sci. 32, 35–42 (2011).21075459 10.1016/j.tips.2010.10.001
206. Xu XY Constrained catecholamines gain β2AR selectivity through allosteric effects on pocket dynamics Nat. Commun. 2023 14 2138 2150 10.1038/s41467-023-37808-y 37059717
Xu, X. Y. et al. Constrained catecholamines gain β2AR selectivity through allosteric effects on pocket dynamics. Nat. Commun. 14, 2138–2150 (2023).37059717 10.1038/s41467-023-37808-y
207. Nicoli A Classification model for the second extracellular loop of Class A GPCRs J. Chem. Inf. Model. 2022 62 511 522 10.1021/acs.jcim.1c01056 35113559
Nicoli, A. et al. Classification model for the second extracellular loop of Class A GPCRs. J. Chem. Inf. Model. 62, 511–522 (2022).35113559 10.1021/acs.jcim.1c01056
208. Wess J Eglen RM Gautam D Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development Nat. Rev. Drug Discov. 2007 6 721 733 10.1038/nrd2379 17762886
Wess, J., Eglen, R. M. & Gautam, D. Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development. Nat. Rev. Drug Discov. 6, 721–733 (2007).17762886 10.1038/nrd2379
209. Yohn SE Weiden PJ Felder CC Stahl SM Muscarinic acetylcholine receptors for psychotic disorders: bench-side to clinic Trends Pharmacol. Sci. 2022 43 1098 1112 10.1016/j.tips.2022.09.006 36273943
Yohn, S. E., Weiden, P. J., Felder, C. C. & Stahl, S. M. Muscarinic acetylcholine receptors for psychotic disorders: bench-side to clinic. Trends Pharmacol. Sci. 43, 1098–1112 (2022).36273943 10.1016/j.tips.2022.09.006
210. Felder CC Muscarinic Acetylcholine-receptors - signal-transduction through multiple effectors FASEB J. 1995 9 619 625 10.1096/fasebj.9.8.7768353 7768353
Felder, C. C. Muscarinic Acetylcholine-receptors - signal-transduction through multiple effectors. FASEB J. 9, 619–625 (1995).7768353 10.1096/fasebj.9.8.7768353
211. Melancon BJ Allosteric modulation of the M-1 muscarinic acetylcholine receptor: improving cognition and a potential treatment for schizophrenia and Alzheimer’s disease Drug Discov. Today 2013 18 1185 1199 10.1016/j.drudis.2013.09.005 24051397
Melancon, B. J. et al. Allosteric modulation of the M-1 muscarinic acetylcholine receptor: improving cognition and a potential treatment for schizophrenia and Alzheimer’s disease. Drug Discov. Today 18, 1185–1199 (2013).24051397 10.1016/j.drudis.2013.09.005
212. Moran SP Maksymetz J Conn PJ Targeting Muscarinic Acetylcholine receptors for the treatment of psychiatric and neurological disorders Trends Pharm. Sci. 2019 40 1006 1020 10.1016/j.tips.2019.10.007 31711626
Moran, S. P., Maksymetz, J. & Conn, P. J. Targeting Muscarinic Acetylcholine receptors for the treatment of psychiatric and neurological disorders. Trends Pharm. Sci. 40, 1006–1020 (2019).31711626 10.1016/j.tips.2019.10.007
213. Miao YL Accelerated structure-based design of chemically diverse allosteric modulators of a muscarinic G protein-coupled receptor Proc. Natl Acad. Sci. USA 2016 113 E5675 E5684 10.1073/pnas.1612353113 27601651
Miao, Y. L. et al. Accelerated structure-based design of chemically diverse allosteric modulators of a muscarinic G protein-coupled receptor. Proc. Natl Acad. Sci. USA 113, E5675–E5684 (2016).27601651 10.1073/pnas.1612353113
214. Shivnaraine RV Allosteric modulation in monomers and oligomers of a G protein-coupled receptor Elife 2016 5 e11685 10.7554/eLife.11685 27151542
Shivnaraine, R. V. et al. Allosteric modulation in monomers and oligomers of a G protein-coupled receptor. Elife 5, e11685 (2016).27151542 10.7554/eLife.11685
215. Croy CH Characterization of the novel positive Allosteric Modulator, LY2119620, at the Muscarinic M-2 and M-4 receptors Mol. Pharmacol. 2014 86 106 115 10.1124/mol.114.091751 24807965
Croy, C. H. et al. Characterization of the novel positive Allosteric Modulator, LY2119620, at the Muscarinic M-2 and M-4 receptors. Mol. Pharmacol. 86, 106–115 (2014).24807965 10.1124/mol.114.091751
216. Kruse AC Activation and allosteric modulation of a muscarinic acetylcholine receptor Nature 2013 504 101 106 10.1038/nature12735 24256733
Kruse, A. C. et al. Activation and allosteric modulation of a muscarinic acetylcholine receptor. Nature 504, 101–106 (2013).24256733 10.1038/nature12735
217. Wang JJ The unconventional activation of the muscarinic acetylcholine receptor M4R by diverse ligands Nat. Commun. 2022 13 2855 2894 10.1038/s41467-022-30595-y 35606397
Wang, J. J. et al. The unconventional activation of the muscarinic acetylcholine receptor M4R by diverse ligands. Nat. Commun. 13, 2855–2894 (2022).35606397 10.1038/s41467-022-30595-y
218. Xu J Structural and dynamic insights into supra-physiological activation and allosteric modulation of a muscarinic acetylcholine receptor Nat. Commun. 2023 14 376 391 10.1038/s41467-022-35726-z 36690613
Xu, J. et al. Structural and dynamic insights into supra-physiological activation and allosteric modulation of a muscarinic acetylcholine receptor. Nat. Commun. 14, 376–391 (2023).36690613 10.1038/s41467-022-35726-z
219. Jiménez-Rosés M Matsoukas MT Caltabiano G Cordomí A Ligand-triggered structural changes in the M2 Muscarinic Acetylcholine receptor J. Chem. Inf. Model. 2018 58 1074 1082 10.1021/acs.jcim.8b00108 29671585
Jiménez-Rosés, M., Matsoukas, M. T., Caltabiano, G. & Cordomí, A. Ligand-triggered structural changes in the M2 Muscarinic Acetylcholine receptor. J. Chem. Inf. Model. 58, 1074–1082 (2018).29671585 10.1021/acs.jcim.8b00108
220. Capelli R Chasing the full free energy landscape of Neuroreceptor/Ligand unbinding by metadynamics simulations J. Chem. Theory Comput. 2019 15 3354 3361 10.1021/acs.jctc.9b00118 30913388
Capelli, R. et al. Chasing the full free energy landscape of Neuroreceptor/Ligand unbinding by metadynamics simulations. J. Chem. Theory Comput. 15, 3354–3361 (2019).30913388 10.1021/acs.jctc.9b00118
221. Leach K Gregory KJ Molecular insights into allosteric modulation of Class C G protein-coupled receptors Pharmacol. Res. 2017 116 105 118 10.1016/j.phrs.2016.12.006 27965032
Leach, K. & Gregory, K. J. Molecular insights into allosteric modulation of Class C G protein-coupled receptors. Pharmacol. Res. 116, 105–118 (2017).27965032 10.1016/j.phrs.2016.12.006
222. Diaz-Soto G The calcium-sensing receptor in health and disease Int. Rev. Cell Mol. Biol. 2016 327 321 369 10.1016/bs.ircmb.2016.05.004 27692178
Diaz-Soto, G. et al. The calcium-sensing receptor in health and disease. Int. Rev. Cell Mol. Biol. 327, 321–369 (2016).27692178 10.1016/bs.ircmb.2016.05.004
223. Hannan FM The calcium-sensing receptor in physiology and in calcitropic and noncalcitropic diseases Nat. Rev. Endocrinol. 2018 15 33 51 10.1038/s41574-018-0115-0 30443043
Hannan, F. M. et al. The calcium-sensing receptor in physiology and in calcitropic and noncalcitropic diseases. Nat. Rev. Endocrinol. 15, 33–51 (2018).30443043 10.1038/s41574-018-0115-0
224. Conigrave AD Ward DT Calcium-sensing receptor (CaSR): Pharmacological properties and signaling pathways Best. Pract. Res. Clin. Endocrinol. Metab. 2013 27 315 331 10.1016/j.beem.2013.05.010 23856262
Conigrave, A. D. & Ward, D. T. Calcium-sensing receptor (CaSR): Pharmacological properties and signaling pathways. Best. Pract. Res. Clin. Endocrinol. Metab. 27, 315–331 (2013).23856262 10.1016/j.beem.2013.05.010
225. Leach K Conigrave AD Sexton PM Christopoulos A Towards tissue-specific pharmacology: insights from the calcium-sensing receptor as a paradigm for GPCR (patho)physiological bias Trends Pharmacol. Sci. 2015 36 215 225 10.1016/j.tips.2015.02.004 25765207
Leach, K., Conigrave, A. D., Sexton, P. M. & Christopoulos, A. Towards tissue-specific pharmacology: insights from the calcium-sensing receptor as a paradigm for GPCR (patho)physiological bias. Trends Pharmacol. Sci. 36, 215–225 (2015).25765207 10.1016/j.tips.2015.02.004
226. Leach K Towards a structural understanding of allosteric drugs at the human calcium-sensing receptor Cell Res 2016 26 574 592 10.1038/cr.2016.36 27002221
Leach, K. et al. Towards a structural understanding of allosteric drugs at the human calcium-sensing receptor. Cell Res 26, 574–592 (2016).27002221 10.1038/cr.2016.36
227. Block GA Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis N. Engl. J. Med. 2004 350 1516 1525 10.1056/NEJMoa031633 15071126
Block, G. A. et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N. Engl. J. Med. 350, 1516–1525 (2004).15071126 10.1056/NEJMoa031633
228. Akizawa T Evocalcet: A new oral calcimimetic for dialysis patients with secondary Hyperparathyroidism Ther. Apher. Dial. 2020 24 248 257 10.1111/1744-9987.13434 31486206
Akizawa, T. et al. Evocalcet: A new oral calcimimetic for dialysis patients with secondary Hyperparathyroidism. Ther. Apher. Dial. 24, 248–257 (2020).31486206 10.1111/1744-9987.13434
229. Hannan FM The calcilytic agent NPS 2143 rectifies hypocalcemia in a mouse model with an activating Calcium-Sensing Receptor (CaSR) mutation: relevance to Autosomal Dominant Hypocalcemia Type 1 (ADH1) Endocrinology 2015 156 3114 3121 10.1210/en.2015-1269 26052899
Hannan, F. M. et al. The calcilytic agent NPS 2143 rectifies hypocalcemia in a mouse model with an activating Calcium-Sensing Receptor (CaSR) mutation: relevance to Autosomal Dominant Hypocalcemia Type 1 (ADH1). Endocrinology 156, 3114–3121 (2015).26052899 10.1210/en.2015-1269
230. Gao Y Asymmetric activation of the calcium-sensing receptor homodimer Nature 2021 595 455 459 10.1038/s41586-021-03691-0 34194040
Gao, Y. et al. Asymmetric activation of the calcium-sensing receptor homodimer. Nature 595, 455–459 (2021).34194040 10.1038/s41586-021-03691-0
231. Venkatakrishnan AJ Molecular signatures of G-protein-coupled receptors Nature 2013 494 185 194 10.1038/nature11896 23407534
Venkatakrishnan, A. J. et al. Molecular signatures of G-protein-coupled receptors. Nature 494, 185–194 (2013).23407534 10.1038/nature11896
232. Liu, F. et al. Structure-based discovery of positive allosteric modulators for the calcium sensing receptor. bioRxiv 573448 (2023).
233. Wang WJ Qiao YH Li ZJ New Insights into Modes of GPCR Activation Trends Pharmacol. Sci. 2018 39 367 386 10.1016/j.tips.2018.01.001 29395118
Wang, W. J., Qiao, Y. H. & Li, Z. J. New Insights into Modes of GPCR Activation. Trends Pharmacol. Sci. 39, 367–386 (2018).29395118 10.1016/j.tips.2018.01.001
234. Weis WI Kobilka BK The molecular basis of G protein-coupled receptor activation Annu. Rev. Biochem. 2018 87 897 919 10.1146/annurev-biochem-060614-033910 29925258
Weis, W. I. & Kobilka, B. K. The molecular basis of G protein-coupled receptor activation. Annu. Rev. Biochem. 87, 897–919 (2018).29925258 10.1146/annurev-biochem-060614-033910
235. Venkatakrishnan AJ Diverse activation pathways in class A GPCRs converge near the G-protein-coupling region Nature 2016 536 484 487 10.1038/nature19107 27525504
Venkatakrishnan, A. J. et al. Diverse activation pathways in class A GPCRs converge near the G-protein-coupling region. Nature 536, 484–487 (2016).27525504 10.1038/nature19107
236. Cattaneo M Platelet P2 receptors: old and new targets for antithrombotic drugs Expert Rev. Cardiovasc Ther. 2007 5 45 55 10.1586/14779072.5.1.45 17187456
Cattaneo, M. Platelet P2 receptors: old and new targets for antithrombotic drugs. Expert Rev. Cardiovasc Ther. 5, 45–55 (2007).17187456 10.1586/14779072.5.1.45
237. Jacobson KA Update of P2Y receptor pharmacology: IUPHAR Review 27 Br. J. Pharmacol. 2020 177 2413 2433 10.1111/bph.15005 32037507
Jacobson, K. A. et al. Update of P2Y receptor pharmacology: IUPHAR Review 27. Br. J. Pharmacol. 177, 2413–2433 (2020).32037507 10.1111/bph.15005
238. Jacobson KA Boeynaems JM P2Y nucleotide receptors: promise of therapeutic applications Drug Discov. Today 2010 15 570 578 10.1016/j.drudis.2010.05.011 20594935
Jacobson, K. A. & Boeynaems, J. M. P2Y nucleotide receptors: promise of therapeutic applications. Drug Discov. Today 15, 570–578 (2010).20594935 10.1016/j.drudis.2010.05.011
239. Cattaneo M New P2Y(12) Inhibitors Circulation 2010 121 171 179 10.1161/CIRCULATIONAHA.109.853069 20048234
Cattaneo, M. New P2Y(12) Inhibitors. Circulation 121, 171–179 (2010).20048234 10.1161/CIRCULATIONAHA.109.853069
240. Mane N Jimenez-Sabado V Jimenez M BPTU, an allosteric antagonist of P2Y1 receptor, blocks nerve mediated inhibitory neuromuscular responses in the gastrointestinal tract of rodents Neuropharmacology 2016 110 376 385 10.1016/j.neuropharm.2016.07.033 27496690
Mane, N., Jimenez-Sabado, V. & Jimenez, M. BPTU, an allosteric antagonist of P2Y1 receptor, blocks nerve mediated inhibitory neuromuscular responses in the gastrointestinal tract of rodents. Neuropharmacology 110, 376–385 (2016).27496690 10.1016/j.neuropharm.2016.07.033
241. Conroy S Kindon N Kellam B Stocks MJ Drug-like antagonists of P2Y receptors-from lead identification to drug development J. Med. Chem. 2016 59 9981 10005 10.1021/acs.jmedchem.5b01972 27413802
Conroy, S., Kindon, N., Kellam, B. & Stocks, M. J. Drug-like antagonists of P2Y receptors-from lead identification to drug development. J. Med. Chem. 59, 9981–10005 (2016).27413802 10.1021/acs.jmedchem.5b01972
242. Zhang DD Two disparate ligand-binding sites in the human P2Y(1) receptor Nature 2015 520 317 321 10.1038/nature14287 25822790
Zhang, D. D. et al. Two disparate ligand-binding sites in the human P2Y(1) receptor. Nature 520, 317–321 (2015).25822790 10.1038/nature14287
243. Wu YR GPCR allosteric modulator discovery Protein Allostery Drug Discov. 2019 1163 225 251 10.1007/978-981-13-8719-7_10
Wu, Y. R. et al. GPCR allosteric modulator discovery. Protein Allostery Drug Discov. 1163, 225–251 (2019).10.1007/978-981-13-8719-7_10
244. Li BB Structural insights into signal transduction of the purinergic receptors P2Y1R and P2Y12R Protein Cell 2023 14 382 386 37155313
Li, B. B. et al. Structural insights into signal transduction of the purinergic receptors P2Y1R and P2Y12R. Protein Cell 14, 382–386 (2023).37155313
245. Zhou QT Common activation mechanism of class A GPCRs Elife 2019 8 e50279 10.7554/eLife.50279 31855179
Zhou, Q. T. et al. Common activation mechanism of class A GPCRs. Elife 8, e50279 (2019).31855179 10.7554/eLife.50279
246. Yuan SG The molecular mechanism of P2Y1 receptor activation Angew. Chem. Int. Ed. 2016 55 10331 10335 10.1002/anie.201605147
Yuan, S. G. et al. The molecular mechanism of P2Y1 receptor activation. Angew. Chem. Int. Ed. 55, 10331–10335 (2016).10.1002/anie.201605147
247. Zou SL Kumar U Cannabinoid receptors and the endocannabinoid system: signaling and function in the central nervous system Int. J. Mol. Sci. 2018 19 833 855 10.3390/ijms19030833 29533978
Zou, S. L. & Kumar, U. Cannabinoid receptors and the endocannabinoid system: signaling and function in the central nervous system. Int. J. Mol. Sci. 19, 833–855 (2018).29533978 10.3390/ijms19030833
248. Brown AJ Novel cannabinoid receptors Br. J. Pharmacol. 2007 152 567 575 10.1038/sj.bjp.0707481 17906678
Brown, A. J. Novel cannabinoid receptors. Br. J. Pharmacol. 152, 567–575 (2007).17906678 10.1038/sj.bjp.0707481
249. Kofuji P Araque A G-protein-coupled receptors in astrocyte-neuron communication Neuroscience 2021 456 71 84 10.1016/j.neuroscience.2020.03.025 32224231
Kofuji, P. & Araque, A. G-protein-coupled receptors in astrocyte-neuron communication. Neuroscience 456, 71–84 (2021).32224231 10.1016/j.neuroscience.2020.03.025
250. Busquets-Garcia A Bains J Marsicano G CB1 receptor signaling in the brain: extracting specificity from ubiquity Neuropsychopharmacol 2018 43 4 20 10.1038/npp.2017.206
Busquets-Garcia, A., Bains, J. & Marsicano, G. CB1 receptor signaling in the brain: extracting specificity from ubiquity. Neuropsychopharmacol 43, 4–20 (2018).10.1038/npp.2017.206
251. Nguyen T Allosteric modulation: an alternate approach targeting the cannabinoid CB1 receptor Med. Res. Rev. 2017 37 441 474 10.1002/med.21418 27879006
Nguyen, T. et al. Allosteric modulation: an alternate approach targeting the cannabinoid CB1 receptor. Med. Res. Rev. 37, 441–474 (2017).27879006 10.1002/med.21418
252. Mackie K Cannabinoid receptors: Where they are and what they do J. Neuroendocrinol. 2008 20 10 14 10.1111/j.1365-2826.2008.01671.x 18426493
Mackie, K. Cannabinoid receptors: Where they are and what they do. J. Neuroendocrinol. 20, 10–14 (2008).18426493 10.1111/j.1365-2826.2008.01671.x
253. Gado F CB1 receptor binding sites for NAM and PAM: A first approach for studying, new n-butyl-diphenylcarboxamides as allosteric modulators Eur. J. Pharm. Sci. 2022 169 106088 10.1016/j.ejps.2021.106088 34863873
Gado, F. et al. CB1 receptor binding sites for NAM and PAM: A first approach for studying, new n-butyl-diphenylcarboxamides as allosteric modulators. Eur. J. Pharm. Sci. 169, 106088 (2022).34863873 10.1016/j.ejps.2021.106088
254. Yuan JY Targeting the endocannabinoid system: Structural determinants and molecular mechanism of allosteric modulation Drug Discov. Today 2023 28 103615 10.1016/j.drudis.2023.103615 37172889
Yuan, J. Y. et al. Targeting the endocannabinoid system: Structural determinants and molecular mechanism of allosteric modulation. Drug Discov. Today 28, 103615 (2023).37172889 10.1016/j.drudis.2023.103615
255. Janero DR Thakur GA Leveraging allostery to improve G protein-coupled receptor (GPCR)-directed therapeutics: cannabinoid receptor 1 as discovery target Expert Opin. Drug Discov. 2016 11 1223 1237 10.1080/17460441.2016.1245289 27712124
Janero, D. R. & Thakur, G. A. Leveraging allostery to improve G protein-coupled receptor (GPCR)-directed therapeutics: cannabinoid receptor 1 as discovery target. Expert Opin. Drug Discov. 11, 1223–1237 (2016).27712124 10.1080/17460441.2016.1245289
256. Gamage TF In-vivo pharmacological evaluation of the CB1-receptor allosteric modulator Org-27569 Behav. Pharm. 2014 25 182 185 10.1097/FBP.0000000000000027
Gamage, T. F. et al. In-vivo pharmacological evaluation of the CB1-receptor allosteric modulator Org-27569. Behav. Pharm. 25, 182–185 (2014).10.1097/FBP.0000000000000027
257. Shao ZH Structure of an allosteric modulator bound to the CB1 cannabinoid receptor Nat. Chem. Biol. 2019 15 1199 1205 10.1038/s41589-019-0387-2 31659318
Shao, Z. H. et al. Structure of an allosteric modulator bound to the CB1 cannabinoid receptor. Nat. Chem. Biol. 15, 1199–1205 (2019).31659318 10.1038/s41589-019-0387-2
258. Obi P Natesan S Membrane lipids are an integral part of transmembrane allosteric sites in GPCRs: A case study of cannabinoid CB1 receptor bound to a negative allosteric modulator, ORG27569, and analogs J. Med. Chem. 2022 65 12240 12255 10.1021/acs.jmedchem.2c00946 36066412
Obi, P. & Natesan, S. Membrane lipids are an integral part of transmembrane allosteric sites in GPCRs: A case study of cannabinoid CB1 receptor bound to a negative allosteric modulator, ORG27569, and analogs. J. Med. Chem. 65, 12240–12255 (2022).36066412 10.1021/acs.jmedchem.2c00946
259. Green HM In vitro characterization of 6-Methyl-3-(2-nitro-1-(thiophen-2yl)ethyl)-2-phenyl-1H-indole (ZCZ011) at the Type 1 Cannabinoid receptor: allosteric agonist or allosteric modulator? ACS Pharm. 2022 5 1279 1291
Green, H. M. et al. In vitro characterization of 6-Methyl-3-(2-nitro-1-(thiophen-2yl)ethyl)-2-phenyl-1H-indole (ZCZ011) at the Type 1 Cannabinoid receptor: allosteric agonist or allosteric modulator? ACS Pharm. 5, 1279–1291 (2022).
260. Saleh N Multiple binding sites contribute to the mechanism of mixed agonistic and positive allosteric modulators of the Cannabinoid CB1 receptor Angew. Chem. Int. Ed. 2018 57 2580 2585 10.1002/anie.201708764
Saleh, N. et al. Multiple binding sites contribute to the mechanism of mixed agonistic and positive allosteric modulators of the Cannabinoid CB1 receptor. Angew. Chem. Int. Ed. 57, 2580–2585 (2018).10.1002/anie.201708764
261. Yang X Molecular mechanism of allosteric modulation for the cannabinoid receptor CB1 Nat. Chem. Biol. 2022 18 831 840 10.1038/s41589-022-01038-y 35637350
Yang, X. et al. Molecular mechanism of allosteric modulation for the cannabinoid receptor CB1. Nat. Chem. Biol. 18, 831–840 (2022).35637350 10.1038/s41589-022-01038-y
262. Wold EA Chen JP Cunningham KA Zhou J Allosteric modulation of Class A GPCRs: Targets, agents, and emerging concepts J. Med. Chem. 2019 62 88 127 10.1021/acs.jmedchem.8b00875 30106578
Wold, E. A., Chen, J. P., Cunningham, K. A. & Zhou, J. Allosteric modulation of Class A GPCRs: Targets, agents, and emerging concepts. J. Med. Chem. 62, 88–127 (2019).30106578 10.1021/acs.jmedchem.8b00875
263. Ahn KH Mahmoud MM Kendall DA Allosteric modulator ORG27569 induces CB1 cannabinoid receptor high affinity agonist binding state, receptor internalization, and G protein-independent ERK1/2 Kinase activation J. Biol. Chem. 2012 287 12070 12082 10.1074/jbc.M111.316463 22343625
Ahn, K. H., Mahmoud, M. M. & Kendall, D. A. Allosteric modulator ORG27569 induces CB1 cannabinoid receptor high affinity agonist binding state, receptor internalization, and G protein-independent ERK1/2 Kinase activation. J. Biol. Chem. 287, 12070–12082 (2012).22343625 10.1074/jbc.M111.316463
264. Shao ZH High-resolution crystal structure of the human CB1 cannabinoid receptor Nature 2016 540 602 606 10.1038/nature20613 27851727
Shao, Z. H. et al. High-resolution crystal structure of the human CB1 cannabinoid receptor. Nature 540, 602–606 (2016).27851727 10.1038/nature20613
265. Kumar KK Structural basis for activation of CB1 by an endocannabinoid analog Nat. Commun. 2023 14 2672 2682 10.1038/s41467-023-37864-4 37160876
Kumar, K. K. et al. Structural basis for activation of CB1 by an endocannabinoid analog. Nat. Commun. 14, 2672–2682 (2023).37160876 10.1038/s41467-023-37864-4
266. Fay JF Farrens DL Structural dynamics and energetics underlying allosteric inactivation of the cannabinoid receptor CB Proc. Natl Acad. Sci. USA 2015 112 8469 8474 10.1073/pnas.1500895112 26100912
Fay, J. F. & Farrens, D. L. Structural dynamics and energetics underlying allosteric inactivation of the cannabinoid receptor CB. Proc. Natl Acad. Sci. USA 112, 8469–8474 (2015).26100912 10.1073/pnas.1500895112
267. Dalton JAR Lans I Giraldo J Quantifying conformational changes in GPCRs: glimpse of a common functional mechanism BMC Bioinforma. 2015 16 124 138 10.1186/s12859-015-0567-3
Dalton, J. A. R., Lans, I. & Giraldo, J. Quantifying conformational changes in GPCRs: glimpse of a common functional mechanism. BMC Bioinforma. 16, 124–138 (2015).10.1186/s12859-015-0567-3
268. Wheatley M Lifting the lid on GPCRs: the role of extracellular loops Br. J. Pharmacol. 2012 165 1688 1703 10.1111/j.1476-5381.2011.01629.x 21864311
Wheatley, M. et al. Lifting the lid on GPCRs: the role of extracellular loops. Br. J. Pharmacol. 165, 1688–1703 (2012).21864311 10.1111/j.1476-5381.2011.01629.x
269. Liu XY Mechanism of beta(2)AR regulation by an intracellular positive allosteric modulator Science 2019 364 1283 1287 10.1126/science.aaw8981 31249059
Liu, X. Y. et al. Mechanism of beta(2)AR regulation by an intracellular positive allosteric modulator. Science 364, 1283–1287 (2019).31249059 10.1126/science.aaw8981
270. Hauser AS GPCR activation mechanisms across classes and macro/microscales Nat. Struct. Mol. Biol. 2021 28 879 888 10.1038/s41594-021-00674-7 34759375
Hauser, A. S. et al. GPCR activation mechanisms across classes and macro/microscales. Nat. Struct. Mol. Biol. 28, 879–888 (2021).34759375 10.1038/s41594-021-00674-7
271. Chan HCS New BINDING SITES, NEW OPPORTUNities for GPCR drug discovery Trends Biochem. Sci. 2019 44 312 330 10.1016/j.tibs.2018.11.011 30612897
Chan, H. C. S. et al. New BINDING SITES, NEW OPPORTUNities for GPCR drug discovery. Trends Biochem. Sci. 44, 312–330 (2019).30612897 10.1016/j.tibs.2018.11.011
272. Beaulieu JM Gainetdinov RR The physiology, signaling, and pharmacology of dopamine receptors Pharmacol. Rev. 2011 63 182 217 10.1124/pr.110.002642 21303898
Beaulieu, J. M. & Gainetdinov, R. R. The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol. Rev. 63, 182–217 (2011).21303898 10.1124/pr.110.002642
273. Chen KYM Keri D Barth P Computational design of G Protein-Coupled Receptor allosteric signal transductions Nat. Chem. Biol. 2020 16 77 86 10.1038/s41589-019-0407-2 31792443
Chen, K. Y. M., Keri, D. & Barth, P. Computational design of G Protein-Coupled Receptor allosteric signal transductions. Nat. Chem. Biol. 16, 77–86 (2020).31792443 10.1038/s41589-019-0407-2
274. Missale C Dopamine receptors: From structure to function Physiol. Rev. 1998 78 189 225 10.1152/physrev.1998.78.1.189 9457173
Missale, C. et al. Dopamine receptors: From structure to function. Physiol. Rev. 78, 189–225 (1998).9457173 10.1152/physrev.1998.78.1.189
275. Kobayashi K Noradrenaline activation of hippocampal dopamine D1 receptors promotes antidepressant effects Proc. Natl Acad. Sci. USA 2022 119 e2117903119 10.1073/pnas.2117903119 35939697
Kobayashi, K. et al. Noradrenaline activation of hippocampal dopamine D1 receptors promotes antidepressant effects. Proc. Natl Acad. Sci. USA 119, e2117903119 (2022).35939697 10.1073/pnas.2117903119
276. Biglan K Safety and efficacy of Mevidalen in Lewy Body Dementia: A Phase 2, randomized, placebo-controlled trial Mov. Disord. 2022 37 513 524 10.1002/mds.28879 34859493
Biglan, K. et al. Safety and efficacy of Mevidalen in Lewy Body Dementia: A Phase 2, randomized, placebo-controlled trial. Mov. Disord. 37, 513–524 (2022).34859493 10.1002/mds.28879
277. Xiao P Ligand recognition and allosteric regulation of DRD1-Gs signaling complexes Cell 2021 184 943 956 10.1016/j.cell.2021.01.028 33571432
Xiao, P. et al. Ligand recognition and allosteric regulation of DRD1-Gs signaling complexes. Cell 184, 943–956 (2021).33571432 10.1016/j.cell.2021.01.028
278. Zhuang YW Mechanism of dopamine binding and allosteric modulation of the human D1 dopamine receptor Cell Res 2021 31 593 596 10.1038/s41422-021-00482-0 33750903
Zhuang, Y. W. et al. Mechanism of dopamine binding and allosteric modulation of the human D1 dopamine receptor. Cell Res 31, 593–596 (2021).33750903 10.1038/s41422-021-00482-0
279. Teng X Ligand recognition and biased agonism of the D1 dopamine receptor Nat. Commun. 2022 13 3186 3196 10.1038/s41467-022-30929-w 35676276
Teng, X. et al. Ligand recognition and biased agonism of the D1 dopamine receptor. Nat. Commun. 13, 3186–3196 (2022).35676276 10.1038/s41467-022-30929-w
280. Sibley DR Luderman KD Free RB Shi L Novel Cryo-EM structures of the D1 dopamine receptor unlock its therapeutic potential Signal Transduct. Target. Ther. 2021 6 205 10.1038/s41392-021-00630-3 34023856
Sibley, D. R., Luderman, K. D., Free, R. B. & Shi, L. Novel Cryo-EM structures of the D1 dopamine receptor unlock its therapeutic potential. Signal Transduct. Target. Ther. 6, 205 (2021).34023856 10.1038/s41392-021-00630-3
281. Lee H Whitfeld PL Mackay CR Receptors for complement C5a. The importance of C5aR and the enigmatic role of C5L2 Immunol. Cell Biol. 2008 86 153 160 10.1038/sj.icb.7100166 18227853
Lee, H., Whitfeld, P. L. & Mackay, C. R. Receptors for complement C5a. The importance of C5aR and the enigmatic role of C5L2. Immunol. Cell Biol. 86, 153–160 (2008).18227853 10.1038/sj.icb.7100166
282. Guo RF Ward PA Role of C5A in inflammatory responses Annu. Rev. Immunol. 2005 23 821 852 10.1146/annurev.immunol.23.021704.115835 15771587
Guo, R. F. & Ward, P. A. Role of C5A in inflammatory responses. Annu. Rev. Immunol. 23, 821–852 (2005).15771587 10.1146/annurev.immunol.23.021704.115835
283. Sun L Ye RD Role of G protein-coupled receptors in inflammation Acta Pharmacol. Sin. 2012 33 342 350 10.1038/aps.2011.200 22367283
Sun, L. & Ye, R. D. Role of G protein-coupled receptors in inflammation. Acta Pharmacol. Sin. 33, 342–350 (2012).22367283 10.1038/aps.2011.200
284. Sadik CD Miyabe Y Sezin T Luster AD The critical role of C5a as an initiator of neutrophil-mediated autoimmune inflammation of the joint and skin Semin. Immunol. 2018 37 21 29 10.1016/j.smim.2018.03.002 29602515
Sadik, C. D., Miyabe, Y., Sezin, T. & Luster, A. D. The critical role of C5a as an initiator of neutrophil-mediated autoimmune inflammation of the joint and skin. Semin. Immunol. 37, 21–29 (2018).29602515 10.1016/j.smim.2018.03.002
285. Woodruff TM Shukla AK The Complement C5a-C5aR1 GPCR Axis in COVID-19 Therapeutics Trends Immunol. 2020 41 965 967 10.1016/j.it.2020.09.008 33023856
Woodruff, T. M. & Shukla, A. K. The Complement C5a-C5aR1 GPCR Axis in COVID-19 Therapeutics. Trends Immunol. 41, 965–967 (2020).33023856 10.1016/j.it.2020.09.008
286. Garred P Tenner AJ Mollnes TE Therapeutic targeting of the complement system: from rare diseases to pandemics Pharmacol. Rev. 2021 73 792 827 10.1124/pharmrev.120.000072 33687995
Garred, P., Tenner, A. J. & Mollnes, T. E. Therapeutic targeting of the complement system: from rare diseases to pandemics. Pharmacol. Rev. 73, 792–827 (2021).33687995 10.1124/pharmrev.120.000072
287. Lee A Avacopan: First approval Drugs 2022 82 79 85 10.1007/s40265-021-01643-6 34826105
Lee, A. Avacopan: First approval. Drugs 82, 79–85 (2022).34826105 10.1007/s40265-021-01643-6
288. Jayne DRW Avacopan for the treatment of ANCA-associated Vasculitis N. Engl. J. Med. 2021 384 599 609 10.1056/NEJMoa2023386 33596356
Jayne, D. R. W. et al. Avacopan for the treatment of ANCA-associated Vasculitis. N. Engl. J. Med. 384, 599–609 (2021).33596356 10.1056/NEJMoa2023386
289. Feng YY Mechanism of activation and biased signaling in complement receptor C5aR1 Cell Res 2023 33 312 324 10.1038/s41422-023-00779-2 36806352
Feng, Y. Y. et al. Mechanism of activation and biased signaling in complement receptor C5aR1. Cell Res 33, 312–324 (2023).36806352 10.1038/s41422-023-00779-2
290. Gurevich VV Gurevich EV GPCR signaling regulation: the role of GRKs and Arrestins Front. Pharmacol. 2019 10 125 10.3389/fphar.2019.00125 30837883
Gurevich, V. V. & Gurevich, E. V. GPCR signaling regulation: the role of GRKs and Arrestins. Front. Pharmacol. 10, 125 (2019).30837883 10.3389/fphar.2019.00125
291. Maharana J Structural snapshots uncover a key phosphorylation motif in GPCRs driving p-arrestin activation Mol. Cell 2023 83 2091 2107 10.1016/j.molcel.2023.04.025 37209686
Maharana, J. et al. Structural snapshots uncover a key phosphorylation motif in GPCRs driving p-arrestin activation. Mol. Cell 83, 2091–2107 (2023).37209686 10.1016/j.molcel.2023.04.025
292. Rasmussen SGF Structure of a nanobody-stabilized active state of the β2 adrenoceptor Nature 2011 469 175 180 10.1038/nature09648 21228869
Rasmussen, S. G. F. et al. Structure of a nanobody-stabilized active state of the β2 adrenoceptor. Nature 469, 175–180 (2011).21228869 10.1038/nature09648
293. Huang WJ Structural insights into μ-opioid receptor activation Nature 2015 524 315 321 10.1038/nature14886 26245379
Huang, W. J. et al. Structural insights into μ-opioid receptor activation. Nature 524, 315–321 (2015).26245379 10.1038/nature14886
294. Groom JR Luster AD CXCR3 ligands: redundant, collaborative and antagonistic functions Immunol. Cell Biol. 2011 89 207 215 10.1038/icb.2010.158 21221121
Groom, J. R. & Luster, A. D. CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunol. Cell Biol. 89, 207–215 (2011).21221121 10.1038/icb.2010.158
295. Lacotte S Brun S Muller S Dumortier H CXCR3, inflammation, and autoimmune diseases Ann. Ny. Acad. Sci. 2009 1173 310 317 10.1111/j.1749-6632.2009.04813.x 19758167
Lacotte, S., Brun, S., Muller, S. & Dumortier, H. CXCR3, inflammation, and autoimmune diseases. Ann. Ny. Acad. Sci. 1173, 310–317 (2009).19758167 10.1111/j.1749-6632.2009.04813.x
296. Milanos L Discovery and characterization of biased allosteric agonists of the chemokine Receptor CXCR3 J. Med. Chem. 2016 59 2222 2243 10.1021/acs.jmedchem.5b01965 26862767
Milanos, L. et al. Discovery and characterization of biased allosteric agonists of the chemokine Receptor CXCR3. J. Med. Chem. 59, 2222–2243 (2016).26862767 10.1021/acs.jmedchem.5b01965
297. Heise CE Pharmacological characterization of CXC chemokine receptor 3 ligands and a small molecule antagonist J. Pharmacol. Exp. Ther. 2005 313 1263 1271 10.1124/jpet.105.083683 15761110
Heise, C. E. et al. Pharmacological characterization of CXC chemokine receptor 3 ligands and a small molecule antagonist. J. Pharmacol. Exp. Ther. 313, 1263–1271 (2005).15761110 10.1124/jpet.105.083683
298. Jenh CH A selective and potent CXCR3 antagonist SCH 546738 attenuates the development of autoimmune diseases and delays graft rejection BMC Immunol. 2012 13 2 10.1186/1471-2172-13-2 22233170
Jenh, C. H. et al. A selective and potent CXCR3 antagonist SCH 546738 attenuates the development of autoimmune diseases and delays graft rejection. BMC Immunol. 13, 2 (2012).22233170 10.1186/1471-2172-13-2
299. Jiao H Structural insights into the activation and inhibition of CXC chemokine receptor 3 Nat. Struct. Mol. Biol. 2024 31 1 11 10.1038/s41594-023-01175-5 38253665
Jiao, H. et al. Structural insights into the activation and inhibition of CXC chemokine receptor 3. Nat. Struct. Mol. Biol. 31, 1–11 (2024).38253665 10.1038/s41594-023-01175-5
300. Rittiner JE AMP is an Adenosine A1 receptor agonist J. Biol. Chem. 2012 287 5301 5309 10.1074/jbc.M111.291666 22215671
Rittiner, J. E. et al. AMP is an Adenosine A1 receptor agonist. J. Biol. Chem. 287, 5301–5309 (2012).22215671 10.1074/jbc.M111.291666
301. Zylka MJ Pain-relieving prospects for adenosine receptors and ectonucleotidases Trends Mol. Med. 2011 17 188 196 10.1016/j.molmed.2010.12.006 21236731
Zylka, M. J. Pain-relieving prospects for adenosine receptors and ectonucleotidases. Trends Mol. Med. 17, 188–196 (2011).21236731 10.1016/j.molmed.2010.12.006
302. Narlawar R Hybrid ortho/allosteric ligands for the Adenosine A1 receptor J. Med. Chem. 2010 53 3028 3037 10.1021/jm901252a 20345101
Narlawar, R. et al. Hybrid ortho/allosteric ligands for the Adenosine A1 receptor. J. Med. Chem. 53, 3028–3037 (2010).20345101 10.1021/jm901252a
303. Lee DF Geron M Scherrer G A modulator-bound GPCR structure enables allosteric non-opioid analgesia Nat. Struct. Mol. Biol. 2021 28 871 872 10.1038/s41594-021-00681-8 34754105
Lee, D. F., Geron, M. & Scherrer, G. A modulator-bound GPCR structure enables allosteric non-opioid analgesia. Nat. Struct. Mol. Biol. 28, 871–872 (2021).34754105 10.1038/s41594-021-00681-8
304. Mattedi G Understanding ligand binding selectivity in a prototypical GPCR family J. Chem. Inf. Model. 2019 59 2830 2836 10.1021/acs.jcim.9b00298 31125224
Mattedi, G. et al. Understanding ligand binding selectivity in a prototypical GPCR family. J. Chem. Inf. Model. 59, 2830–2836 (2019).31125224 10.1021/acs.jcim.9b00298
305. Draper-Joyce CJ Positive allosteric mechanisms of adenosine A(1) receptor-mediated analgesia Nature 2021 597 571 576 10.1038/s41586-021-03897-2 34497422
Draper-Joyce, C. J. et al. Positive allosteric mechanisms of adenosine A(1) receptor-mediated analgesia. Nature 597, 571–576 (2021).34497422 10.1038/s41586-021-03897-2
306. Li Y Sun JX Li DM Lin JP The full activation mechanism of the adenosine A1 receptor revealed by GaMD and Su-GaMD simulations Proc. Natl Acad. Sci. USA 2022 119 e2203702119 10.1073/pnas.2203702119 36215480
Li, Y., Sun, J. X., Li, D. M. & Lin, J. P. The full activation mechanism of the adenosine A1 receptor revealed by GaMD and Su-GaMD simulations. Proc. Natl Acad. Sci. USA 119, e2203702119 (2022).36215480 10.1073/pnas.2203702119
307. Niswender CM Conn PJ Metabotropic Glutamate receptors: physiology, pharmacology, and disease Annu. Rev. Pharmacol. Toxicol. 2010 50 295 322 10.1146/annurev.pharmtox.011008.145533 20055706
Niswender, C. M. & Conn, P. J. Metabotropic Glutamate receptors: physiology, pharmacology, and disease. Annu. Rev. Pharmacol. Toxicol. 50, 295–322 (2010).20055706 10.1146/annurev.pharmtox.011008.145533
308. Andre MAE Gunturkun O Manahan-Vaughan D The metabotropic Glutamate receptor, mGlu5, is required for extinction learning that occurs in the absence of a context change Hippocampus 2015 25 149 158 10.1002/hipo.22359 25160592
Andre, M. A. E., Gunturkun, O. & Manahan-Vaughan, D. The metabotropic Glutamate receptor, mGlu5, is required for extinction learning that occurs in the absence of a context change. Hippocampus 25, 149–158 (2015).25160592 10.1002/hipo.22359
309. Brambilla CR mGluR5 receptor availability is associated with lower levels of negative symptoms and better cognition in male patients with chronic schizophrenia Hum. Brain Mapp. 2020 41 2762 2781 10.1002/hbm.24976 32150317
Brambilla, C. R. et al. mGluR5 receptor availability is associated with lower levels of negative symptoms and better cognition in male patients with chronic schizophrenia. Hum. Brain Mapp. 41, 2762–2781 (2020).32150317 10.1002/hbm.24976
310. Roth BL Molecular pharmacology of metabotropic receptors targeted by neuropsychiatric drugs Nat. Struct. Mol. Biol. 2019 26 535 544 10.1038/s41594-019-0252-8 31270468
Roth, B. L. Molecular pharmacology of metabotropic receptors targeted by neuropsychiatric drugs. Nat. Struct. Mol. Biol. 26, 535–544 (2019).31270468 10.1038/s41594-019-0252-8
311. Lindsley CW Practical strategies and concepts in GPCR allosteric modulator discovery: recent advances with metabotropic glutamate receptors Chem. Rev. 2016 116 6707 6741 10.1021/acs.chemrev.5b00656 26882314
Lindsley, C. W. et al. Practical strategies and concepts in GPCR allosteric modulator discovery: recent advances with metabotropic glutamate receptors. Chem. Rev. 116, 6707–6741 (2016).26882314 10.1021/acs.chemrev.5b00656
312. Liauw BWH Conformational fingerprinting of allosteric modulators in metabotropic glutamate receptor 2 Elife 2022 11 e78982 10.7554/eLife.78982 35775730
Liauw, B. W. H. et al. Conformational fingerprinting of allosteric modulators in metabotropic glutamate receptor 2. Elife 11, e78982 (2022).35775730 10.7554/eLife.78982
313. Gutzeit VA Conformational dynamics between transmembrane domains and allosteric modulation of a metabotropic glutamate receptor Elife 2019 8 e45116 10.7554/eLife.45116 31172948
Gutzeit, V. A. et al. Conformational dynamics between transmembrane domains and allosteric modulation of a metabotropic glutamate receptor. Elife 8, e45116 (2019).31172948 10.7554/eLife.45116
314. Ellaithy A Younkin J González-Maeso J Logothetis DE Positive allosteric modulators of metabotropic glutamate 2 receptors in schizophrenia treatment Trends Neurosci. 2015 38 506 516 10.1016/j.tins.2015.06.002 26148747
Ellaithy, A., Younkin, J., González-Maeso, J. & Logothetis, D. E. Positive allosteric modulators of metabotropic glutamate 2 receptors in schizophrenia treatment. Trends Neurosci. 38, 506–516 (2015).26148747 10.1016/j.tins.2015.06.002
315. Vafabakhsh R Levitz J Isacoff EY Conformational dynamics of a class C G-protein-coupled receptor Nature 2015 524 497 501 10.1038/nature14679 26258295
Vafabakhsh, R., Levitz, J. & Isacoff, E. Y. Conformational dynamics of a class C G-protein-coupled receptor. Nature 524, 497–501 (2015).26258295 10.1038/nature14679
316. Gentry PR Sexton PM Christopoulos A Novel allosteric modulators of G protein-coupled receptors J. Biol. Chem. 2015 290 19478 19488 10.1074/jbc.R115.662759 26100627
Gentry, P. R., Sexton, P. M. & Christopoulos, A. Novel allosteric modulators of G protein-coupled receptors. J. Biol. Chem. 290, 19478–19488 (2015).26100627 10.1074/jbc.R115.662759
317. Stansley BJ Conn PJ Neuropharmacological insight from allosteric modulation of mGlu receptors Trends Pharmacol. Sci. 2019 40 240 252 10.1016/j.tips.2019.02.006 30824180
Stansley, B. J. & Conn, P. J. Neuropharmacological insight from allosteric modulation of mGlu receptors. Trends Pharmacol. Sci. 40, 240–252 (2019).30824180 10.1016/j.tips.2019.02.006
318. Jones-Tabah J Targeting G protein-coupled receptors in the treatment of Parkinson’s disease J. Mol. Biol. 2023 435 167927 10.1016/j.jmb.2022.167927 36563742
Jones-Tabah, J. Targeting G protein-coupled receptors in the treatment of Parkinson’s disease. J. Mol. Biol. 435, 167927 (2023).36563742 10.1016/j.jmb.2022.167927
319. Luessen DJ Conn PJ Allosteric modulators of metabotropic glutamate receptors as novel therapeutics for neuropsychiatric disease Pharmacol. Rev. 2022 74 630 661 10.1124/pharmrev.121.000540 35710132
Luessen, D. J. & Conn, P. J. Allosteric modulators of metabotropic glutamate receptors as novel therapeutics for neuropsychiatric disease. Pharmacol. Rev. 74, 630–661 (2022).35710132 10.1124/pharmrev.121.000540
320. Foster DJ Conn PJ Allosteric modulation of GPCRs: New insights and potential utility for treatment of schizophrenia and other CNS disorders Neuron 2017 94 431 446 10.1016/j.neuron.2017.03.016 28472649
Foster, D. J. & Conn, P. J. Allosteric modulation of GPCRs: New insights and potential utility for treatment of schizophrenia and other CNS disorders. Neuron 94, 431–446 (2017).28472649 10.1016/j.neuron.2017.03.016
321. Christppher J. A. et al. Fragment and structure-based drug discovery for a Class C GPCR: Discovery of the mGlu5 negative allosteric modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile). J. Med. Chem. 58, 6653–6664 (2015).
322. Cong XJ Allosteric modulation mechanism of the mGIuR(5) Transmembrane domain J. Chem. Inf. Model. 2019 59 2871 2878 10.1021/acs.jcim.9b00045 31025859
Cong, X. J. et al. Allosteric modulation mechanism of the mGIuR(5) Transmembrane domain. J. Chem. Inf. Model. 59, 2871–2878 (2019).31025859 10.1021/acs.jcim.9b00045
323. del Torrent CL Mechanisms underlying allosteric molecular switches of metabotropic glutamate Receptor 5 J. Chem. Inf. Model. 2019 59 2456 2466 10.1021/acs.jcim.8b00924 30811196
del Torrent, C. L. et al. Mechanisms underlying allosteric molecular switches of metabotropic glutamate Receptor 5. J. Chem. Inf. Model. 59, 2456–2466 (2019).30811196 10.1021/acs.jcim.8b00924
324. Grushevskyi EO Stepwise activation of a class C GPCR begins with millisecond dimer rearrangement Proc. Natl Acad. Sci. USA 2019 116 10150 10155 10.1073/pnas.1900261116 31023886
Grushevskyi, E. O. et al. Stepwise activation of a class C GPCR begins with millisecond dimer rearrangement. Proc. Natl Acad. Sci. USA 116, 10150–10155 (2019).31023886 10.1073/pnas.1900261116
325. Kumar, K. K. et al. Step-wise activation of a Family C GPCR. Biorxiv.10.1101/2023.08.29.555158 (2023).
326. Schwartz TW Molecular mechanism of 7TM receptor activation - A global toggle switch model Annu. Rev. Pharmacol. Toxicol. 2006 46 481 519 10.1146/annurev.pharmtox.46.120604.141218 16402913
Schwartz, T. W. et al. Molecular mechanism of 7TM receptor activation - A global toggle switch model. Annu. Rev. Pharmacol. Toxicol. 46, 481–519 (2006).16402913 10.1146/annurev.pharmtox.46.120604.141218
327. Harmar AJ Family-B G-protein-coupled receptors Genome Biol. 2001 2 reviews3013.3011 3013.3010 10.1186/gb-2001-2-12-reviews3013 11790261
Harmar, A. J. Family-B G-protein-coupled receptors. Genome Biol. 2, reviews3013.3011–3013.3010 (2001).11790261 10.1186/gb-2001-2-12-reviews3013
328. Vilardaga JP Molecular mechanisms of PTH/PTHrP Class B GPCR signaling and pharmacological implications Endocr. Rev. 2023 44 474 491 10.1210/endrev/bnac032 36503956
Vilardaga, J. P. et al. Molecular mechanisms of PTH/PTHrP Class B GPCR signaling and pharmacological implications. Endocr. Rev. 44, 474–491 (2023).36503956 10.1210/endrev/bnac032
329. Wootten D Allostery and biased agonism at Class B G protein-coupled receptors Chem. Rev. 2017 117 111 138 10.1021/acs.chemrev.6b00049 27040440
Wootten, D. et al. Allostery and biased agonism at Class B G protein-coupled receptors. Chem. Rev. 117, 111–138 (2017).27040440 10.1021/acs.chemrev.6b00049
330. Sutkeviciute I Precise druggability of the PTH type 1 receptor Nat. Chem. Biol. 2022 18 272 280 10.1038/s41589-021-00929-w 34949836
Sutkeviciute, I. et al. Precise druggability of the PTH type 1 receptor. Nat. Chem. Biol. 18, 272–280 (2022).34949836 10.1038/s41589-021-00929-w
331. Tamura T Identification of an orally active small-molecule PTHR1 agonist for the treatment of hypoparathyroidism Nat. Commun. 2016 7 13384 13397 10.1038/ncomms13384 27857062
Tamura, T. et al. Identification of an orally active small-molecule PTHR1 agonist for the treatment of hypoparathyroidism. Nat. Commun. 7, 13384–13397 (2016).27857062 10.1038/ncomms13384
332. Nishimura Y Lead optimization and avoidance of reactive metabolite leading to PCO371, a potent, selective, and orally available human parathyroid hormone receptor 1 (hPTHR1) agonist J. Med. Chem. 2020 63 5089 5099 10.1021/acs.jmedchem.9b01743 32022560
Nishimura, Y. et al. Lead optimization and avoidance of reactive metabolite leading to PCO371, a potent, selective, and orally available human parathyroid hormone receptor 1 (hPTHR1) agonist. J. Med. Chem. 63, 5089–5099 (2020).32022560 10.1021/acs.jmedchem.9b01743
333. Hiesinger K Dar’in D Proschak E Krasavin M Spirocyclic scaffolds in medicinal chemistry J. Med. Chem. 2021 64 150 183 10.1021/acs.jmedchem.0c01473 33381970
Hiesinger, K., Dar’in, D., Proschak, E. & Krasavin, M. Spirocyclic scaffolds in medicinal chemistry. J. Med. Chem. 64, 150–183 (2021).33381970 10.1021/acs.jmedchem.0c01473
334. Xiao H Sun Q Sun Q A promising small molecule binding pocket in class B GPCRs: expanding potential for drug development Signal Transduct. Target. Ther. 2023 8 313 10.1038/s41392-023-01598-y 37567868
Xiao, H., Sun, Q. & Sun, Q. A promising small molecule binding pocket in class B GPCRs: expanding potential for drug development. Signal Transduct. Target. Ther. 8, 313 (2023).37567868 10.1038/s41392-023-01598-y
335. Kobayashi K Class B1 GPCR activation by an intracellular agonist Nature 2023 618 1085 1093 10.1038/s41586-023-06169-3 37286611
Kobayashi, K. et al. Class B1 GPCR activation by an intracellular agonist. Nature 618, 1085–1093 (2023).37286611 10.1038/s41586-023-06169-3
336. Zhao LH Conserved class B GPCR activation by a biased intracellular agonist Nature 2023 621 635 641 10.1038/s41586-023-06467-w 37524305
Zhao, L. H. et al. Conserved class B GPCR activation by a biased intracellular agonist. Nature 621, 635–641 (2023).37524305 10.1038/s41586-023-06467-w
337. Wootten D Mechanisms of signalling and biased agonism in G protein-coupled receptors Nat. Rev. Mol. Cell Biol. 2018 19 638 653 10.1038/s41580-018-0049-3 30104700
Wootten, D. et al. Mechanisms of signalling and biased agonism in G protein-coupled receptors. Nat. Rev. Mol. Cell Biol. 19, 638–653 (2018).30104700 10.1038/s41580-018-0049-3
338. Huang SJ GPCRs steer Gi and Gs selectivity via TM5-TM6 switches as revealed by structures of serotonin receptors Mol. Cell 2022 82 2681 2695 10.1016/j.molcel.2022.05.031 35714614
Huang, S. J. et al. GPCRs steer Gi and Gs selectivity via TM5-TM6 switches as revealed by structures of serotonin receptors. Mol. Cell 82, 2681–2695 (2022).35714614 10.1016/j.molcel.2022.05.031
339. Hilger D Structural insights into differences in G protein activation by family A and family B GPCRs Science 2020 369 eaba3373 10.1126/science.aba3373 32732395
Hilger, D. et al. Structural insights into differences in G protein activation by family A and family B GPCRs. Science 369, eaba3373 (2020).32732395 10.1126/science.aba3373
340. Evenseth LSM Gabrielsen M Sylte I The GABA(B)Receptor-structure, ligand binding and drug development Molecules 2020 25 3093 3111 10.3390/molecules25133093 32646032
Evenseth, L. S. M., Gabrielsen, M. & Sylte, I. The GABA(B)Receptor-structure, ligand binding and drug development. Molecules 25, 3093–3111 (2020).32646032 10.3390/molecules25133093
341. Cryan JF Kaupmann K Don’t worry ‘B’ happy!:: a role for GABAB receptors in anxiety and depression Trends Pharmacol. Sci. 2005 26 36 43 10.1016/j.tips.2004.11.004 15629203
Cryan, J. F. & Kaupmann, K. Don’t worry ‘B’ happy!:: a role for GABAB receptors in anxiety and depression. Trends Pharmacol. Sci. 26, 36–43 (2005).15629203 10.1016/j.tips.2004.11.004
342. Wieronska JM Pilc A Depression and schizophrenia viewed from the perspective of amino acidergic neurotransmission: Antipodes of psychiatric disorders Pharmacol. Ther. 2019 193 75 82 10.1016/j.pharmthera.2018.08.010 30149102
Wieronska, J. M. & Pilc, A. Depression and schizophrenia viewed from the perspective of amino acidergic neurotransmission: Antipodes of psychiatric disorders. Pharmacol. Ther. 193, 75–82 (2019).30149102 10.1016/j.pharmthera.2018.08.010
343. Tyacke RJ Lingford-Hughes A Reed LJ Nutt DJ GABAB receptors in addiction and its treatment Adv. Pharm. 2010 58 373 396 10.1016/S1054-3589(10)58014-1
Tyacke, R. J., Lingford-Hughes, A., Reed, L. J. & Nutt, D. J. GABAB receptors in addiction and its treatment. Adv. Pharm. 58, 373–396 (2010).10.1016/S1054-3589(10)58014-1
344. Filip M GABAB receptors as a therapeutic strategy in substance use disorders: Focus on positive allosteric modulators Neuropharmacology 2015 88 36 47 10.1016/j.neuropharm.2014.06.016 24971600
Filip, M. et al. GABAB receptors as a therapeutic strategy in substance use disorders: Focus on positive allosteric modulators. Neuropharmacology 88, 36–47 (2015).24971600 10.1016/j.neuropharm.2014.06.016
345. Xue L Rearrangement of the transmembrane domain interfaces associated with the activation of a GPCR hetero-oligomer Nat. Commun. 2019 10 2765 2776 10.1038/s41467-019-10834-5 31235691
Xue, L. et al. Rearrangement of the transmembrane domain interfaces associated with the activation of a GPCR hetero-oligomer. Nat. Commun. 10, 2765–2776 (2019).31235691 10.1038/s41467-019-10834-5
346. Farran B An update on the physiological and therapeutic relevance of GPCR oligomers Pharmacol. Res. 2017 117 303 327 10.1016/j.phrs.2017.01.008 28087443
Farran, B. An update on the physiological and therapeutic relevance of GPCR oligomers. Pharmacol. Res. 117, 303–327 (2017).28087443 10.1016/j.phrs.2017.01.008
347. Liu L Allosteric ligands control the activation of a class C GPCR heterodimer by acting at the transmembrane interface Elife 2021 10 e70188 10.7554/eLife.70188 34866572
Liu, L. et al. Allosteric ligands control the activation of a class C GPCR heterodimer by acting at the transmembrane interface. Elife 10, e70188 (2021).34866572 10.7554/eLife.70188
348. Galvez T Allosteric interactions between GB1 and GB2 subunits are required for optimal GABAB receptor function EMBO J. 2001 20 2152 2159 10.1093/emboj/20.9.2152 11331581
Galvez, T. et al. Allosteric interactions between GB1 and GB2 subunits are required for optimal GABAB receptor function. EMBO J. 20, 2152–2159 (2001).11331581 10.1093/emboj/20.9.2152
349. Gusach A García-Nafría J Tate CG New insights into GPCR coupling and dimerisation from cryo-EM structures Curr. Opin. Struct. Biol. 2023 80 102574 10.1016/j.sbi.2023.102574 36963163
Gusach, A., García-Nafría, J. & Tate, C. G. New insights into GPCR coupling and dimerisation from cryo-EM structures. Curr. Opin. Struct. Biol. 80, 102574 (2023).36963163 10.1016/j.sbi.2023.102574
350. Zemoura K Ralvenius WT Malherbe P Benke D The positive allosteric GABA(B) receptor modulator rac-BHFF enhances baclofen-mediated analgesia in neuropathic mice Neuropharmacology 2016 108 172 178 10.1016/j.neuropharm.2016.04.028 27108932
Zemoura, K., Ralvenius, W. T., Malherbe, P. & Benke, D. The positive allosteric GABA(B) receptor modulator rac-BHFF enhances baclofen-mediated analgesia in neuropathic mice. Neuropharmacology 108, 172–178 (2016).27108932 10.1016/j.neuropharm.2016.04.028
351. Mao CY Cryo-EM structures of inactive and active GABA(B) receptor Cell Res 2020 30 564 573 10.1038/s41422-020-0350-5 32494023
Mao, C. Y. et al. Cryo-EM structures of inactive and active GABA(B) receptor. Cell Res 30, 564–573 (2020).32494023 10.1038/s41422-020-0350-5
352. Shaye H Structural basis of the activation of a metabotropic GABA receptor Nature 2020 584 298 303 10.1038/s41586-020-2408-4 32555460
Shaye, H. et al. Structural basis of the activation of a metabotropic GABA receptor. Nature 584, 298–303 (2020).32555460 10.1038/s41586-020-2408-4
353. Kim Y Structural basis for activation of the Heterodimeric GABA(B) receptor J. Mol. Biol. 2020 432 5966 5984 10.1016/j.jmb.2020.09.023 33058878
Kim, Y. et al. Structural basis for activation of the Heterodimeric GABA(B) receptor. J. Mol. Biol. 432, 5966–5984 (2020).33058878 10.1016/j.jmb.2020.09.023
354. Monnier C Trans-activation between 7TM domains: implication in heterodimeric GABAB receptor activation EMBO J. 2011 30 32 42 10.1038/emboj.2010.270 21063387
Monnier, C. et al. Trans-activation between 7TM domains: implication in heterodimeric GABAB receptor activation. EMBO J. 30, 32–42 (2011).21063387 10.1038/emboj.2010.270
355. Knudsen LB Small-molecule agonists for the glucagon-like peptide 1 receptor Proc. Natl Acad. Sci. USA 2007 104 937 942 10.1073/pnas.0605701104 17213325
Knudsen, L. B. et al. Small-molecule agonists for the glucagon-like peptide 1 receptor. Proc. Natl Acad. Sci. USA 104, 937–942 (2007).17213325 10.1073/pnas.0605701104
356. Wootten D Differential activation and modulation of the Glucagon-Like Peptide-1 receptor by small molecule ligands Mol. Pharmacol. 2013 83 822 834 10.1124/mol.112.084525 23348499
Wootten, D. et al. Differential activation and modulation of the Glucagon-Like Peptide-1 receptor by small molecule ligands. Mol. Pharmacol. 83, 822–834 (2013).23348499 10.1124/mol.112.084525
357. Willard FS Ho JD Sloop KW Discovery and pharmacology of the covalent GLP-1 receptor (GLP-1R) allosteric modulator BETP: A novel tool to probe GLP-1R pharmacology Adv. Pharm. 2020 88 173 191 10.1016/bs.apha.2020.02.001
Willard, F. S., Ho, J. D. & Sloop, K. W. Discovery and pharmacology of the covalent GLP-1 receptor (GLP-1R) allosteric modulator BETP: A novel tool to probe GLP-1R pharmacology. Adv. Pharm. 88, 173–191 (2020).10.1016/bs.apha.2020.02.001
358. Cong ZT Molecular insights into ago-allosteric modulation of the human glucagon-like peptide-1 receptor Nat. Commun. 2021 12 3763 10.1038/s41467-021-24058-z 34145245
Cong, Z. T. et al. Molecular insights into ago-allosteric modulation of the human glucagon-like peptide-1 receptor. Nat. Commun. 12, 3763 (2021).34145245 10.1038/s41467-021-24058-z
359. Cong ZT Structural perspective of class B1 GPCR signaling Trends Pharmacol. Sci. 2022 43 321 334 10.1016/j.tips.2022.01.002 35078643
Cong, Z. T. et al. Structural perspective of class B1 GPCR signaling. Trends Pharmacol. Sci. 43, 321–334 (2022).35078643 10.1016/j.tips.2022.01.002
360. Bian YM Jun JJ Cuyler J Xie XQ Covalent allosteric modulation: An emerging strategy for GPCRs drug discovery Eur. J. Med. Chem. 2020 206 112690 10.1016/j.ejmech.2020.112690 32818870
Bian, Y. M., Jun, J. J., Cuyler, J. & Xie, X. Q. Covalent allosteric modulation: An emerging strategy for GPCRs drug discovery. Eur. J. Med. Chem. 206, 112690 (2020).32818870 10.1016/j.ejmech.2020.112690
361. Lu SY Zhang J Designed covalent allosteric modulators: an emerging paradigm in drug discovery Drug Discov. Today 2017 22 447 453 10.1016/j.drudis.2016.11.013 27888140
Lu, S. Y. & Zhang, J. Designed covalent allosteric modulators: an emerging paradigm in drug discovery. Drug Discov. Today 22, 447–453 (2017).27888140 10.1016/j.drudis.2016.11.013
362. Guo D Hillger JM IJzerman AP Heitman LH Drug-target residence Time-A Case for G protein-coupled receptors Med. Res. Rev. 2014 34 856 892 10.1002/med.21307 24549504
Guo, D., Hillger, J. M., IJzerman, A. P. & Heitman, L. H. Drug-target residence Time-A Case for G protein-coupled receptors. Med. Res. Rev. 34, 856–892 (2014).24549504 10.1002/med.21307
363. Jazayeri A Extra-helical binding site of a glucagon receptor antagonist Nature 2016 533 274 277 10.1038/nature17414 27111510
Jazayeri, A. et al. Extra-helical binding site of a glucagon receptor antagonist. Nature 533, 274–277 (2016).27111510 10.1038/nature17414
364. Zhang HN Structure of the full-length glucagon class B G-protein-coupled receptor Nature 2017 546 259 264 10.1038/nature22363 28514451
Zhang, H. N. et al. Structure of the full-length glucagon class B G-protein-coupled receptor. Nature 546, 259–264 (2017).28514451 10.1038/nature22363
365. Song GJ Human GLP-1 receptor transmembrane domain structure in complex with allosteric modulators Nature 2017 546 312 315 10.1038/nature22378 28514449
Song, G. J. et al. Human GLP-1 receptor transmembrane domain structure in complex with allosteric modulators. Nature 546, 312–315 (2017).28514449 10.1038/nature22378
366. Hollenstein K Insights into the structure of class B GPCRs Trends Pharmacol. Sci. 2014 35 12 22 10.1016/j.tips.2013.11.001 24359917
Hollenstein, K. et al. Insights into the structure of class B GPCRs. Trends Pharmacol. Sci. 35, 12–22 (2014).24359917 10.1016/j.tips.2013.11.001
367. Cho YM Merchant CE Kieffer TJ Targeting the glucagon receptor family for diabetes and obesity therapy Pharmacol. Ther. 2012 135 247 278 10.1016/j.pharmthera.2012.05.009 22659620
Cho, Y. M., Merchant, C. E. & Kieffer, T. J. Targeting the glucagon receptor family for diabetes and obesity therapy. Pharmacol. Ther. 135, 247–278 (2012).22659620 10.1016/j.pharmthera.2012.05.009
368. Kjolbye LR Lipid modulation of a Class B GPCR: Elucidating the modulatory role of PI(4,5)P2 lipids J. Chem. Inf. Model. 2022 62 6788 6802 10.1021/acs.jcim.2c00635 36036575
Kjolbye, L. R. et al. Lipid modulation of a Class B GPCR: Elucidating the modulatory role of PI(4,5)P2 lipids. J. Chem. Inf. Model. 62, 6788–6802 (2022).36036575 10.1021/acs.jcim.2c00635
369. Scheen AJ Paquot N Lefebvre PJ Investigational glucagon receptor antagonists in Phase I and II clinical trials for diabetes Expert Opin. Investig. Drugs 2017 26 1373 1389 10.1080/13543784.2017.1395020 29052441
Scheen, A. J., Paquot, N. & Lefebvre, P. J. Investigational glucagon receptor antagonists in Phase I and II clinical trials for diabetes. Expert Opin. Investig. Drugs 26, 1373–1389 (2017).29052441 10.1080/13543784.2017.1395020
370. Pettus J Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trial Nat. Med. 2022 28 2092 2099 10.1038/s41591-022-02011-x 36192552
Pettus, J. et al. Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trial. Nat. Med. 28, 2092–2099 (2022).36192552 10.1038/s41591-022-02011-x
371. Oh DY Olefsky JM G protein-coupled receptors as targets for anti-diabetic therapeutics Nat. Rev. Drug Discov. 2016 15 161 172 10.1038/nrd.2015.4 26822831
Oh, D. Y. & Olefsky, J. M. G protein-coupled receptors as targets for anti-diabetic therapeutics. Nat. Rev. Drug Discov. 15, 161–172 (2016).26822831 10.1038/nrd.2015.4
372. Xiong, Y. S. et al. Discovery of a Novel Glucagon Receptor Antagonist N-[(4-{(1S)-1-[3-(3,5-Dichlorophenyl)-5-(6-methoxynaphthalen-2-yl)-1H-pyrazol-1-yl]ethyl}phenyl)carbonyl]-beta-alanine (MK-0893) for the Treatment of Type II Diabetes. J. Med. Chem. 55, 6137–6148 (2012).
373. Sammons MF Lee ECY Recent progress in the development of small-molecule glucagon receptor antagonists Bioorg. Med. Chem. Lett. 2015 25 4057 4064 10.1016/j.bmcl.2015.07.092 26271588
Sammons, M. F. & Lee, E. C. Y. Recent progress in the development of small-molecule glucagon receptor antagonists. Bioorg. Med. Chem. Lett. 25, 4057–4064 (2015).26271588 10.1016/j.bmcl.2015.07.092
374. Ding TY Karlov DS Pino-Angeles A Tikhonova IG Intermolecular interactions in G protein-coupled receptor allosteric sites at the membrane interface from molecular dynamics simulations and quantum chemical calculations J. Chem. Inf. Model. 2022 62 4736 4747 10.1021/acs.jcim.2c00788 36178787
Ding, T. Y., Karlov, D. S., Pino-Angeles, A. & Tikhonova, I. G. Intermolecular interactions in G protein-coupled receptor allosteric sites at the membrane interface from molecular dynamics simulations and quantum chemical calculations. J. Chem. Inf. Model. 62, 4736–4747 (2022).36178787 10.1021/acs.jcim.2c00788
375. Chen K Tail engagement of arrestin at the glucagon receptor Nature 2023 620 904 910 10.1038/s41586-023-06420-x 37558880
Chen, K. et al. Tail engagement of arrestin at the glucagon receptor. Nature 620, 904–910 (2023).37558880 10.1038/s41586-023-06420-x
376. Zacarias NVO Intracellular receptor modulation: novel approach to target GPCRs Trends Pharmacol. Sci. 2018 39 547 559 10.1016/j.tips.2018.03.002 29653834
Zacarias, N. V. O. et al. Intracellular receptor modulation: novel approach to target GPCRs. Trends Pharmacol. Sci. 39, 547–559 (2018).29653834 10.1016/j.tips.2018.03.002
377. Krumm BE Neurotensin receptor allosterism revealed in complex with a biased allosteric modulator Biochemistry 2023 62 1233 1248 10.1021/acs.biochem.3c00029 36917754
Krumm, B. E. et al. Neurotensin receptor allosterism revealed in complex with a biased allosteric modulator. Biochemistry 62, 1233–1248 (2023).36917754 10.1021/acs.biochem.3c00029
378. Vandercappellen J Van Damme J Struyf S The role of CXC chemokines and their receptors in cancer Cancer Lett. 2008 267 226 244 10.1016/j.canlet.2008.04.050 18579287
Vandercappellen, J., Van Damme, J. & Struyf, S. The role of CXC chemokines and their receptors in cancer. Cancer Lett. 267, 226–244 (2008).18579287 10.1016/j.canlet.2008.04.050
379. Poeta VM Massara M Capucetti A Bonecchi R Chemokines and chemokine receptors: new targets for cancer immunotherapy Front. Immunol. 2019 10 379 10.3389/fimmu.2019.00379 30894861
Poeta, V. M., Massara, M., Capucetti, A. & Bonecchi, R. Chemokines and chemokine receptors: new targets for cancer immunotherapy. Front. Immunol. 10, 379 (2019).30894861 10.3389/fimmu.2019.00379
380. Proudfoot AEI Chemokine receptors: Multifaceted therapeutic targets Nat. Rev. Immunol. 2002 2 106 115 10.1038/nri722 11910892
Proudfoot, A. E. I. Chemokine receptors: Multifaceted therapeutic targets. Nat. Rev. Immunol. 2, 106–115 (2002).11910892 10.1038/nri722
381. Camba-Gomez M Arosa L Gualillo O Conde-Aranda J Chemokines and chemokine receptors in inflammatory bowel disease: Recent findings and future perspectives Drug Discov. Today 2022 27 1167 1175 10.1016/j.drudis.2021.12.004 34896626
Camba-Gomez, M., Arosa, L., Gualillo, O. & Conde-Aranda, J. Chemokines and chemokine receptors in inflammatory bowel disease: Recent findings and future perspectives. Drug Discov. Today 27, 1167–1175 (2022).34896626 10.1016/j.drudis.2021.12.004
382. Wendland M CCR9 is a homing receptor for plasmacytoid dendritic cells to the small intestine Proc. Natl Acad. Sci. USA 2007 104 6347 6352 10.1073/pnas.0609180104 17404233
Wendland, M. et al. CCR9 is a homing receptor for plasmacytoid dendritic cells to the small intestine. Proc. Natl Acad. Sci. USA 104, 6347–6352 (2007).17404233 10.1073/pnas.0609180104
383. Schall TJ Proudfoot AEI Overcoming hurdles in developing successful drugs targeting chemokine receptors Nat. Rev. Immunol. 2011 11 355 363 10.1038/nri2972 21494268
Schall, T. J. & Proudfoot, A. E. I. Overcoming hurdles in developing successful drugs targeting chemokine receptors. Nat. Rev. Immunol. 11, 355–363 (2011).21494268 10.1038/nri2972
384. Feagan BG Randomised clinical trial: vercirnon, an oral CCR9 antagonist, vs. placebo as induction therapy in active Crohn’s disease Aliment. Pharmacol. Ther. 2015 42 1170 1181 10.1111/apt.13398 26400458
Feagan, B. G. et al. Randomised clinical trial: vercirnon, an oral CCR9 antagonist, vs. placebo as induction therapy in active Crohn’s disease. Aliment. Pharmacol. Ther. 42, 1170–1181 (2015).26400458 10.1111/apt.13398
385. Oswald C Intracellular allosteric antagonism of the CCR9 receptor Nature 2016 540 462 465 10.1038/nature20606 27926729
Oswald, C. et al. Intracellular allosteric antagonism of the CCR9 receptor. Nature 540, 462–465 (2016).27926729 10.1038/nature20606
386. Wagner JR Emerging computational methods for the rational discovery of allosteric drugs Chem. Rev. 2016 116 6370 6390 10.1021/acs.chemrev.5b00631 27074285
Wagner, J. R. et al. Emerging computational methods for the rational discovery of allosteric drugs. Chem. Rev. 116, 6370–6390 (2016).27074285 10.1021/acs.chemrev.5b00631
387. Erlandson SC McMahon C Kruse AC Structural basis for G protein-coupled receptor signaling Annu. Rev. Biophys. 2018 47 1 18 10.1146/annurev-biophys-070317-032931 29498889
Erlandson, S. C., McMahon, C. & Kruse, A. C. Structural basis for G protein-coupled receptor signaling. Annu. Rev. Biophys. 47, 1–18 (2018).29498889 10.1146/annurev-biophys-070317-032931
388. Cooke RM Brown AJH Marshall FH Mason JS Structures of G protein-coupled receptors reveal new opportunities for drug discovery Drug Discov. Today 2015 20 1355 1364 10.1016/j.drudis.2015.08.003 26303408
Cooke, R. M., Brown, A. J. H., Marshall, F. H. & Mason, J. S. Structures of G protein-coupled receptors reveal new opportunities for drug discovery. Drug Discov. Today 20, 1355–1364 (2015).26303408 10.1016/j.drudis.2015.08.003
389. Thal DM Recent advances in the determination of G protein-coupled receptor structures Curr. Opin. Struct. Biol. 2018 51 28 34 10.1016/j.sbi.2018.03.002 29547818
Thal, D. M. et al. Recent advances in the determination of G protein-coupled receptor structures. Curr. Opin. Struct. Biol. 51, 28–34 (2018).29547818 10.1016/j.sbi.2018.03.002
390. Dror RO Pathway and mechanism of drug binding to G-protein-coupled receptors Proc. Natl Acad. Sci. USA 2011 108 13118 13123 10.1073/pnas.1104614108 21778406
Dror, R. O. et al. Pathway and mechanism of drug binding to G-protein-coupled receptors. Proc. Natl Acad. Sci. USA 108, 13118–13123 (2011).21778406 10.1073/pnas.1104614108
391. Changeux JP Christopoulos A Allosteric modulation as a unifying mechanism for receptor function and regulation Cell 2016 166 1084 1102 10.1016/j.cell.2016.08.015 27565340
Changeux, J. P. & Christopoulos, A. Allosteric modulation as a unifying mechanism for receptor function and regulation. Cell 166, 1084–1102 (2016).27565340 10.1016/j.cell.2016.08.015
392. Kenakin T Theoretical aspects of GPCR-ligand complex pharmacology Chem. Rev. 2017 117 4 20 10.1021/acs.chemrev.5b00561 26856272
Kenakin, T. Theoretical aspects of GPCR-ligand complex pharmacology. Chem. Rev. 117, 4–20 (2017).26856272 10.1021/acs.chemrev.5b00561
393. Nussinov R Tsai CJ The different ways through which specificity works in orthosteric and allosteric drugs Curr. Pharm. Des. 2012 18 1311 1316 10.2174/138161212799436377 22316155
Nussinov, R. & Tsai, C. J. The different ways through which specificity works in orthosteric and allosteric drugs. Curr. Pharm. Des. 18, 1311–1316 (2012).22316155 10.2174/138161212799436377
394. Wright SC Bouvier M Illuminating the complexity of GPCR pathway selectivity - advances in biosensor development Curr. Opin. Struct. Biol. 2021 69 142 149 10.1016/j.sbi.2021.04.006 34048988
Wright, S. C. & Bouvier, M. Illuminating the complexity of GPCR pathway selectivity - advances in biosensor development. Curr. Opin. Struct. Biol. 69, 142–149 (2021).34048988 10.1016/j.sbi.2021.04.006
395. Cheng L Orthosteric ligand selectivity and allosteric probe dependence at Hydroxycarboxylic acid receptor HCAR2 Signal Transduct. Target. Ther. 2023 8 364 10.1038/s41392-023-01625-y 37743365
Cheng, L. et al. Orthosteric ligand selectivity and allosteric probe dependence at Hydroxycarboxylic acid receptor HCAR2. Signal Transduct. Target. Ther. 8, 364 (2023).37743365 10.1038/s41392-023-01625-y
396. Powers AS Structural basis of efficacy-driven ligand selectivity at GPCRs (Feb, 10.1038/s41589-022-01247-5, 2023) Nat. Chem. Biol. 2023 19 529 529 10.1038/s41589-023-01297-3 36879062
Powers, A. S. et al. Structural basis of efficacy-driven ligand selectivity at GPCRs (Feb, 10.1038/s41589-022-01247-5, 2023). Nat. Chem. Biol. 19, 529–529 (2023).36879062 10.1038/s41589-023-01297-3
397. Liu HT Structure-guided development of selective M3 muscarinic acetylcholine receptor antagonists Proc. Natl Acad. Sci. USA 2018 115 12046 12050 10.1073/pnas.1813988115 30404914
Liu, H. T. et al. Structure-guided development of selective M3 muscarinic acetylcholine receptor antagonists. Proc. Natl Acad. Sci. USA 115, 12046–12050 (2018).30404914 10.1073/pnas.1813988115
398. Chatzigoulas A Cournia Z Rational design of allosteric modulators: Challenges and successes Wires Comput. Mol. Sci. 2021 11 e1529 10.1002/wcms.1529
Chatzigoulas, A. & Cournia, Z. Rational design of allosteric modulators: Challenges and successes. Wires Comput. Mol. Sci. 11, e1529 (2021).10.1002/wcms.1529
399. Nussinov R Tsai CJ Unraveling structural mechanisms of allosteric drug action Trends Pharmacol. Sci. 2014 35 256 264 10.1016/j.tips.2014.03.006 24742712
Nussinov, R. & Tsai, C. J. Unraveling structural mechanisms of allosteric drug action. Trends Pharmacol. Sci. 35, 256–264 (2014).24742712 10.1016/j.tips.2014.03.006
400. Nussinov R Tsai CJ Liu J Principles of allosteric interactions in cell signaling J. Am. Chem. Soc. 2014 136 17692 17701 10.1021/ja510028c 25474128
Nussinov, R., Tsai, C. J. & Liu, J. Principles of allosteric interactions in cell signaling. J. Am. Chem. Soc. 136, 17692–17701 (2014).25474128 10.1021/ja510028c
401. Morimoto J Hayashi Y Suga H Discovery of macrocyclic peptides armed with a mechanism-based warhead: Isoform-selective inhibition of human Deacetylase SIRT2 Angew. Chem. Int. Ed. 2012 51 3423 3427 10.1002/anie.201108118
Morimoto, J., Hayashi, Y. & Suga, H. Discovery of macrocyclic peptides armed with a mechanism-based warhead: Isoform-selective inhibition of human Deacetylase SIRT2. Angew. Chem. Int. Ed. 51, 3423–3427 (2012).10.1002/anie.201108118
402. Orr STM Mechanism-Based Inactivation (MBI) of Cytochrome P450 Enzymes: Structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks J. Med. Chem. 2012 55 4896 4933 10.1021/jm300065h 22409598
Orr, S. T. M. et al. Mechanism-Based Inactivation (MBI) of Cytochrome P450 Enzymes: Structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks. J. Med. Chem. 55, 4896–4933 (2012).22409598 10.1021/jm300065h
403. Pan Y Mader MM Principles of Kinase allosteric inhibition and pocket validation J. Med. Chem. 2022 65 5288 5299 10.1021/acs.jmedchem.2c00073 35312319
Pan, Y. & Mader, M. M. Principles of Kinase allosteric inhibition and pocket validation. J. Med. Chem. 65, 5288–5299 (2022).35312319 10.1021/acs.jmedchem.2c00073
404. Ippolito M Identification of a β-arrestin-biased negative allosteric modulator for the β2-adrenergic receptor Proc. Natl Acad. Sci. USA 2023 120 e2302668120 10.1073/pnas.2302668120 37490535
Ippolito, M. et al. Identification of a β-arrestin-biased negative allosteric modulator for the β2-adrenergic receptor. Proc. Natl Acad. Sci. USA 120, e2302668120 (2023).37490535 10.1073/pnas.2302668120
405. Schuss C Structure-activity relationship study of the high-affinity Neuropeptide Y-4 receptor positive allosteric modulator VU0506013 J. Med. Chem. 2023 66 8745 8766 10.1021/acs.jmedchem.3c00383 37339079
Schuss, C. et al. Structure-activity relationship study of the high-affinity Neuropeptide Y-4 receptor positive allosteric modulator VU0506013. J. Med. Chem. 66, 8745–8766 (2023).37339079 10.1021/acs.jmedchem.3c00383
406. Wang XD Intermediate-state-trapped mutants pinpoint G protein-coupled receptor conformational allostery Nat. Commun. 2023 14 1325 1334 10.1038/s41467-023-36971-6 36899002
Wang, X. D. et al. Intermediate-state-trapped mutants pinpoint G protein-coupled receptor conformational allostery. Nat. Commun. 14, 1325–1334 (2023).36899002 10.1038/s41467-023-36971-6
407. Lu SY Activation pathway of a G protein-coupled receptor uncovers conformational intermediates as targets for allosteric drug design Nat. Commun. 2021 12 4721 4735 10.1038/s41467-021-25020-9 34354057
Lu, S. Y. et al. Activation pathway of a G protein-coupled receptor uncovers conformational intermediates as targets for allosteric drug design. Nat. Commun. 12, 4721–4735 (2021).34354057 10.1038/s41467-021-25020-9
408. Ni D Discovery of cryptic allosteric sites using reversed allosteric communication by a combined computational and experimental strategy Chem. Sci. 2021 12 464 476 10.1039/D0SC05131D
Ni, D. et al. Discovery of cryptic allosteric sites using reversed allosteric communication by a combined computational and experimental strategy. Chem. Sci. 12, 464–476 (2021).10.1039/D0SC05131D
409. Lu X Lan X Lu S Zhang J Progressive computational approaches to facilitate decryption of allosteric mechanism and drug discovery Curr. Opin. Struct. Biol. 2023 83 8 10.1016/j.sbi.2023.102701
Lu, X., Lan, X., Lu, S. & Zhang, J. Progressive computational approaches to facilitate decryption of allosteric mechanism and drug discovery. Curr. Opin. Struct. Biol. 83, 8 (2023).10.1016/j.sbi.2023.102701
410. Hollingsworth SA Cryptic pocket formation underlies allosteric modulator selectivity at muscarinic GPCRs Nat. Commun. 2019 10 3289 3297 10.1038/s41467-019-11062-7 31337749
Hollingsworth, S. A. et al. Cryptic pocket formation underlies allosteric modulator selectivity at muscarinic GPCRs. Nat. Commun. 10, 3289–3297 (2019).31337749 10.1038/s41467-019-11062-7
411. Hertig S Latorraca NR Dror RO Revealing atomic-level mechanisms of protein allostery with molecular dynamics simulations Plos Comput. Biol. 2016 12 e1004746 10.1371/journal.pcbi.1004746 27285999
Hertig, S., Latorraca, N. R. & Dror, R. O. Revealing atomic-level mechanisms of protein allostery with molecular dynamics simulations. Plos Comput. Biol. 12, e1004746 (2016).27285999 10.1371/journal.pcbi.1004746
412. Bartuzi D Kaczor AA Matosiuk D Interplay between two allosteric sites and their influence on agonist binding in human μ opioid receptor J. Chem. Inf. Model. 2016 56 563 570 10.1021/acs.jcim.5b00705 26863088
Bartuzi, D., Kaczor, A. A. & Matosiuk, D. Interplay between two allosteric sites and their influence on agonist binding in human μ opioid receptor. J. Chem. Inf. Model. 56, 563–570 (2016).26863088 10.1021/acs.jcim.5b00705
413. Kumar A Predicting allosteric pockets in protein biological assemblages Bioinformatics 2023 39 btad275 10.1093/bioinformatics/btad275 37115636
Kumar, A. et al. Predicting allosteric pockets in protein biological assemblages. Bioinformatics 39, btad275 (2023).37115636 10.1093/bioinformatics/btad275
414. Smith RD Carlson HA Identification of cryptic binding sites using MixMD with standard and accelerated molecular dynamics J. Chem. Inf. Model. 2021 61 1287 1299 10.1021/acs.jcim.0c01002 33599485
Smith, R. D. & Carlson, H. A. Identification of cryptic binding sites using MixMD with standard and accelerated molecular dynamics. J. Chem. Inf. Model. 61, 1287–1299 (2021).33599485 10.1021/acs.jcim.0c01002
415. Zhang OD Learning on topological surface and geometric structure for 3D molecular generation Nat. Comput. Sci. 2023 3 849 859 10.1038/s43588-023-00530-2 38177756
Zhang, O. D. et al. Learning on topological surface and geometric structure for 3D molecular generation. Nat. Comput. Sci. 3, 849–859 (2023).38177756 10.1038/s43588-023-00530-2
416. Leander M Functional plasticity and evolutionary adaptation of allosteric regulation Proc. Natl Acad. Sci. USA 2020 117 25445 25454 10.1073/pnas.2002613117 32999067
Leander, M. et al. Functional plasticity and evolutionary adaptation of allosteric regulation. Proc. Natl Acad. Sci. USA 117, 25445–25454 (2020).32999067 10.1073/pnas.2002613117
417. Wang Q Toward understanding the molecular basis for chemical allosteric modulator design J. Mol. Graph. Model. 2012 38 324 333 10.1016/j.jmgm.2012.07.006 23085171
Wang, Q. et al. Toward understanding the molecular basis for chemical allosteric modulator design. J. Mol. Graph. Model. 38, 324–333 (2012).23085171 10.1016/j.jmgm.2012.07.006
418. Strasser A Wittmann HJ Seifert R Binding kinetics and pathways of ligands to GPCRs Trends Pharmacol. Sci. 2017 38 717 732 10.1016/j.tips.2017.05.005 28645833
Strasser, A., Wittmann, H. J. & Seifert, R. Binding kinetics and pathways of ligands to GPCRs. Trends Pharmacol. Sci. 38, 717–732 (2017).28645833 10.1016/j.tips.2017.05.005
419. Herenbrink CK The role of kinetic context in apparent biased agonism at GPCRs Nat. Commun. 2016 7 10842 10855 10.1038/ncomms10842 26905976
Herenbrink, C. K. et al. The role of kinetic context in apparent biased agonism at GPCRs. Nat. Commun. 7, 10842–10855 (2016).26905976 10.1038/ncomms10842
420. Diaz O Allosteric binding cooperativity in a kinetic context Drug Discov. Today 2023 28 103441 10.1016/j.drudis.2022.103441 36372329
Diaz, O. et al. Allosteric binding cooperativity in a kinetic context. Drug Discov. Today 28, 103441 (2023).36372329 10.1016/j.drudis.2022.103441
421. Alhadeff R Vorobyov I Yoon HW Warshel A Exploring the free-energy landscape of GPCR activation Proc. Natl Acad. Sci. USA 2018 115 10327 10332 10.1073/pnas.1810316115 30257944
Alhadeff, R., Vorobyov, I., Yoon, H. W. & Warshel, A. Exploring the free-energy landscape of GPCR activation. Proc. Natl Acad. Sci. USA 115, 10327–10332 (2018).30257944 10.1073/pnas.1810316115
422. Shukla AK Biasing GPCR Signaling from Inside Sci. Signal. 2014 7 pe3 10.1126/scisignal.2005021 24473194
Shukla, A. K. Biasing GPCR Signaling from Inside. Sci. Signal. 7, pe3 (2014).24473194 10.1126/scisignal.2005021
423. Gurevich VV Gurevich EV Biased GPCR signaling: Possible mechanisms and inherent limitations Pharmacol. Ther. 2020 211 107540 10.1016/j.pharmthera.2020.107540 32201315
Gurevich, V. V. & Gurevich, E. V. Biased GPCR signaling: Possible mechanisms and inherent limitations. Pharmacol. Ther. 211, 107540 (2020).32201315 10.1016/j.pharmthera.2020.107540
424. Seyedabadi M Ghahremani MH Albert PR Biased signaling of G protein coupled receptors (GPCRs): Molecular determinants of GPCR/transducer selectivity and therapeutic potential Pharmacol. Therapeut. 2019 200 148 178 10.1016/j.pharmthera.2019.05.006
Seyedabadi, M., Ghahremani, M. H. & Albert, P. R. Biased signaling of G protein coupled receptors (GPCRs): Molecular determinants of GPCR/transducer selectivity and therapeutic potential. Pharmacol. Therapeut. 200, 148–178 (2019).10.1016/j.pharmthera.2019.05.006
425. Bermudez M Nguyen TN Omieczynski C Wolber G Strategies for the discovery of biased GPCR ligands Drug Discov. Today 2019 24 1031 1037 10.1016/j.drudis.2019.02.010 30831262
Bermudez, M., Nguyen, T. N., Omieczynski, C. & Wolber, G. Strategies for the discovery of biased GPCR ligands. Drug Discov. Today 24, 1031–1037 (2019).30831262 10.1016/j.drudis.2019.02.010
426. Seyedabad M Gharghabi M Gurevich EV Gurevich VV Structural basis of GPCR coupling to distinct signal transducers: implications for biased signaling Trends Biochem. Sci. 2022 47 570 581 10.1016/j.tibs.2022.03.009 35396120
Seyedabad, M., Gharghabi, M., Gurevich, E. V. & Gurevich, V. V. Structural basis of GPCR coupling to distinct signal transducers: implications for biased signaling. Trends Biochem. Sci. 47, 570–581 (2022).35396120 10.1016/j.tibs.2022.03.009
427. Wang XD The Potential of 19F NMR application in GPCR biased drug discovery Trends Pharmacol. Sci. 2021 42 19 30 10.1016/j.tips.2020.11.001 33250272
Wang, X. D. et al. The Potential of 19F NMR application in GPCR biased drug discovery. Trends Pharmacol. Sci. 42, 19–30 (2021).33250272 10.1016/j.tips.2020.11.001
428. Okashah N Variable G protein determinants of GPCR coupling selectivity Proc. Natl Acad. Sci. USA 2019 116 12054 12059 10.1073/pnas.1905993116 31142646
Okashah, N. et al. Variable G protein determinants of GPCR coupling selectivity. Proc. Natl Acad. Sci. USA 116, 12054–12059 (2019).31142646 10.1073/pnas.1905993116
429. Guarnera E Berezovsky IN On the perturbation nature of allostery: sites, mutations, and signal modulation Curr. Opin. Struct. Biol. 2019 56 18 27 10.1016/j.sbi.2018.10.008 30439587
Guarnera, E. & Berezovsky, I. N. On the perturbation nature of allostery: sites, mutations, and signal modulation. Curr. Opin. Struct. Biol. 56, 18–27 (2019).30439587 10.1016/j.sbi.2018.10.008
430. Ni D Along the allostery stream: Recent advances in computational methods for allosteric drug discovery Wires Comput. Mol. Sci. 2022 12 e1585 10.1002/wcms.1585
Ni, D. et al. Along the allostery stream: Recent advances in computational methods for allosteric drug discovery. Wires Comput. Mol. Sci. 12, e1585 (2022).10.1002/wcms.1585
431. Tee WV Guarnera E Berezovsky IN Reversing allosteric communication: From detecting allosteric sites to inducing and tuning targeted allosteric response Plos Comput. Biol. 2018 14 e1006228 10.1371/journal.pcbi.1006228 29912863
Tee, W. V., Guarnera, E. & Berezovsky, I. N. Reversing allosteric communication: From detecting allosteric sites to inducing and tuning targeted allosteric response. Plos Comput. Biol. 14, e1006228 (2018).29912863 10.1371/journal.pcbi.1006228
432. Newman AH Battiti FO Bonifazi A 2016 Philip S. Portoghese medicinal chemistry lectureship: designing bivalent or bitopic molecules for G-protein coupled receptors. the whole is greater than the sum of its parts J. Med. Chem. 2020 63 1779 1797 10.1021/acs.jmedchem.9b01105 31499001
Newman, A. H., Battiti, F. O. & Bonifazi, A. 2016 Philip S. Portoghese medicinal chemistry lectureship: designing bivalent or bitopic molecules for G-protein coupled receptors. the whole is greater than the sum of its parts. J. Med. Chem. 63, 1779–1797 (2020).31499001 10.1021/acs.jmedchem.9b01105
433. Aurelio L A structure-activity relationship study of bitopic N6-substituted adenosine derivatives as biased Adenosine A1 receptor agonists J. Med. Chem. 2018 61 2087 2103 10.1021/acs.jmedchem.8b00047 29446948
Aurelio, L. et al. A structure-activity relationship study of bitopic N6-substituted adenosine derivatives as biased Adenosine A1 receptor agonists. J. Med. Chem. 61, 2087–2103 (2018).29446948 10.1021/acs.jmedchem.8b00047
434. Feng ZW Hu GX Ma SF Xie XQ Computational advances for the development of allosteric modulators and bitopic ligands in G protein-coupled receptors AAPS J. 2015 17 1080 1095 10.1208/s12248-015-9776-y 25940084
Feng, Z. W., Hu, G. X., Ma, S. F. & Xie, X. Q. Computational advances for the development of allosteric modulators and bitopic ligands in G protein-coupled receptors. AAPS J. 17, 1080–1095 (2015).25940084 10.1208/s12248-015-9776-y
435. Ni D Combining ALLOSTERIC AND ORTHOSTERIC DRUGS TO OVERCOME DRUG RESISTANce Trends Pharmacol. Sci. 2020 41 336 348 10.1016/j.tips.2020.02.001 32171554
Ni, D. et al. Combining ALLOSTERIC AND ORTHOSTERIC DRUGS TO OVERCOME DRUG RESISTANce. Trends Pharmacol. Sci. 41, 336–348 (2020).32171554 10.1016/j.tips.2020.02.001
436. Huang BS St Onge CM Ma HG Zhang Y Design of bivalent ligands targeting putative GPCR dimers Drug Discov. Today 2020 26 189 199 10.1016/j.drudis.2020.10.006 33075471
Huang, B. S., St Onge, C. M., Ma, H. G. & Zhang, Y. Design of bivalent ligands targeting putative GPCR dimers. Drug Discov. Today 26, 189–199 (2020).33075471 10.1016/j.drudis.2020.10.006
437. Romantini N Exploring the signaling space of a GPCR using bivalent ligands with a rigid oligoproline backbone Proc. Natl Acad. Sci. USA 2021 118 e2108776118 10.1073/pnas.2108776118 34810259
Romantini, N. et al. Exploring the signaling space of a GPCR using bivalent ligands with a rigid oligoproline backbone. Proc. Natl Acad. Sci. USA 118, e2108776118 (2021).34810259 10.1073/pnas.2108776118
438. Picard LP Prosser RS Advances in the study of GPCRs by 19F NMR Curr. Opin. Struct. Biol. 2021 69 169 176 10.1016/j.sbi.2021.05.001 34130235
Picard, L. P. & Prosser, R. S. Advances in the study of GPCRs by 19F NMR. Curr. Opin. Struct. Biol. 69, 169–176 (2021).34130235 10.1016/j.sbi.2021.05.001
439. Calebiro D Sungkaworn T Single-MOLECULE IMAGing of GPCR Interactions Trends Pharmacol. Sci. 2018 39 109 122 10.1016/j.tips.2017.10.010 29157577
Calebiro, D. & Sungkaworn, T. Single-MOLECULE IMAGing of GPCR Interactions. Trends Pharmacol. Sci. 39, 109–122 (2018).29157577 10.1016/j.tips.2017.10.010
440. Kumari P Ghosh E Shukla AK Emerging Approaches to GPCR ligand screening for drug discovery Trends Mol. Med. 2015 21 687 701 10.1016/j.molmed.2015.09.002 26481827
Kumari, P., Ghosh, E. & Shukla, A. K. Emerging Approaches to GPCR ligand screening for drug discovery. Trends Mol. Med. 21, 687–701 (2015).26481827 10.1016/j.molmed.2015.09.002
441. Lee HM Giguere PM Roth BL DREADDs: novel tools for drug discovery and development Drug Discov. Today 2014 19 469 473 10.1016/j.drudis.2013.10.018 24184433
Lee, H. M., Giguere, P. M. & Roth, B. L. DREADDs: novel tools for drug discovery and development. Drug Discov. Today 19, 469–473 (2014).24184433 10.1016/j.drudis.2013.10.018
442. Jabeen A Ranganathan S Applications of machine learning in GPCR bioactive ligand discovery Curr. Opin. Struct. Biol. 2019 55 66 76 10.1016/j.sbi.2019.03.022 31005679
Jabeen, A. & Ranganathan, S. Applications of machine learning in GPCR bioactive ligand discovery. Curr. Opin. Struct. Biol. 55, 66–76 (2019).31005679 10.1016/j.sbi.2019.03.022
443. Jumper J Highly accurate protein structure prediction with AlphaFold Nature 2021 596 583 589 10.1038/s41586-021-03819-2 34265844
Jumper, J. et al. Highly accurate protein structure prediction with AlphaFold. Nature 596, 583–589 (2021).34265844 10.1038/s41586-021-03819-2
444. Baek M Accurate prediction of protein structures and interactions using a three-track neural network Science 2021 373 871 876 10.1126/science.abj8754 34282049
Baek, M. et al. Accurate prediction of protein structures and interactions using a three-track neural network. Science 373, 871–876 (2021).34282049 10.1126/science.abj8754
445. Huang XP Allosteric ligands for the pharmacologically dark receptors GPR68 and GPR65 Nature 2015 527 477 483 10.1038/nature15699 26550826
Huang, X. P. et al. Allosteric ligands for the pharmacologically dark receptors GPR68 and GPR65. Nature 527, 477–483 (2015).26550826 10.1038/nature15699
446. He XH AlphaFold2 versus experimental structures: evaluation on G protein-coupled receptors Acta Pharmacol. Sin. 2023 44 1 7 10.1038/s41401-022-00938-y 35778488
He, X. H. et al. AlphaFold2 versus experimental structures: evaluation on G protein-coupled receptors. Acta Pharmacol. Sin. 44, 1–7 (2023).35778488 10.1038/s41401-022-00938-y
447. Kapla J Can molecular dynamics simulations improve the structural accuracy and virtual screening performance of GPCR models? Plos Comput. Biol. 2021 17 e1008936 10.1371/journal.pcbi.1008936 33983933
Kapla, J. et al. Can molecular dynamics simulations improve the structural accuracy and virtual screening performance of GPCR models? Plos Comput. Biol. 17, e1008936 (2021).33983933 10.1371/journal.pcbi.1008936
448. Xie J Pan GX Li YB Lai LH How protein topology controls allosteric regulations J. Chem. Phys. 2023 158 105102 10.1063/5.0138279 36922138
Xie, J., Pan, G. X., Li, Y. B. & Lai, L. H. How protein topology controls allosteric regulations. J. Chem. Phys. 158, 105102 (2023).36922138 10.1063/5.0138279
449. Xie J Coevolution-based prediction of key allosteric residues for protein function regulation Elife 2023 12 e81850 10.7554/eLife.81850 36799896
Xie, J. et al. Coevolution-based prediction of key allosteric residues for protein function regulation. Elife 12, e81850 (2023).36799896 10.7554/eLife.81850
450. Chen LF Sequence-based drug design as a concept in computational drug design Nat. Commun. 2023 14 4217 4237 10.1038/s41467-023-39856-w 37452028
Chen, L. F. et al. Sequence-based drug design as a concept in computational drug design. Nat. Commun. 14, 4217–4237 (2023).37452028 10.1038/s41467-023-39856-w
451. Cheng RKY Structural insight into allosteric modulation of protease-activated receptor 2 Nature 2017 545 112 115 10.1038/nature22309 28445455
Cheng, R. K. Y. et al. Structural insight into allosteric modulation of protease-activated receptor 2. Nature 545, 112–115 (2017).28445455 10.1038/nature22309
452. Lin X Structural basis of ligand recognition and self-activation of orphan GPR52 Nature 2020 579 152 157 10.1038/s41586-020-2019-0 32076264
Lin, X. et al. Structural basis of ligand recognition and self-activation of orphan GPR52. Nature 579, 152–157 (2020).32076264 10.1038/s41586-020-2019-0
453. Duan J Structures of full-length glycoprotein hormone receptor signalling complexes Nature 2021 598 688 692 10.1038/s41586-021-03924-2 34552239
Duan, J. et al. Structures of full-length glycoprotein hormone receptor signalling complexes. Nature 598, 688–692 (2021).34552239 10.1038/s41586-021-03924-2
454. Vuckovic Z Pharmacological hallmarks of allostery at the M4 muscarinic receptor elucidated through structure and dynamics Elife 2023 12 e83477 10.7554/eLife.83477 37248726
Vuckovic, Z. et al. Pharmacological hallmarks of allostery at the M4 muscarinic receptor elucidated through structure and dynamics. Elife 12, e83477 (2023).37248726 10.7554/eLife.83477
455. Duan J Hormone- and antibody-mediated activation of the thyrotropin receptor Nature 2022 609 854 859 10.1038/s41586-022-05173-3 35940204
Duan, J. et al. Hormone- and antibody-mediated activation of the thyrotropin receptor. Nature 609, 854–859 (2022).35940204 10.1038/s41586-022-05173-3
456. Liu YF Ligand recognition and allosteric modulation of the human MRGPRX1 receptor Nat. Chem. Biol. 2022 19 416 422 10.1038/s41589-022-01173-6 36302898
Liu, Y. F. et al. Ligand recognition and allosteric modulation of the human MRGPRX1 receptor. Nat. Chem. Biol. 19, 416–422 (2022).36302898 10.1038/s41589-022-01173-6
457. Wu HX Structure of a Class C GPCR Metabotropic Glutamate Receptor 1 Bound to an Allosteric Modulator Science 2014 344 58 64 10.1126/science.1249489 24603153
Wu, H. X. et al. Structure of a Class C GPCR Metabotropic Glutamate Receptor 1 Bound to an Allosteric Modulator. Science 344, 58–64 (2014).24603153 10.1126/science.1249489
458. Wen TL Structural basis for activation and allosteric modulation of full-length calcium-sensing receptor Sci. Adv. 2021 7 eabg1483 10.1126/sciadv.abg1483 34088669
Wen, T. L. et al. Structural basis for activation and allosteric modulation of full-length calcium-sensing receptor. Sci. Adv. 7, eabg1483 (2021).34088669 10.1126/sciadv.abg1483
459. Park J Symmetric activation and modulation of the human calcium-sensing receptor Proc. Natl Acad. Sci. USA 2021 118 e2115849118 10.1073/pnas.2115849118 34916296
Park, J. et al. Symmetric activation and modulation of the human calcium-sensing receptor. Proc. Natl Acad. Sci. USA 118, e2115849118 (2021).34916296 10.1073/pnas.2115849118
460. Lin SL Structures of G(i)-bound metabotropic glutamate receptors mGlu2 and mGlu4 Nature 2021 594 583 588 10.1038/s41586-021-03495-2 34135510
Lin, S. L. et al. Structures of G(i)-bound metabotropic glutamate receptors mGlu2 and mGlu4. Nature 594, 583–588 (2021).34135510 10.1038/s41586-021-03495-2
461. Du J Structures of human mGlu2 and mGlu7 homo- and heterodimers Nature 2021 594 589 593 10.1038/s41586-021-03641-w 34135509
Du, J. et al. Structures of human mGlu2 and mGlu7 homo- and heterodimers. Nature 594, 589–593 (2021).34135509 10.1038/s41586-021-03641-w
462. Byrne EFX Structural basis of Smoothened regulation by its extracellular domains Nature 2016 535 517 522 10.1038/nature18934 27437577
Byrne, E. F. X. et al. Structural basis of Smoothened regulation by its extracellular domains. Nature 535, 517–522 (2016).27437577 10.1038/nature18934
463. Ho JD Structural basis for GPR40 allosteric agonism and incretin stimulation Nat. Commun. 2018 9 1645 1655 10.1038/s41467-017-01240-w 29695780
Ho, J. D. et al. Structural basis for GPR40 allosteric agonism and incretin stimulation. Nat. Commun. 9, 1645–1655 (2018).29695780 10.1038/s41467-017-01240-w
464. Lu J Structural basis for the cooperative allosteric activation of the free fatty acid receptor GPR40 Nat. Struct. Mol. Biol. 2017 24 570 577 10.1038/nsmb.3417 28581512
Lu, J. et al. Structural basis for the cooperative allosteric activation of the free fatty acid receptor GPR40. Nat. Struct. Mol. Biol. 24, 570–577 (2017).28581512 10.1038/nsmb.3417
465. Liu XY An allosteric modulator binds to a conformational hub in the beta(2) adrenergic receptor Nat. Chem. Biol. 2020 16 749 755 10.1038/s41589-020-0549-2 32483378
Liu, X. Y. et al. An allosteric modulator binds to a conformational hub in the beta(2) adrenergic receptor. Nat. Chem. Biol. 16, 749–755 (2020).32483378 10.1038/s41589-020-0549-2
466. Robertson N Structure of the complement C5a receptor bound to the extra-helical antagonist NDT9513727 Nature 2018 553 111 114 10.1038/nature25025 29300009
Robertson, N. et al. Structure of the complement C5a receptor bound to the extra-helical antagonist NDT9513727. Nature 553, 111–114 (2018).29300009 10.1038/nature25025
467. Liu H Orthosteric and allosteric action of the C5a receptor antagonists Nat. Struct. Mol. Biol. 2018 25 472 481 10.1038/s41594-018-0067-z 29867214
Liu, H. et al. Orthosteric and allosteric action of the C5a receptor antagonists. Nat. Struct. Mol. Biol. 25, 472–481 (2018).29867214 10.1038/s41594-018-0067-z
468. Wang XW Structural insights into dimerization and activation of the mGlu2-mGlu3 and mGlu2-mGlu4 heterodimers Cell Res 2023 33 762 774 10.1038/s41422-023-00830-2 37286794
Wang, X. W. et al. Structural insights into dimerization and activation of the mGlu2-mGlu3 and mGlu2-mGlu4 heterodimers. Cell Res 33, 762–774 (2023).37286794 10.1038/s41422-023-00830-2
469. Li, F. H. et al. Molecular recognition and activation mechanism of short-chain fatty acid receptors FFAR2/3. Cell Res. 10.1038/s41422-023-00914-z (2024).
470. Hollenstein K Structure of class B GPCR corticotropin-releasing factor receptor 1 Nature 2013 499 438 443 10.1038/nature12357 23863939
Hollenstein, K. et al. Structure of class B GPCR corticotropin-releasing factor receptor 1. Nature 499, 438–443 (2013).23863939 10.1038/nature12357
471. Christopher JA Structure-based optimization strategies for G Protein-Coupled Receptor (GPCR) allosteric modulators: a case study from analyses of new metabotropic Glutamate Receptor 5 (mGlu(5)) X-ray Structures J. Med. Chem. 2019 62 207 222 10.1021/acs.jmedchem.7b01722 29455526
Christopher, J. A. et al. Structure-based optimization strategies for G Protein-Coupled Receptor (GPCR) allosteric modulators: a case study from analyses of new metabotropic Glutamate Receptor 5 (mGlu(5)) X-ray Structures. J. Med. Chem. 62, 207–222 (2019).29455526 10.1021/acs.jmedchem.7b01722
472. Chen G Activation and allosteric regulation of the orphan GPR88-Gi1 signaling complex Nat. Commun. 2022 13 2375 2386 10.1038/s41467-022-30081-5 35501348
Chen, G. et al. Activation and allosteric regulation of the orphan GPR88-Gi1 signaling complex. Nat. Commun. 13, 2375–2386 (2022).35501348 10.1038/s41467-022-30081-5
473. Liu XY Mechanism of intracellular allosteric beta(2)AR antagonist revealed by X-ray crystal structure Nature 2017 548 480 484 10.1038/nature23652 28813418
Liu, X. Y. et al. Mechanism of intracellular allosteric beta(2)AR antagonist revealed by X-ray crystal structure. Nature 548, 480–484 (2017).28813418 10.1038/nature23652
474. Zheng Y Structure of CC chemokine receptor 2 with orthosteric and allosteric antagonists Nature 2016 540 458 461 10.1038/nature20605 27926736
Zheng, Y. et al. Structure of CC chemokine receptor 2 with orthosteric and allosteric antagonists. Nature 540, 458–461 (2016).27926736 10.1038/nature20605
475. Jaeger K Structural basis for allosteric ligand recognition in the human CC chemokine receptor 7 Cell 2019 178 1222 1230 10.1016/j.cell.2019.07.028 31442409
Jaeger, K. et al. Structural basis for allosteric ligand recognition in the human CC chemokine receptor 7. Cell 178, 1222–1230 (2019).31442409 10.1016/j.cell.2019.07.028
476. Liu KW Structural basis of CXC chemokine receptor 2 activation and signalling Nature 2020 585 135 140 10.1038/s41586-020-2492-5 32610344
Liu, K. W. et al. Structural basis of CXC chemokine receptor 2 activation and signalling. Nature 585, 135–140 (2020).32610344 10.1038/s41586-020-2492-5
477. Lees JA An inverse agonist of orphan receptor GPR61 acts by a G protein-competitive allosteric mechanism Nat. Commun. 2023 14 5938 10.1038/s41467-023-41646-3 37741852
Lees, J. A. et al. An inverse agonist of orphan receptor GPR61 acts by a G protein-competitive allosteric mechanism. Nat. Commun. 14, 5938 (2023).37741852 10.1038/s41467-023-41646-3
478. Duan J GPCR activation and GRK2 assembly by a biased intracellular agonist Nature 2023 620 676 681 10.1038/s41586-023-06395-9 37532940
Duan, J. et al. GPCR activation and GRK2 assembly by a biased intracellular agonist. Nature 620, 676–681 (2023).37532940 10.1038/s41586-023-06395-9
